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Abstract 
The incidence of adenocarcinoma of the oesophagus (ACO) is rapidly rising, with the 
UK white male population currently experiencing the highest incidence worldwide. 
ACO arises on a background of Barrett’s oesophagus (BO), a condition characterised 
by metastatic remodelling of the lower oesophagus in response to reflux of gastric 
contents. Previous work within our laboratory has shown that Barrett’s epithelium 
expresses the gastrin activated CCK2 receptor, that gastrin stimulates proliferation of 
BO cells, and that Barrett’s patients with the highest circulating gastrin concentrations 
are more likely to exhibit dysplasia. 
Patients diagnosed with BO are often prescribed proton pump inhibitors (PPIs) to 
reduce damage when acid reflux occurs. A common consequence of PPI usage is a 
significant increase in circulating gastrin concentration. The idea underlying the 
present study is that gastrin drives the progression of BO to ACO. If so, there is a need 
for biomarkers of the effect of gastrin on Barrett’s epithelium that might be useful in 
tracking the progression of BO to ACO and in monitoring the effectiveness of novel 
anti-gastrin therapies.  
Circulating gastrin concentration was analysed by radioimmunoassay and related to 
putative biomarker mRNA and miRNA expression quantified by qPCR in gastric and 
oesophageal biopsies from BO patients. Using gastric adenocarcinoma cell lines 
expressing the CCK2 receptor and treated with gastrin, putative protein biomarkers 
were analysed using western blot. 
Treatment with PPIs was associated with significant increases in circulating gastrin in 
control and Barrett’s patients. Abundance of CgA and HDC mRNA was also 
significantly elevated in gastric biopsies of both groups treated with PPIs. In gastric 
biopsies from patients with preneoplastic conditions CgA was significantly decreased 
in the highest risk group.  
Interestingly, BO biopsies exhibited a significantly lower abundance of CgA, MMP-
1, MMP-7, COX-2 and SHH transcripts in patients with high circulating gastrin (>100 
pM). In serum, miR-21, -221 and 222 abundances were significantly elevated when 
circulating gastrin was 30-100 pM but not >100 pM; tissue miR-221 and 222 was 
lower with gastrin >100 pM.  
6 
 
The expression of putative biomarkers in vitro varied between cell lines, although 
TIMP-1 and MMP-1 exhibited consistent responses to gastrin. 
Unexpectedly, in stomach and BO biopsies, CCK2 receptor mRNA abundance was 
significantly depressed in patients with elevated circulating gastrin concentration. 
Whilst changes in CCK2 receptor expression relative to gastrin have been suggested 
previously, the regulatory mechanisms are not completely understood. This result was 
surprising and may account for the pattern of association of putative gastrin-regulated 
biomarkers and circulating gastrin. The result also has wider-reaching implications for 
the interpretation of previous studies and for the design of future studies of the effect 
of gastrin on the progression of preneoplastic conditions in the gastrointestinal tract. 
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Chapter 1 
Introduction 
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1.1 Perspective 
Cancer is a genetic disease characterised by inherited or acquired mutations that 
disrupt critical gene functions implicated in the regulation of cellular proliferation, 
migration, differentiation and programmed death. The result of this disruption is the 
conversion of healthy cells to neoplastic ones which have become unresponsive to the 
physiological cues that regulate cell proliferation, differentiation, migration, invasion 
and programmed death, characteristics collectively attributed as the  “hallmarks” of 
cancer.1 Neoplastic cells can then recruit surrounding normal cells to form a tumorous 
mass (neoplasm) complete with a protumourigenic microenvironment. Neoplastic 
cells can also metastasise from their site of origin to form secondary neoplasms in 
other organs that exhibit a favourable microenvironment,2 compounding difficulties 
in treatment and increasing the risk of mortality either via tumour spread to vital 
organs or through multiple organ failure.  
 
This process of development is similar for all solid tumours including those found in 
gastro-intestinal (GI) cancers. Neoplasms can, in principle, occur in any region along 
the length of the GI tract. However they occur predominantly at the upper 
(oesophagus, stomach) or lower (colon) ends, indicating that the anti-oncogenic 
mechanisms of the small intestine are normally extraordinarily efficient compared 
with other regions of the gut. Gastrointestinal malignancies are a leading cause of 
morbidity and mortality worldwide with three million new cases identified each year 
resulting in two million deaths annually (data collected in 2000).3 Gastric cancer (GC) 
is currently the fourth most common cancer worldwide and second most common 
cause of cancer-related death, with 990,000 people diagnosed each year of whom 
738,000 die of the disease.4 Oesophageal cancer is currently the eighth most common 
cancer worldwide and the sixth most common cause of cancer-related deaths, with an 
overall ratio of mortality to incidence of 0.88 (data collected in 2012).5  
The progression of healthy cells towards neoplastic ones usually occurs over a 
relatively long time period and involves many stages of transition, during which cells 
slowly acquire pro-oncogenic genetic mutations.6 As cells undergo this progression 
they become further removed, morphologically, functionally and genetically, from the 
normal cells of their tissues of origin. The conditions that lie intermediate between 
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normal tissue and cancer are known as preneoplastic or precancerous conditions;7 they 
represent a stage at which there is a significantly increased risk of cancer, although 
many patients may die of unrelated conditions before development of cancer. 
Preneoplastic conditions are often associated with chronic inflammation, an example 
of this being Barrett’s oesophagus (BO) arising on a background of oesophagitis due 
to gastric contents reflux being associated with increased risk of progression to 
adenocarcinoma of the oesophagus (ACO).8 Identifying patients with preneoplastic 
changes, in particular those most at risk of progression to cancer, is essential for early 
cancer detection to improve treatment outcome. Diagnosis based on histopathology 
tends to be invasive e.g. requiring endoscopy and biopsies, whereas assays based on 
the quantification of validated biomarkers, for example in blood, are clearly an 
attractive alternative for monitoring both cancer risk and treatment in high risk 
patients. 
1.2 Organisation and control of the gastro-intestinal tract 
The primary function of the gastro-intestinal tract (GIT) is the transport of water, 
electrolytes and nutrients into the body and the provision of an environment that 
promotes the conversion of food into its constituent nutrients that are appropriate for 
transport. At the most basic level, the morphology of the  GIT consists of four distinct 
layers; the mucosa forming the innermost, lumen-facing, layer consisting of epithelial 
cells responsible for secretion (fluid, electrolytes, enzymes and mucous) and 
absorption, the submucosa comprising connective tissue that supports the mucosa, the 
muscularis externa surrounding the submucosa which provides muscular control of 
the GIT and so determines the rate of progression of luminal contents along the tract, 
and the outermost serosa, a mixture of epithelial and connective tissues encapsulating 
the tract.9 The common GI cancers all arise from epithelial cells of the mucosa (some 
rare exceptions being MALT lymphoma and GI stromal tumours).  
1.2.1 Control mechanisms of the GI tract 
The GIT is unique in that it is controlled by neurons of both the central nervous system 
(CNS) and its own intrinsic nervous system, the enteric nervous system (ENS), located 
in the wall of the tract. Neuronal control mechanisms are integrated with a complex 
network of paracrine (local) signalling molecules e.g. cytokines, chemokines and 
growth factors, as well as a system of hormonal (blood-borne) control factors. 
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Collectively the constituents of this network make an important contribution to the 
cancer microenvironment and may influence tumour progression, or not, depending 
on the circumstances.  
 
The peptide hormones of the gut normally regulate the secretion of digestive enzymes, 
the transit of nutrients through the tract and food intake. They modulate the functions 
of many different cell types located both within and outside the GIT including the 
brain and secondary digestive organs such as the pancreas. They are produced by 
specialised endocrine cells dispersed within the GI epithelium, from the stomach to 
the rectum; important examples include the cells producing gastrin, cholecystokinin 
(CCK), somatostatin, ghrelin, secretin and glucagon-like peptides.10 
 
In addition to nutrients, the GIT inevitably has direct contact with ingested 
microorganisms and toxic substances that may lead to inflammation and increased risk 
of cancer.11 Protective mechanisms are therefore well developed to ensure separation 
of the luminal contents and potential pathogens contained therein from the internal 
environment of the host. The first layer of defence within the GIT is tight junctions 
between epithelial cells, which are selective and capable of excluding noxious luminal 
contents such as gastric acid, colonic bacteria and bacterial antigens.12 The GIT also 
exhibits well developed adaptive immune defence mechanisms that limit the 
attachment, colonisation and potential damage caused by pathogens.13  
 
A particularly well characterised example of the interactions between the microbiota 
and inflammatory/immune mechanisms relevant to cancer development is the 
relationship between Helicobacter pylori infection in the stomach and GC. Chronic 
inflammation caused by an immune response to dysbiosis in patients with 
inflammatory bowel disease has also been linked to the increased risk of development 
of colorectal cancer.14,15 
 
An area of considerable research interest in recent years has been the elucidation of 
the human microbiome i.e the “human microbiome project”, particularly with respect 
to changes in the intestinal microbiome in health and disease.16 The gut microbiome, 
consists of bacteria, archaea, viruses and eukaryotic microbes; the precise balance 
between the different constituents of the microbiota is fundamental to maintaining 
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healthy human physiology and plays a pivotal role in metabolic function, protection 
against pathogens and educating the immune system.17 Dysbiosis of the GIT is also 
suspected to play a role in diseases not typically associated with the GIT including 
cardiovascular disease, Parkinson’s disease18 and systemic metabolic diseases such as 
diabetes and obesity.19 
1.2.2 Hormones of the GI tract. 
The first GI hormone to be discovered was secretin in 1902.20 The landmark discovery 
by Bayliss and Starling was then followed by the discovery of gastrin by Edkins in 
1906.21 The two hormones account for the regulation of pancreatic and gastric 
secretion, respectively. In 1928 Ivy and Oldberg discovered a hormone capable of 
contracting the gallbladder to secrete bile into the intestine – cholecystokinin.22 In the 
1960s and 70s advances in peptide biochemistry spurred the purification to 
homogeneity, elucidation of structure and subsequent synthesis of these hormones and 
also led to the discovery of more regulatory peptides including vasoactive intestinal 
peptide23, gastric inhibitory peptide,24 motilin25 and gastrin-releasing peptide.26 via the 
work of several international teams of researchers including Gregory, Dockray and 
Kenner in the UK, Rehfeld in Denmark, Wunsch in Germany, Jorpes and Mutt in 
Sweden and Yahaihara in Japan.27 Relatively recently it has become clear that these 
hormones may also influence cell proliferation and contribute to cancer progression.  
1.3 Gastrin 
Edkins’ original findings became controversial when it was later discovered that 
histamine also stimulated acid secretion, since many then believed that histamine was 
the main active factor in tissue extracts of the type prepared by Edkins. The matter 
was resolved in 1942 when S.A. Komarov developed a histamine-free method of 
producing mucosal extracts and reproduced Edkins’ findings.28 In 1964, gastrin 
became the first GI hormone for which the molecular structure was elucidated 
following the work of Gregory and Tracy who isolated heptadecapeptide gastrin (G17) 
from pig antrum.29 The elucidation of the molecular structure and the ability to 
produce pure gastrin, then facilitated the development of a gastrin radioimmunoassay 
in 196830 that could accurately quantify circulating serum gastrin concentrations from 
patients and animals and thereby gave birth to a new generation of  gastrin research.31 
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1.3.1 Gastrin biosynthesis 
Under normal conditions the gastrin gene is expressed in specialised entero-endocrine 
cells of the antrum known as G-cells. It is encoded by a 4.3 kb gene located on 
chromosome 17(q21) 32 and consists of three exons that encode for a prepropeptide of 
101 amino acid residues (in humans) with a calculated molecular mass of 11.4 kDa.33, 
34 Preprogastrin consists of an N-terminal 21 amino acid signal sequence followed by 
a spacer peptide, a bioactive domain and a C-terminal hexapeptide flanking peptide 
(CTFP). The precursor undergoes extensive post-translation processing within G-cells 
before secretion. During translation, the signal sequence determines the translocation 
of the elongating polypeptide to the endoplasmic reticulum (ER), where it is cleaved 
to produce progastrin. As progastrin travels through the Golgi complex to the trans-
Golgi network it is O-sulphated on tyrosine-8735, 36 and/or phosphorylated on serine-
96.37 The extent of O-sulphation depends on the species, cellular origins and 
developmental stage with approximately 50% of adult human G-cell derived gastrin 
sulphated. The effects of progastrin phosphorylation are currently not completely 
understood as it is not essential for progastrin processing, however it is believed that 
it may modulate cleavage of the CTFP which subsequently affects the conversion of 
glycine-extended gastrin intermediates to C-terminal amidated peptides.38 Following 
sulphation and/or phosphorylation progastrin exits the trans-Golgi network into 
immature secretary granules where it undergoes major proteolytic processing into 
biologically active peptides as the secretary granules mature.  
 
Processing of progastrin requires convertase-specific cleavage by prohormone 
convertases (PC); in immature granules with a neutral pH, progastrin is cleaved by 
PC1/3 to release the CTFP and spacer peptide to generate G34-Gly-Arg-Arg before 
the two basic residues are removed by carboxy-peptidase E resulting in glycine-
extended G34 (G34-Gly). As secretory granules mature and the internal pH becomes 
acidic, PC2 is activated and cleaves a proportion of G34-Gly into G17-Gly.39 Both 
glycine-extended gastrin forms are substrates for peptidyl-glycine ɑ-amidating 
monooxygenase (PAM) for conversion to the bioactive amidated gastrins, G34 and 
G17 (fig. 1.3.1.1).39 In humans > 98% of progastrin is converted to α-amidated 
bioactive gastrins, the majority being G17 (85%) and G34 (10%) forms, however G34 
is considered the major biologically active circulating form of gastrin due to its much 
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longer half-life and preferential release.40, 41 A detailed schematic showing how 
different lengths of gastrin hormone are derived from the common precursor 
preprograstrin is displayed in figure 1.3.1.1. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.1.1 – A schematic representation of preprogastrin and the pathways of 
progastrin proteolytic processing to produce amidated gastrins G34 and G17. 
1.3.2 Stimulation of gastrin synthesis and release 
The secretion of gastrin from G-cells is controlled by gastric luminal contents 
including gastric pH, nervous reflexes and paracrine signalling from adjacent cells. 
Expression of the gastrin gene within G-cells is also regulated by luminal contents42 
and pH of the stomach,43 secondary to paracrine signalling exerted by the GI inhibitory 
hormone somatostatin. G-cells exhibit an open morphology whereby different 
domains in the plasma membrane are in contact with either the basement membrane 
or gut lumen; the latter allows the cells to sense luminal content of which protein and 
amino acids, notably phenylalanine and tryptophan, are the most potent stimulators.44, 
45 Pepsin, released as pepsinogen from gastric chief cells and activated by gastric acid, 
digests dietary protein into the amino acids including those previously mentioned 
which stimulate gastrin release from G-cells.10 The release of gastrin is also stimulated 
if gastric pH rises above 3 via both direct action on the G-cell46 and indirectly through 
reduction in the release of inhibitory somatostatin from adjacent D-cells47 (fig. 1.4.1). 
However in normal subjects an acute rise in pH is not sufficient to stimulate gastrin 
release. Modulation of both the parasympathetic and sympathetic nervous pathways 
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has also been shown to regulate gastric acid secretion via the release of gastrin-
releasing peptide.48, 49 
 
The plasma concentration of amidated gastrins in fasted humans ranges up to 30 
pmol/L, however after a mixed meal consisting of carbohydrates, protein and fats the 
concentration of plasma gastrin increases 2-3 fold with a postprandial peak after 30-
60 minutes.50 
1.3.3 Inhibition of gastrin synthesis and release 
Somatostatin plays a dual role in inhibiting gastrin release, both by inhibiting secretion 
of gastrin from G-cells via activation of somatostatin receptor 2 and by inhibiting 
gastrin gene expression. Whilst the paracrine signalling pathways regulating 
transcription are not completely understood, a number of pathways have been reported 
to be involved - the most well elucidated being the epidermal growth factor (EGF) 
pathway. EGF stimulates gastrin gene expression via a GC-rich sequence in the 
gastrin gene promoter, EGF stimulates the mitogen-activated protein kinase pathway, 
which in turn phosphorylates transcription factor specificity protein 1 and allows 
binding to the promotor region and gene transcription.51 Somatostatin has been shown 
to inhibit basal gastrin gene expression and EGF-stimulated gene transcription via 
suppression of protein kinase A activity and interaction with sequences adjacent to the 
gastrin promotor sequence induced by EGF.52, 53 Transforming growth factor-β, Wnt 
and nuclear factor-κ-B signalling pathways have also been reported as being involved 
in transcription of the gastrin gene.54 In terms of gastrin gene transcription inhibition, 
recent experimental data has identified a role of the inflammatory cytokine 
interleukin-1β as an inhibitor of gene transcription via a NF-κB/histone deacetylase 
repressor complex.55 
1.4 Overview of the actions of gastrin 
The main biological actions of amidated gastrins are exerted via activation of the G-
protein coupled cholecystokinin 2 receptor (CCK2R). The latter is typically expressed 
in the periphery by parietal cells and enterochromaffin-like (ECL) cells and there is 
species specific expression in pancreatic acinar cells. The primary physiological 
function of gastrin is the stimulation of gastric acid secretion from parietal cells. This 
is achieved via the activation of CCK2Rs by gastrin on neighbouring ECL cells, 
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resulting in histamine release which acts as a paracrine mediator stimulating acid 
release from parietal cells (fig 1.4.1). In addition, gastrin also regulates ECL and 
parietal cell numbers, ECL cell proliferation, gene expression and parietal cell 
maturity56 and migration along gastric glands57 playing a pivotal role in the 
organisation and function of the gastric epithelium.58 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.1 – Overview of gastrin release and stimulation in the stomach. 
1.4.1 Proliferative effects of gastrins 
Changes in cell proliferation and cell loss induced by gastrin through the CCK2R were 
first described by Johnson in 197459 and his continued research then went on to 
identify the proliferative role of gastrin in a rat duodenal ulcer healing model.60 
Following on from this, the utilisation of genetically manipulated gastrin-deficient 
mouse models identified that gastrin production was crucial for regulating the 
maturation of gastric parietal cells and that gastrin is also a trophic factor for 
development of the colonic mucosa.56 Similar mouse studies utilising transgenic 
models overexpressing Gly-extended gastrin and progastrin reported increases in 
colonic mucosal thickness and colonic proliferation when compared to wild type and 
gastrin-deficient mouse models61 and this effect was reversed through deletion or 
antagonism of the CCK2R.62 Moreover, the main physiological target of gastrin, 
enterochromaffin-like (ECL) cells, have been shown to proliferate in response to 
gastrin in both culture63 and in vivo64 and hypergastrinaemia is associated with 
increased ECL cell numbers65 and spontaneous ECL cell carcinoid tumours.66 
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Collectively this work provides an experimental foundation for understanding the 
possible role of gastrin in cancer. 
 
The proliferative effects of gastrin have also been identified in pancreatic and CHO 
cell lines through a PKC/MAPK pathway67 and in pituitary GH3 cells however this 
proliferation mechanism was MAPK independent.68 In some cell lines, however, 
gastrin acting at the CCK2R has been identified as inhibiting cellular proliferation 
including certain pancreatic cancer cell lines,69, 70 CHO cells70 and AGS cells 
transfected with the human CCK2R.71 Conversely, gastrin has also been shown to 
induce proliferation of transfected AGS cells in a co-culture cell model72 indicating 
that gastrin can play a dual role – directly inhibiting or indirectly stimulating 
proliferation through a paracrine mechanism.  
1.4.2 Gastrin in disease 
A number of conditions and medications are associated with hypergastrinaemia. These 
fall into two major categories: those accompanied by gastric acid hypersecretion and 
those associated with hypochlorhydria or achlorhydria. Well studied examples of 
conditions resulting in hypergastrinaemia accompanied by gastric acid hypersecretion 
include duodenal ulcer disease, Zollinger-Ellison syndrome i.e. gastrin-secreting 
tumours, antral G-cell hyperplasia and gastric outlet obstruction. All of these share the 
clinical features of peptic ulcer disease and/or gastroesophageal reflux disease and 
complications thereof.73 Conditions resulting in hypergastrinaemia accompanied by 
reduced or absent gastric acid hypersecretion (and attributable to loss of suppression 
of gastrin release by gastric acid) include patients treated with protein pump inhibitors 
(PPIs),74 corporal atrophic gastritis75 and some sub-groups of patients with H. pylori 
infection.76 
1.4.3 Causes of hypergastrinaemia 
1.4.3.1 Zollinger-Ellison Syndrome 
Zollinger-Ellison syndrome (ZES) is a characterised by significantly increased serum 
gastrin concentration due to gastrin production from neuroendocrine tumours – 
gastrinomas – which either develop sporadically  or as one of the tumours in patients 
suffering from multiple endocrine neoplasia (MEN)-1 syndrome. Symptoms of ZES 
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reflect the hypergastrinaemia caused by the presence of gastrinoma and commonly 
include diarrhoea, multiple relapsing ulcers in atypical locations throughout the GI 
tract, and gastric mucosal hypertrophy.77 Diagnosis of gastrinoma is typically 
performed based on the response of serum gastrin concentration to an IV injection of 
secretin, with an increase of ≥50 pM considered positive.78 
1.4.3.2 Autoimmune gastritis 
Chronic atrophic corporal gastritis type A is an autoimmune inflammatory disease 
characterised by the destruction of the oxyntic mucosa caused by the presence of 
autoantibodies to the H+/K+-ATPase proton pump expressed by gastric parietal cells 
responsible for gastric acid production.79 Loss of parietal cells leads to achlorhydria 
and so removes the negative feedback mechanism provided by somatostatin on G-cells 
resulting in hypergastrinaemia; the secondary loss of intrinsic factor which is produced 
by parietal cells results in pernicious anaemia (PA).80 Hypergastrinaemia secondary to 
hypochlorhydria in patients with PA, is a well-known risk factor for ECL cell 
hyperplasia and gastric carcinoid neuroendocrine tumours. 81-83 Loss of intrinsic factor 
prevents absorption of vitamin B12 from the diet resulting in PA and presenting as 
fatigue, typically most affecting the elderly.84 
1.4.3.3 Proton pump inhibitors 
The widespread use of PPIs, such as omeprazole, lansoprazole, rabeprazole and others, 
has been common for nearly 30 years. It has recently become a topic of increased 
clinical interest due to reports detailing their usage as a potential risk factor for GC85, 
86 amongst other adverse effects including increased risk of pneumonia, C. difficile 
infection, bone fractures, hypomagnesaemia and acute interstitial nephritis.87 
Treatment with PPIs blocks the H+,K+-ATPase proton pump responsible for H+ ion 
secretion into the lumen of the stomach from parietal cells88 increasing gastric pH and 
stimulating gastrin release from G-cells, with prolonged usage resulting in 
hypergastrinaemia. They have also been linked to morphological changes in the 
stomach including parietal cell hyperplasia,89 ECL cell hyperplasia,90 fundic gland 
polys91 and, in rare cases, gastric carcinoids.92 Recent research has identified that PPIs 
can also influence the gastric microbiome and increase the risk of certain bacterial 
infections including C. difficile, Salmonella and Campylobacter populations.93 
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ECL-cell proliferation as a result of PPI-induced hypergastrinaemia can lead to 
increased acid secretion once PPI treatment is discontinued.94 A number of studies 
have documented the phenomenon of rebound acid hypersecretion following cessation 
of a minimum of 8 weeks of PPI treatment.95, 96 The increased secretory capacity of 
the gastric mucosa reflects the degree of ECL cell hyperplasia and increased gastrin 
stimulated acid secretion can be detected 2-3 months post PPI withdrawal.97 In the 
most extreme cases rebound hypersecretion has been reported 11 months after 
cessation of only a 2 month PPI treatment period.98 The consequences of rebound 
hypersecretion mimic those for which PPIs are originally indicated, typically 
dyspepsia, heartburn or gastro-oesophageal reflux disease99, 100 even in patients that 
were asymptomatic before PPI administration.101 
1.4.3.4 H. pylori infection 
Infection with H. pylori is one of the most common causes of moderate 
hypergastrinaemia. The bacteria cause damage to gastric glands via infiltration and 
release of virulence factors102, 103 which stimulates cytokine release and recruitment of 
inflammatory cells (lymphocytes, neutrophils etc.) and activation of inflammatory 
regulators such as cyclooxygenase-2 (COX-2).104, 105 The resulting chronic 
inflammation of the gastric mucosa leads to gastric atrophy106 characterised by the loss 
of parietal cells and gastric glands resulting in hypochlorhydria.107 Depending on the 
gastric location and severity of the H. pylori infection, an increase in gastrin 
concentration can be caused either via removal of G-cell inhibition by suppression of 
D-cells (antral infection) or via parietal cell loss resulting in decreased acid secretion 
(corpus infection).108 There is also evidence to suggest H. pylori infection can inhibit 
acid secretion from parietal cells by inhibiting H+/K+‐ATPase α subunit gene 
expression.109 The chronic inflammation induced by H. pylori infection has also been 
linked to being the greatest risk factor for the development of sporadic GC.110 
 
However, despite H. pylori infecting >50% of the world’s population, only 
approximately 1% of those infected will develop GC; indicating currently unknown 
additional factors that play a role in GC development. Recent research has focused on 
the possible role of the gastric microbiome in facilitating H. pylori driven progression 
to GC. A study performed in China found that GC mucosa was associated with marked 
differences in the microbiome compared to samples obtained from patients with 
31 
 
superficial gastritis, atrophic gastritis and intestinal metaplasia (IM).111 Specifically, 
gastric mucosa exhibited enriched bacterial populations typically associated with the 
oral cavity, although it is unclear whether the changes in the microbiome predate GC 
development and contribute to it or result as a consequence of the creation of the 
tumour microenvironment favouring the opportunistic growth of the 
microorganisms.112 Significant differences in the gastric microbiome between patients 
with autoimmune associated atrophic gastritis and H. pylori associated atrophic 
gastritis (both associated with the development of different types of GC) which was 
independent of H. pylori induced hypochlorydia have also been identified.113 
1.4.4 Role of gastrin in cancer 
1.4.4.1 Gastric cancer 
Gastric adenocarcinoma has been associated with a significant elevation in serum 
gastrin concentration for approximately 40 years.114 Within animal models exhibiting 
preneoplastic phenotypes there appears to be a synergistic relationship with 
hypergastrinaemia that accelerates the progression to cancer115 which implicates 
gastrin as a potential driving factor of progression to cancer in humans. Very recently 
a Finnish group identified that patients with high gastrin concentrations measured in 
the 1980s had an increased risk of gastric cancer development decades later116 and 
multiple groups have identified increased risk of gastric cancer in patients treated long-
term with PPIs85, 117 potentially via PPI induced hypergastrinaemia. 
1.4.4.2 Colorectal cancer 
Typically the colorectal mucosa does not appear to regularly express CCK2Rs118 
however some early studies did suggest that certain colorectal carcinomas and cell 
lines synthesised gastrin and exhibited expression of the CCK2R.119, 120 Moreover, the 
growth of some colorectal carcinoma cell lines was stimulated by exogenous gastrin 
stimulation, which was then inhibited in the presence of a gastrin receptor 
antagonist.121 Further research then identified increased serum gastrin precursor 
concentration in colorectal carcinoma patients122 which was reduced post-resection, 
but amidated gastrin concentration remained similar.123 These results lead to the 
current hypothesis, that colorectal cancers produce progastrin but are unable to process 
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progastrin to amidated gastrins122 and it is these non-amidated forms of gastrin that 
promote the acceleration of colon carcinogenesis (see section 1.6.1 below). 
1.4.4.3 Thyroid cancer 
 Medullary thyroid cancer (MTC) results from the malignant de-differentiation of 
calcitonin-producing C cells. It was discovered that high-affinity CCK2 receptors 
were present in MTC however they were absent in non-medullary thyroid carcinomas 
or in normal thyroid glands.124 Prior to this, diagnosis of MTC was performed using a 
pentagastrin provocation test where IV administration stimulated a significant increase 
in plasma calcitonin concentration, secreted  from the thyroid 125 this test remains the 
gold standard for MTC diagnosis.126 
 
Gastrin has also been suspected to stimulate the growth of other cancers, in 
epidemiological studies of patients with ZES and atrophic gastritis there is a 
significant increase in cancer risk in the stomach, oesophagus and pancreas.127-129 
1.5 Novel functions of gastrin 
In addition to its well documented gastric acid regulatory and proliferative effects, 
recent research has identified a plethora of previously unrecognised potential functions 
of gastrin including roles in stimulating cell migration, invasion, apoptosis and 
tubulogenesis.130, 131 The role of gastrin in cell migration and invasion can be linked 
to its regulation of a number of proteins that exert effects on tissue remodelling 
including matrix metalloproteinases (MMPs),132, 133 plasminogen activator inhibitors 
(PAIs)134, 135 and tissue inhibitors of metalloproteinases (TIMPs).136 In the context of 
cell survival, gastrin has been implicated in the upregulation of pro-apoptotic PAI-2137 
and conversely the upregulation of pro-survival factors clusterin138 and the putative 
protective trefoil factors (TFFs).139 The expression of some of these novel gastrin-
regulated proteins have been considered potential biomarkers of gastrin 
responsiveness (see section 1.8.1). 
1.6 “Non-Classical” gastrins 
Originally only the common C-terminally amidated gastrins, G17 and G34, were 
considered to be biologically active. Subsequent research however has identified 
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biological actions attributed to other progastrin derivatives, collectively called the 
non-classical gastrins.61, 140, 141 As explained previously, the extensive processing of 
preprogastrin translated from the gastrin gene generates a number of intermediate 
peptides and fragments including a CTFP, progastrin, G34-Gly, G17-Gly, G17-CFP 
and G34-CFP; these may actually be the predominant forms found in cells lacking the 
regulated secretory pathway.120 A recent review summised that although progastrin 
and glycine-extended gastrins are the predominant forms found in many cancers and 
cell lines including colon,142 oesophagus143 lung144 and ovarian145 that express the 
gastrin gene, they are unable to process the translation products fully to the amidated 
gastrins, except in negligible amounts. 146  
1.6.1 Progastrin 
Research concerning the biological effects of progastrin and its derivatives has mainly 
focused on the colon. Transgenic mice over-expressing progastrin exhibit increased 
colonic proliferation and susceptibility to cancer formation,147, 148 whilst progastrin 
expression by human primary colorectal cancer cells was found to be vital for tumour 
formation.149 Overexpression of progastrin has also been shown to impart 
tumourogenic and metastatic potential to human embryonic epithelial cells.150 
Progastrin has also been identified as playing a possible role in gastric antral stem cell 
expansion and carcinogenesis.151 
 
How progastrin exerts these effects is currently not completely understood. Several 
putative receptors for progastrin have been proposed152 including the classical gastrin 
activated CCK2 receptor.153 Recently G-protein coupled receptor 56 activation has 
been implicated154 and a novel mechanism of clathrin-dependent endocytosis via cell-
surface annexin AnxA2 has also been proposed.155 Despite these advances, more 
research is required to fully elucidate the role of progastrin in carcinogenesis and the 
mechanisms involved. 
1.6.2 Gly-gastrins 
Discovery of the proliferating effect of Gly-gastrins was initially described in a 
pancreatic cell line141 and since then has also been identified in colonic mucosa156 and 
oesophageal cancer cell lines.157 G17-Gly has also been identified exhibiting anti-
apoptotic activity in both Barrett’s oesophagus and oesophageal adenocarcinoma cell 
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lines.158 Evidence has emerged suggesting that G17-Gly acts synergistically with 
amidated gastrins in the stomach159 and, considering amidated gastrin has been linked 
to proliferation in Barrett’s metaplasia,160 this may also the case for the oesophagus 
although so far it has not been investigated. 
 
As with progastrin, a specific receptor for Gly-extended gastrins has not been 
identified, with arguments for and against the involvement of the CCK2R.152 Recent 
work suggests a role for cell-surface bound F1-ATPase, at least within colonic 
epithelial cell proliferation, as a Gly-gastrin receptor.161 As with progastrin, more 
research is required to explore the role of Gly gastrins in carcinogenesis and the 
mechanisms involved. 
1.7 The CCK2 receptor 
The first of the CCK family of peptides to be isolated was CCK33, in 1968 by Mutt 
and Jorpes.162 Another form, CCK8, was one of the first gastrointestinal peptides to 
be discovered in the brain.163 Cholecystokinin receptors were pharmacologically 
classified into two subtypes – CCKA and B164 with the latter also being referred to as 
gastrin-CCK-B165 (now referred to as CCK1 and 2 respectively). The CCK1 receptor 
was initially cloned and sequenced from rat pancreatic mRNA, later both receptors 
where cloned from rat brain and rat pancreatic cell lines in 1992 by Wank et. al.166, 167 
This work was also important in identifying that the cDNA sequences of CCK1 and 
CCK2 receptors in the brain were the same as those of the corresponding receptor in 
the GI system. Cholecystokinin contains an identical C-terminal pentapeptide 
sequence to that of gastrin, which explains why both gastrin and CCK are able to bind 
to CCK receptors. However differences in receptor affinity for gastrin are striking. 
The CCK1 receptor binds gastrin with a relatively low affinity, 500-1000 times lower 
than sulphated CCK, whereas the CCK2 receptor binds gastrin and CCK with similar 
affinities.168 In the central nervous system CCK is the predominant ligand for the 
CCK2R because it is expressed in high concentrations by neurons, while gastrin is the 
predominant ligand in the periphery as, under physiological conditions, its plasma 
concentration is 5-10 times higher than that of CCK.169 
 
In the GI tract, CCK1 receptors are expressed on gastric D-cells, chief cells, smooth 
muscle cells, enteric neurons, smooth muscle cells, vagal afferent neurons and 
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pancreatic acinar cells. In the CNS, CCK1 receptors are expressed in the anterior 
pituitary and areas of the midbrain.170 Whereas CCK2R are normally expressed by 
parietal cells, ECL cells, some smooth muscle cells, neurons in many parts of the CNS 
as well as in the peripheral nervous system and pancreatic acinar cells.10 
1.7.1 Activation of CCK2R by gastrin 
Gastrin regulates acid secretion from parietal cells in large part by stimulating release 
of histamine from ECL cells via CCK2R activation, which in turn activates histamine 
subtype 2 receptors on parietal cells to induce acid secretion. In most cell types 
studied, including ECL cells, CCK2R is coupled to members of the Gq/11 subfamily 
of heterotrimeric GTP-binding proteins which mediate receptor activation of 
phospholipase C (PLC)-β. In turn PLC-β produces secondary messengers inositol 
1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG); IP3 binds to and activates 
Ca2+ channels in the ER membrane resulting in rapid Ca2+ efflux into the cell 
cytoplasm. Elevated cytoplasm Ca2+ concentration and DAG go on to activate 
numerous Ca2+ and lipid-regulated proteins including members of the protein kinase 
C (PKC) family. 
 
Recently the CCK2R has been indicated in playing a role in various cancers. It has 
been known for some time that there are multiple splice variants of the CCK2R. Of 
particular interest is variant CCK2R i4sv which was identified in 100% of insulinomas 
and gastrointestinal stromal tumours and 67% of small cell lung cancers across a panel 
of 81 different tumours.171 It is thought to regulate cancer cell proliferation, however 
this mechanism may be independent of gastrin stimulation.172 Studies of archived 
pancreatic cancer material have also shown expression of CCK2R mRNA and variants 
thereof.173 
1.7.2 Expression of the CCK2R 
Although the mechanisms controlling CCK2R expression are not completely 
understood, it is known that binding sites for transcription factors SP1, C/EBP and 
GATA are essential for functional receptor production. Some evidence suggests that 
gastrin itself is capable of upregulating the expression of the CCK2R. Gastrin 
treatment of RGM1 cells significantly increased endogenous CCK2R expression 
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whilst in the stomach of hypergastrinaemic animals increased CCK2R abundance has 
also been observed.174 In cases of gastric mucosal damage CCK2R expression 
increases progressively at the repair margin and de novo expression of the CCK2R has 
been observed in the submucosa beneath the repairing mucosa. Many of the cells that 
expressed the CCK2R in response to injury were identified as myofibroblasts. These 
data suggest that increased CCK2R expression might influence the outcome of 
epithelial inflammation or injury and that the response may be mediated in part by 
myofibroblasts.174 There is also emerging evidence of regulation of CCK2R 
expression by miR148b in gastric and colorectal cancers.175, 176 
1.7.3 Antagonists of the CCK2R 
The initial discovery of CCK2 receptor antagonists (CCK2RA) began with asperlicin, 
a benzodiazepine-related natural product with weak affinity for CCK1 receptors. This 
discovery led to the development of a number of benzodiazepine-derived CCK2RA 
such as L-364,718 (devazepide) and L-365,260. Other classes of antagonists include 
the dipeptoid CI-988,177 benzodiazepine derivatives YM022,178 Z-360179 and YF476 
(netazepide).180, 181 Two new classes of CCK2RA have also recently been invented: 
JB95008 which is a substituted imidazole182 and JNJ-26070109183 which is a 
benzamide derivative. Whilst no CCK2RA are currently on the market, the most 
promising candidates netazapide and Z-360 are in active clinical development 
indicated for the treatment of type 1 gastric NETs184, 185 and pancreatic cancer179, 186 
respectively. A new benzodiazepine derivative CCK2RA – ceclazepide – that offers 
greater selectivity, solubility and bioavailability compared to netazepide is also in pre-
clinical development.187 
 
In their use as a research tool, animal models treated with JNJ-26070109 and 
netazepide188 both exhibited dose-dependent inhibition of pentagastrin-stimulated acid 
secretion in rats and dogs. Netazepide also prevented the increases in ECL-cell activity 
and density, oxyntic mucosal thickness, mucosal histidine decarboxylase (HDC) 
activity and serum pancreastatin caused by typical PPI induced hypergastrinaemia in 
rats.189 Netazepide has also been identified as preventing ECL-derived gastric 
carcinoids accelerated by PPI induced hypergastrinaemia and causing the regression 
of existing carcinoids.190 In human trials, L-365,260191 and netazepide192 have both 
exhibited dose-dependent inhibition of pentagastrin-stimulated acid secretion, with the 
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latter suppressing acid production as effectively as the PPI rabeprazole. Furthermore, 
netazepide treatment of patients with chronic atrophic gastritis, achlorhydria, 
hypergastrinaemia and multiple gastric neuroendocrine tumours (NETs) caused a 
reduction in tumour number and size and normalised expression of the NET biomarker 
chromogranin A (CgA).184 
 
The latest generation of CCK2RA represent a leap forward in their suitability for use 
in indications such as hypergastrinaemia, acid-related conditions, H. pylori infection 
and conditions of CCK2R overexpression without the potential side effects associated 
with PPIs. 
1.8 The ECL cell: significance for biomarkers of gastrin responsiveness 
ECL cells reside in the oxyntic glands, located in the corpus of the stomach alongside 
parietal and chief cells. They are the predominant expressors of the CCK2 receptor in 
the periphery, activation of which via gastrin stimulates both the release of histamine 
(see above) from the cell and increases its synthesis within the cell.58 Histamine 
synthesis is dependent on the activation of HDC and thus, as the expression of HDC 
is induced by gastrin, HDC transcript abundance can be (and has previously been) 
used as a biomarker of gastrin stimulation of ECL cells.193-195 Histamine is generated 
in the ECL cell cytosol and transported into secretory vesicles by vesicular monoamine 
transporter 2 (VMAT)-2, the expression of which is also regulated by gastrin so 
provides a further potential biomarker of gastrin responsiveness of ECL cells.196, 197 
 
The majority protein component of ECL cell secretory vesicles is contributed by 
members of the chromogranin family. There are nine members, with the most well 
investigated being chromogranins A, B and C.198 Members of this family occur in 
neuroendocrine cells throughout the body and play a chaperone role in the packaging 
of secretary products into the regulated secretory pathway and are secreted alongside 
them.199 They can also act as precursors of biologically active peptides; for example, 
processing of CgA produces pancreastatin and pancreastatin-related products of which 
ECL cells contain and secrete the majority in the body.194 Circulating CgA is therefore 
often used as a biomarker of ECL cell function. Gastrin regulates CgA gene expression 
in ECL cells200, 201 and measurement of the concentration of circulating CgA has also 
been used as a biomarker not just of ECL mass and activity, but also as an indicator 
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of responsiveness to gastrin;185 CgA has been well characterised as such, particularly 
for diagnosis of ECL cell hyperplasia and NETs.202-204 
 
Gastrin plays an important role in regulating the ECL cell population.63 Sustained 
hypergastrinaemia however induces ECL cell hypertrophy after approximately one 
week, hyperplasia after approximately 10 weeks (with ECL cell number plateauing at 
20 weeks), signs of linear hyperplasia (focal multiple micronodules) at approximately 
one year205 and a transition to dysplasia (defined as ECL tumours) after two years.194 
The development of hypertrophy and subsequent hyperplasia and dysplasia can be 
blocked via the use of CCK2RAs, demonstrating that progression is gastrin driven.189, 
190, 206 
1.9 Gastrin-regulated gene expression 
A number of downstream targets of gastrin (that represent potential biomarkers of 
cellular response to gastrin) have been studied in addition to the well characterised 
examples of CgA and HDC mentioned previously.185, 195, 207, 208 These include MMPs 
-1, -7 and -9, TFFs -1 and -2, the regenerating family of proteins (Reg), COX-2 and 
microRNAs -21, -221 and -222. 
1.9.1 Putative biomarkers of gastrin responsiveness 
1.9.1.1 Matrix metalloproteinases 
The MMPs are a family of zinc-dependent endopeptidases that play crucial roles 
during tissue remodelling and organ development via rearrangement of the 
extracellular matrix.209 If the function or expression of MMPs goes awry however, 
they can contribute to virtually all steps in tumour progression210 through extracellular 
matrix degradation paving the way for tumour cell invasion and metastasis. Gastrin 
has been shown to stimulate the expression of multiple members of the MMP family 
including MMP-1211 in parietal and chief cells and MMP-7132 and MMP-9212 in ECL 
cells.  
1.9.1.2 Trefoil factor family 
The TFF family of peptides are a polypeptide family secreted onto epithelial surfaces 
in conjunction with mucus by mucus-secreting cells. They are believed to play roles 
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in the maintenance and repair of the gastric mucosa and as a tumour suppressor.213 
Specifically TFF1 and 2 are implicated in repairing the GI mucosa through cell 
migration post-injury.214, 215 TFF1 protects against inflammation of the gastric 
mucosa216 and both have been indicated as tumour suppressors in GC217, 218. A number 
of studies have suggested that hypergastrinaemia can regulate the expression of both 
TFF1139 and TFF2215 mRNA abundance via both direct CCK2 receptor activation and 
indirect paracrine signalling pathways. Reduced expression of TFF1 and 2 has also 
been observed in gastric preneoplastic conditions and cancer.218 
1.9.1.3 Regenerating protein family 
The Reg family of proteins (also known as pancreatic stone protein, pancreatic thread 
protein, lithostathine and islet of Langerhans regenerating protein) are a large family 
of proteins associated with binding of extracellular calcium, cellular proliferation and 
differentiation; they show a characteristic distribution in various organs with strong 
expression along the entire GIT and accessory organs such as the pancreas.219 
Members of the group also exhibit dramatic (>100 fold) increases in expression in 
response to cell stimulation in a wide variety of circumstances. Gastrin has been 
identified in regulating the expression of the Reg1 mRNA in both chief and ECL 
cells220 suspected to be responsible for gastrin-induced cell growth.221  
1.9.1.4 Cyclooxygenase-2 
The enzyme COX-2 catalyses the conversion of arachidonic acid to prostaglandins, 
responsible for inflammatory reactions and tumour development.222, 223 Research has 
identified that H. pylori induced hypergastrinaemia is often associated with increased 
COX-2 expression.224 Further work has identified CCK2 receptor activation by gastrin 
stimulates expression of COX-2 mRNA in GC cells irrespective of H. pylori 
infection225 via activation of the secondary messaging JAK2/STAT3/PI3K/Akt 
pathway. 
1.9.1.5 MicroRNAs 
Recent advancements in experimental techniques have allowed the analysis of small 
noncoding RNA species known as microRNAs (miRNAs) that have been shown to 
regulate gene expression and play important roles in a wide range of physiological and 
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pathological processes, including the promotion of GI cancers.226-229 Gastrin has 
previously been shown to induce the expression of miRNA-222 in CCK2R transfected 
AGS cells and in mouse models exhibiting hypergastrinaemia.230 There may also be 
other miRNAs that are regulated by gastrin, however there has been very little research 
comparing the two. 
1.9.2 Cellular mechanisms of gastrin-regulated gene expression  
Direct gastrin-dependent gene expression within ECL cells is responsible for the 
increased expression of HDC, VMAT and CgA.231 Increased HDC gene transcription 
in response to gastrin is mediated by an enhancer-like response element which consists 
of two overlapping nuclear factors – gastrin response elements 1 and 2.232 Gastrin 
stimulation of HDC transcription was shown to be mediated by PKC233 indirect 
activation of c-fos and c-jun234 and Raf dependent MAP kinase stimulation 
(MAPK).235 Gastrin regulated transcription of CgA has been identified as being under 
the control of transcriptional factors Sp1, Egr-1 and cyclic AMP-response element-
binding protein (CREB),236 the activation of which is modulated via a PKC/MEK-
1/ERK-1/-2 pathway.231 Transcription of VMAT regulated by gastrin is dependent on 
the binding of a currently uncharacterised transcription factor to an AP2/Sp1 site 
within the promotor region and CREB binding to a upstream CRE consensus 
element.237 This activation is again suspected to be modulated downstream of PKC238 
identifying a common mediator of gastrin stimulated expression within ECL cells that 
activates a diverse network of secondary signalling pathways to differentially regulate 
CgA and HDC production. 
1.9.3 Indirect actions of gastrin 
In addition to direct effects of gastrin on cells expressing the CCK2R (parietal, ECL) 
recent work has suggested that gastrin also activates a number of paracrine signalling 
pathways involved in cell secretion, proliferation and inflammation. These include 
release of somatostatin,239 activation of COX-2,240-242 shedding or induction of 
members of the EGF family,72, 243 fibroblast growth factor (FGF)-1,244 Reg245, 246 and 
the chemokine IL-8.247 
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1.10 Gastric cancer and preneoplastic conditions 
The development of intestinal type gastric adenocarcinoma – the most prevalent form 
of GC248 – represents the culmination of an inflammation-metaplasia-dysplasia-
carcinoma sequence originally characterised by Correa.249-251 Progression typically 
proceeds from normal mucosa through chronic non-atrophic gastritis (for which H. 
pylori infection is the most frequent cause), atrophic gastritis (defined as loss of 
parietal cells and oxyntic glands) and IM (defined as presence of goblet cells) to 
dysplasia and finally carcinoma. In this sequence, chronic atrophic gastritis and IM 
both confer a high risk for the development of GC as they constitute the background 
on which dysplasia and carcinoma arise252 and are considered to be preneoplastic 
conditions.253 Therefore conditions known to induce inflammation of the gastric 
mucosa and gastritis such as H. pylori infection and autoimmune atrophic gastritis 
themselves also represent preneoplastic conditions. Despite increasing the risk of GC 
however, not all patients with preneoplastic changes progress to GC. A recent large-
scale study within a western population identified that patients with atrophic gastritis 
and IM had a 20 year average risk of progression to GC of 2% and 2.6% 
respectively.254 There exists an obvious clinical need to be able to identify those 
patients most at risk of progression to cancer from those simply harbouring the 
preneoplastic condition, we believe that finding the right gastrin-regulated biomarkers 
has the potential to do this. 
1.11 Oesophageal adenocarcinoma and Barrett’s oesophagus 
Gastro-oesophageal reflux disease (GORD) is defined as reflux of the gastric contents 
that causes troublesome symptoms, mucosal injury in the oesophagus or a combination 
of both.255 It is currently the most common gastrointestinal diagnosis in the USA with 
the western world in general exhibiting the highest prevalence worldwide of between 
10-30%256 with evidence suggesting a continuing upward trend.257 Evidence shows a 
strong link between obesity and GORD,258 thought to be due to increased abdominal 
pressure facilitating reflux. The chronic inflammation caused by reflux then leads to 
the development of BO.259  
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1.11.1 Barrett’s oesophagus 
Barrett’s oesophagus is the metaplastic replacement of the stratified squamous 
epithelium that typically lines the oesophagus with specialised intestinal columnar 
epithelial cells in response to inflammation initiated by GORD (fig 1.10.2.1).260 
Although IM is the most common form and the epithelial type linked to 
adenocarcinoma development,261 BO can also present with cardia and gastric fundic-
type columnar epithelium.262 Barrett’s metaplasia appears to be a protective adaptation 
for the lower oesophagus against the damaging consequences of reflux of gastric acid 
and bile salts,263 however in doing so it predisposes towards oesophageal 
adenocarcinoma. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10.2.1 – A diagrammatic representation of typical cells of the oesophagus 
transitioning through BO and epithelial dysplasia towards oesophageal 
carcinoma. Produced by Jennifer Parsons Brumbaugh © (2000–2004) Johns Hopkins 
University and taken from http://pathology.jhu.edu/beweb/understanding.cfm. 
1.11.2 Cancer of the oesophagus 
The majority of oesophageal cancers can be subdivided into two histologically distinct 
subtypes – ACO and squamous cell carcinoma (SCC) and typically develop in the 
lower third and upper two thirds of the oesophagus respectively.264 Of the two 
subtypes, the epidemiology of ACO has evolved rapidly over recent years and in many 
higher-income western countries has become the predominant histological type with 
incidence increasing more rapidly than that of other GI cancers. The UK in particular 
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has experienced an alarming increase in incidence of ACO with a cumulative risk 
increase of 10-fold for men and 5-fold for women within just over a generation. In 
contrast, SCC is more common in eastern Asia and the incidence has remained stable 
or decreased within the same time frame.265  
 
The incidence of BO within the adult western population is approximately 2%,266 
increasing up to 10% in individuals with symptoms of GORD.267 However, not all 
patients suffering from BO progress to cancer and risk of developing cancer increases 
progressively in patients as the severity of epithelial dysplasia increases (see fig 
1.10.2.1). The latest estimated progression rate is 0.22-0.83% per annum for patients 
with non-dysplastic Barrett’s,268, 269 however there is a large degree of variance within 
the literature depending on sample size and location in which the study was performed. 
In the UK alone, there were around 8,900 diagnoses of ACO a year (data collected in 
2014) with five year survival rates as low as 15% (data collected 2010-2011).270 A 
combination of rapidly increasing incidence and a dismal five year survival rate 
positions ACO as a serious current and future public health risk, particularly within 
the UK’s white male population who currently represent the most at-risk group. 
However, it is possible to improve the poor prognosis of the disease through earlier 
detection, with data from the Netherlands showing an improvement in 5-year survival 
rates from 17% to 74%271, 272 when patients with BO of at least 2 cm in length 
underwent endoscopic surveillance every three years and patients with low-grade 
dysplasia surveyed every year. 
 
Clinical guidelines state the need for periodic endoscopy surveillance of patients to 
monitor progression of the condition.273 However this is time-consuming, invasive for 
the patient and expensive, considering the low percentage of patients that will 
experience progression towards ACO. There exists then a need to more accurately 
determine which BO patients will progress using, where possible, less invasive 
methods. Well characterised biomarkers have the potential to meet this need. 
1.12 Causes of Barrett’s Oesophagus 
The most important pathogenic factor for the development of BO has been shown to 
be the presence of severe, chronic, reflux disease. Patients with BO typically have 
decreased cardiac sphincter pressures and oesophageal dysmotility compared with 
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other forms of GORD reducing their ability to prevent gastric reflux and clearance of 
gastric contents when reflux does occur.274 Reflux leads to long-term exposure of the 
lower oesophageal epithelium to gastric acid and bile salts, with bile salt presence 
being more common in BO patients than in other forms of GORD.275  It is believed 
that the combination of both gastric acid and bile salt reflux, experienced to a greater 
extent in BO than other forms of GORD, explains why only 5-15% of chronic reflux 
sufferers present with BO.276 Exposure to bile salts alone does not seem to contribute 
to the development of BO,277 but exposure of oesophageal cells to bile salts and a low 
pH environment results in oxidative stress and DNA damage278 activating the NF-κB 
pathway for programmed cell death.279  
 
Recently, other potential noxious components of gastro-oesophageal reflux have 
emerged and a role for nitric oxide (NO) produced from dietary nitrates has been 
implicated. Following a meal rich in nitrates, NO generated from those nitrates has 
been shown to reach genotoxic concentrations at the gastro-oesophageal junction in 
GORD patients both with and without Barrett’s oesophagus.280 Dietary nitrate 
supplementation has also been shown to accelerate the development of oesophageal 
metaplasia in rat models with surgically-induced reflux oesophagitis.281 Oesophageal 
tissue samples from rat models with surgically-induced reflux oesophagitis, fed a diet 
supplemented with nitrates, exhibited reduced expression of transcription factors that 
promote stratified squamous epithelium development, SOX2 and p63,282 alongside 
increased expression of CDX2, a transcription factor that promotes intestinal 
differentiation. 282, 283 The combination of these events implicates that NO can drive 
the development of Barrett’s by inhibiting the production of normal stratified 
squamous epithelium and create an environment favouring intestinal epithelium 
differentiation instead. 
1.13 The role of gastrin in Barrett’s oesophagus 
The current first-line therapeutic treatment for patients with BO is PPIs which, as 
outlined previously, inhibit gastric acid secretion causing an increase in gastric pH.284 
This in turn causes reduced damaged to the lower oesophagus when reflux of the 
stomach contents does occur. However, treatment with PPIs at therapeutic doses may 
induce hypergastrinaemia in some patients. It is therefore significant that studies have 
suggested increased expression of functional CCK2 receptors in Barrett’s epithelium 
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(BE)160 compared to normal squamous epithelium indicating a potential role for 
gastrin to act on BE.  
 
The well-known role of gastrin as a growth factor for gastrointestinal cells expressing 
the CCK2 receptor has already been mentioned285 and further research on CCK2 
receptor expressing BE and oesophageal adenocarcinoma cell lines have demonstrated 
gastrin stimulated proliferation129 and protection from apoptosis.286 Gastrin is also 
capable of stimulating expression of COX-2 in CCK2 expressing oesophageal cells 
which is known to be associated with the development of oesophageal and other GI 
malignancies.287, 288 A recent meta-analysis of Barrett’s patients including patients 
with dysplasia (low and high grade) and ACO showed that patients in the highest 
quartile of serum gastrin had a significantly increased risk of high-grade dysplasia and 
ACO.289 Collectively, the data support the hypothesis that gastrin could be a driver of 
BO progression towards ACO via its role as a known growth factor and inducer of 
genes associated with inflammation and cellular invasion through degradation of 
extracellular matrix. 
1.14 Biomarkers of Barrett’s progression 
The prospect of using biomarkers to track Barrett’s progression toward 
adenocarcinoma has been approached before using immunohistochemical (IHC) 
techniques on biopsies retrieved during routine surveillance however success has been 
varied. A recent systematic review and meta-analysis comparing 16 different 
biomarkers across 36 studies identified a significant relationship between aberrant p53 
expression and increased risk of  development of high-grade dysplasia or ACO from 
non-dysplastic and low-grade dysplasia patients; aberrant Aspergillus oryzae lectin 
(AOL) staining was also identified as a cross-study potential predictor of neoplastic 
progression in BO biopsies.290 Whilst IHC techniques may offer benefits in prediction 
of progression due to their ease of use and having multiple studies corroborating 
suspected targets, they remain reliant on the collection of biopsies by endoscopy which 
is costly and invasive for the patient.  
 
Novel technologies are currently being developed to avoid the use of endoscopy to 
collect oesophageal cells for analysis and make the process less invasive. Promising 
results have been obtained using a device called the Cytosponge which consists of a 
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foam sponge inside a gelatin capsule attached to a string which is swallowed by the 
patient. After approximately five minutes, the gelatin capsule is dissolved allowing 
the sponge to expand within the oesophagus. Retrieval of the sponge by pulling the 
string collects epithelial cells from the length of the oesophagus for analysis by a 
variety of techniques.291 Another approach has been to use untethered microgrippers 
that are dispersed in water and swallowed by the patient. Once swallowed, body heat 
closes the grippers which can then be retrieved from biopsies using a magnet. 
Currently the technology has only been successfully tested in pigs.292  
 
The ideal biomarker-based assay would be minimally invasive (ideally blood-based), 
compatible with existing techniques that could be performed in the majority of 
diagnostic laboratories and thoroughly validated using multiple targets. The 
correlation between serum gastrin and risk of progression towards ACO may represent 
the first step in a blood-based biomarker for progression and proteins regulated by 
gastrin an extension of that. Currently the literature has focused solely on biopsy-based 
biomarkers (see table 1.14.1) so there exists a gap in knowledge of whether blood 
based biomarkers alongside biopsy based biomarkers could be a useful tool in 
monitoring BO.  
 
Paper Biomarkers examined 
Moore et. al185 CgA, HDC, MMP-7, PAI-1 and -2 
Boyce et. al293 CgA 
Higham et. al195 CgA, HDC, VMAT2, Somatostatin 
 
Table 1.14.1 – Published works identifying biomarkers of gastrin stimulation in 
cells of the GIT. A table consisting of the papers that have previous identified and 
used biomarkers of gastrin responsiveness in humans. 
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1.15 Aims and Objectives 
This investigation focuses on the idea, suggested above, that gastrin stimulates the 
progression of BO progression towards dysplasia and finally cancer. To approach this, 
it was hypothesised that putative biomarkers of gastrin responsiveness in Barrett’s 
tissue biopsies would provide a novel resource for further study. Since much of the 
existing relevant literature is based on the stomach, and to provide a basis for 
comparison, the potential of putative biomarkers of gastrin-responsiveness in gastric 
preneoplastic conditions was also examined. Since determination of serum gastrin is 
important in both cases, there was a requirement to validate the relevant gastrin 
radioimmunoassay to a standard compatible with good clinical laboratory practice and 
FDA guidelines.  
The specific aims were: 
 To validate the reliability and accuracy of our gastrin RIA 
 To characterise the expression of gastrin-regulated genes in preneoplastic 
conditions of the stomach and oesophagus. 
 To identify if a significant relationship exists between serum gastrin 
concentration and expression of gastrin regulated genes in preneoplastic 
conditions of the stomach 
 To identify the expression profile of putative biomarkers of gastrin-
responsiveness in BO biopsies 
 To validate identified putative biomarkers of gastrin-responsiveness in 
calibrated cell lines of gastric cancer transfected with the CCK2R. 
  
48 
 
 
 
 
 
 
 
 
 
 
 
49 
 
Chapter 2 
Materials and Methods 
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2.1 Sample collection and storage 
2.1.1 Patient Recruitment 
2.1.1.1 Series 1 
Subjects were selected from a cohort of ∼1,400 patients, aged 18 and over, who had 
clinical indications for undergoing diagnostic upper gastrointestinal endoscopy. 
Control subjects were selected for investigation if they were H. pylori negative and 
exhibited no endoscopic or histological evidence of upper gastrointestinal neoplasia 
or preneoplastic pathology (atrophic gastritis, gastric intestinal metaplasia, or Barrett's 
oesophagus). Barrett’s or gastric preneoplastic (atrophy, intestinal metaplasia or both) 
patient groups included subjects that were H. pylori negative and exhibited endoscopic 
and histological evidence of the relevant condition. Further exclusion criteria included 
diabetes mellitus, coma or hemodynamic instability, being moribund or having 
terminal malignancy, cirrhosis (Child B or C), abnormal clotting or bleeding 
diasthesis, inability to give informed consent, contraindication to endoscopy, 
pregnancy, HIV, hepatitis B or C infections.  
Subjects underwent diagnostic gastroscopy in the Gastroenterology Unit at the Royal 
Liverpool University Hospital. Endoscopic pinch biopsies of gastric corpus and 
antrum (2–4 of each) were obtained for histology; H. pylori status was determined on 
the basis of serology, antral urease test (Pronto Dry; Medical Instrument, Solothurn, 
Switzerland), and antral and corpus histology. The study was approved by the 
Liverpool Local Research Ethics Committee and by the Royal Liverpool and 
Broadgreen University Hospitals NHS Trust, and all patients gave written, informed 
consent.211 
2.1.1.2 Series 2 
Subjects were recruited from a list of patients having already been identified at 
previous endoscopy as having Barrett’s oesophagus (confirmed by histopathology) of 
a continuous length of at least 2 cm and were already attending the hospital for a 
routine surveillance endoscopy. Exclusion criteria for the study were the same as those 
defined in 2.1.1.1. Potential patients were presented with a participant information 
sheet and consent form upon their arrival in clinic and given 10-15 minutes to read the 
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documents before being approached by a member of the research team prior to 
endoscopy and details of the project explained and any questions answered. If the 
patient was willing to participate in the study the consent form was completed.  
 
Whole 
Group 
IM 
Only 
Mixed 
Metaplasia 
Dysplasia 
(LGD,HGD) 
Cancer 
Number of 
patients 
54 36 11 5 2 
N male 45 28 12 4 2 
N female 9 8 0 1 0 
Mean age 62 62 58 62 66 
Mean gastrin 
(pM) 
104 107 82 119 89 
 
Table 2.1 – Breakdown of Barrett’s biopsy sub-groups. All Barrett’s biopsies 
underwent histopathological examination and were organised into various sub-groups 
for data analysis. Biopsies were grouped based on the most severe histological 
diagnosis (from least to most severe: IM, mixed metaplasia, dysplasia and finally 
cancer). 
At the time of endoscopy, if the patient had consented, up to 20 mL of blood was taken 
from the patient with up to 6 Barrett’s pinch biopsies taken for research purposes in 
addition to those required for routine histopathology. The study was approved by the 
Liverpool Local Research Ethics Committee and by the Royal Liverpool and 
Broadgreen University Hospitals NHS Trust or University of Szeged ethics 
committee. 
In both studies (series 1 and 2) patients had the right to withdraw consent at any time, 
upon which all biological samples would be destroyed and any derived data deleted. 
A breakdown of Series 2 patient information and gastrin concentration, grouped by 
histological findings is shown in table 2.1.  
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2.1.2 Human blood samples 
Human venous blood samples for serum were drawn into 7.5 mL Sarstedt S-
Monovette® tubes with clotting activator (Sarstedt, Germany) and stored on ice 
immediately until centrifuged (2500 x g, 10 min, 4°C) and serum separated. Venous 
blood samples for plasma were drawn into 9 mL Sarstedt S-Monovette® (Sarstedt, 
Germany) tubes with K2 EDTA gel at a concentration of 1.6 mg/mL of blood and 
stored on ice immediately until centrifuged (2500 x g, 10 min, 4°C) and plasma 
separated. Serum or plasma were stored frozen at -20°C. 
2.1.3 Human tissue samples 
2.1.3.1 Gastric biopsies 
Enrolled subjects underwent routine upper GI gastroscopy using Olympus Evis Lucera 
H240/H260 endoscopes (Olympus, Southend-on-Sea, UK) including pinch biopsy 
(Single-Use Radial Jaw 4 - Boston Scientific, Hemel Hempstead, UK) of gastric 
mucosa. Biopsies were obtained from the antrum and corpus for histopathological 
assessment and from the corpus (8 biopsies) for subsequent determination of putative 
biomarkers by quantitative polymerase-chain reaction (qPCR).294 
2.1.3.2 Oesophageal biopsies  
Enrolled subjects underwent routine upper GI gastroscopy using the same equipment 
defined in 2.1.3.1, and biopsies were taken of Barrett’s mucosa.  
2.1.3.3 Processing of biopsy material 
Specimens for histology were fixed and stored in 10% neutral-buffered formalin and 
then embedded in paraffin for slide preparation and staining with haematoxylin and 
eosin. Slides were prepared and reported on by the hospital histopathology service in 
the first instance. We subsequently cut additional slides from the paraffin blocks for 
submission to the study pathologist. A single, expert gastrointestinal (GI) pathologist 
(Dr. Laszlo Tiszlavicz, Department of Pathology, University of Szeged, Szeged, 
Hungary) examined all study specimens and prepared standardised reports 
incorporating descriptive diagnoses and scores for the modified Sydney 
classification,107 Padova classification295 and modified Vienna classification.296,294 
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Biopsies for putative biomarker analysis by qPCR were placed immediately in 1 mL 
RNAlater® RNA stabilising buffer (ThermoFisher Scientific, UK) and stored on ice 
before incubation at 4°C for 24 h. Samples were then transferred to a fresh 1 mL of 
RNAlater® and stored at -20°C until use. 
2.2 Radioimmunoassay 
2.2.2 Production of stripped plasma 
Human stripped plasma, to be used as a diluent for human plasma samples and 
standards, was generated from a frozen sample of 500 mL of outdated blood bank 
human plasma (Baxter healthcare, UK) was defrosted and stripped of endogenous 
peptides by incubation with 50 g activated charcoal (Sigma-Aldrich) at 4°C for 30 min 
and then centrifuged (3000 x g, 4°C, 10 min). The supernatant was initially filtered 
through glass fibre filter paper (Whatman GF/B, Sigma-Aldrich) to remove larger 
particulates of charcoal then filtered through Sep-Pak C18 cartridges (Waters, UK) 
that had been primed with 10 mL acetonitrile 50% v/v in distilled water and washed 
with 10mL 0.02 M sodium barbitone buffer pH 8.2 to remove very fine charcoal 
particulates and hydrophobic solutes. The plasma was then aliquoted and stored at -
20°C. 
2.2.3 Determination of circulating gastrin concentration 
Circulating gastrin concentrations were analysed in duplicate by radioimmunoassay 
(RIA). Samples were diluted 1:20 in Veronal buffer (0.02 M sodium barbitone), 
containing 0.5 g/L sodium azide and 0.1% bovine serum albumin (Jackson 
immunoresearch, USA) adjusted to pH 8.4, then incubated in the presence of 100 µL 
[125I]Tyr12 radiolabelled G17 peptide (Lot. No. CP21770, Perkin Elmer customs and 
radiotherapeutics division, Poland) and 100 µL antibody for 48 h at 4°C. Three 
antibodies were assessed for specificity to different gastrin peptides – L2,297 L650 and 
1295298 (all produced by the University of Liverpool, UK) at concentrations of 
1:300,000, 1:40,000 and 1:100,000 respectively. Ultimately antibody L2 was utilised 
for total serum gastrin concentration quantification as a result of validation 
experiments performed in chapter 3. 
Post-incubation, the free radiolabel was separated from antibody-bound by addition of 
100 µL dextran-coated charcoal (5 g activated charcoal, 250 mg dextran (Sigma-
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Aldrich), 250 mg skimmed milk powder (Marvel International Food Logistics Ltd., 
UK)  and 50 mL distilled H2O) and centrifugation at 1976 x g for 10 min at 4°C. The 
supernatant was decanted and the radioactivity of both supernatant and pellet counted 
for 1 min using a Packard Bell RIAstar gamma counter. The ratio of bound to free 
(B/F) label in the sample minus the non-specific binding of the radiolabel was 
calculated.   
Quantification of unknown gastrin concentration was determined by comparing the 
B/F for samples to that of a standard curve included in each assay. Standard curve was 
generated via the serial dilution of synthetic human gastrin peptides covering a final 
concentration range of 0.1-100 pM with the addition of a volume of charcoal-stripped 
human plasma identical to sample volume in unknown tubes to account for any matrix 
effect.  
A number of progastrin derived peptides were used for antibody validation including 
synthetic human non-sulphated G17 (Bachem, UK), G34 (Pharmaceuticals, USA), 
G17-CFP (Pepsyn, University of Liverpool, UK) and G17-Gly (Pepsyn, University of 
Liverpool, UK). A number of different synthetic human non-sulphated G17 peptides 
were also tested to determine which supplier produced the peptide with the greatest 
specificity for our antibodies – suppliers included Bachem, UK; Phoenix 
Pharmaceuticals, USA; Sigma-Aldrich, UK and Anaspec, Belgium. The G17 peptide 
produced by Sigma-Aldrich exhibited the greatest specificity towards our antibodies 
in experiments presented in chapter 3 and thus was the standard used for all patient 
circulating gastrin quantification. 
2.3 Enzyme-linked immunosorbent assays (ELISA) 
2.3.1 H. pylori status  
Serum samples collected for the series 2 cohort were tested for the presence of 
antibodies to H. pylori using a commercial H. pylori ELISA kit (Biohit HealthCare, 
UK) according to manufacturer’s instructions. Serum samples were diluted 1:200 on 
manufacturer’s recommendation using the supplied diluent and vortexed. To the plate 
100 µL of diluent buffer (blank), supplied calibrator solutions and supplied positive 
and negative control samples were added in duplicate as well as patient samples; 
samples were then sealed and incubated for 30 min at 37°C. The solution was then 
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removed by inverting the plate and firmly tapping on absorbent tissue, and the plate 
was washed three times with 350 µL of supplied wash buffer per well, ensuring all 
wash buffer was removed between washes by firmly tapping the inverted plate onto 
absorbent tissue. To each well, 100 µL of conjugated antibody solution was added and 
the plate incubated at 37°C for 30 min before removal, after which the washing step 
was repeated. Next, 100 µL of supplied substrate solution was added to each well and 
incubated in the dark at room temperature for 30 min before 100 µL of provided stop 
solution was added to complete the reaction. The absorbance of the well was then 
measured at 450 nM on a Tecan GENios plate reader using manufacturer supplied 
software. Using a calculation provided by the manufacturer to convert absorbance to 
enzyme immune units (EIU) combined with the calibrator curve run in-plate, sample 
absorbance was transformed with an EIU result of <40 representing a negative result 
and >40 representing positive. 
2.4 Gene expression analysis 
2.4.1 RNA extraction from biopsies 
Biopsies were removed from -20°C storage and emptied onto absorbent paper to 
absorb the RNAlater® in which they had been stored, then placed in 1mL TRIzol® 
reagent (ThermoFisher Scientific) and homogenised for 15-20 sec. Once 
homogenised, 200µL of chloroform (VWR, UK) was added to each sample and the 
samples were vigorously shaken by hand for 15 sec before being allowed to settle for 
5 min at room temperature and centrifuged (15 min, 12,000 x g, 4°C). 
The clear aqueous phase was carefully removed by pipetting into a new Eppendorf 
tube, to which 500 µL of isopropanol was added (Sigma-Aldrich), the tubes were then 
again vigorously shaken by hand for 15 sec settling for 5 min at room temperature. 
Samples were then centrifuged (10 min, 12,000 x g, 4°C), and the supernatants poured 
off and discarded. To the remaining RNA pellet, 500µL of ice-cold 75% ethanol 
(diluted with DEPC treated H2O from VWR) was added before briefly vortexing and 
centrifuging (5 min, 12,000 x g, 4°C). 
The supernatant was again discarded and to the pellet 500 µL ice-cold 100% ethanol 
(VWR) was added before briefly vortexing and centrifuging (5 min, 12,000 x g, 4°C). 
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The supernatant was then discarded and the pellets were allowed to air dry for 30 min 
at room temperature inside a clean PCR hood. 
Once dry, 50 µL DEPC treated DNase/RNase-free distilled water (ThermoFisher 
Scientific) was added to the RNA pellets which were then re-suspended by placing 
onto a shaker for 15 min. The RNA concentration was then quantified using a 
Nanodrop 2000c.  
2.4.2 Reverse transcription of RNA to cDNA 
Based on the RNA concentration, a volume equivalent to 4 µg RNA was reverse 
transcribed. To this, 2 µL of oligo dT primer (Promega, UK) was added and the total 
volume made up to 39 µL with DEPC treated water. The tubes were then briefly 
microfuged and incubated at 70°C for 5 min before being allowed to cool to 40°C. 
Once the tubes had cooled to room temperature 12 µL 5 x AMV buffer (Promega), 5 
µL 12.5 mM DNTPs (Sigma-Aldrich), 1 µL RNAsin (Promega) and 3 µL AMV 
reverse transcriptase (Promega) was added. The tubes were then pulsed using a 
microfuge and incubated at 42°C for 1 h, following which they were incubated at 80°C 
for 5 min before being cooled on ice. The samples were then divided into 4.3 µL 
aliquots and stored at -20°C ready for qPCR. 
2.4.3 Singleplex qPCR of biopsy cDNA 
Real time qPCRs were carried out using an Applied Biosystems AB7500 system with 
manufacturer supplied software (version 1.4.1). Reagents used were PrecisionPLUS 
low ROX mastermix (PrimerDesign, UK) and Taqman™ technology based 
primer/probe pairs. Primers and probes were designed using Primer Express v3.0 to 
be intron spanning and were purchased from Eurogentec (Belgium) and sequences are 
displayed in table 2.2. 
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Primer and probe sequences used were as follows:  
Gene 
Designation 
Sequence 
GAPDH 
Forward GCT CCT CCT GTT CGA CAG TCA 
Reverse ACC TTC CCC ATG GTG TCT GA 
Probe CGT CGC CAG CCG AGC CAC A-FAM 
CGA 
Forward GAT ACC GAG GTG ATG AAA TGC A 
Reverse 
TCC TTC AGT AAA TTC TGA TGT CTC 
AGA 
Probe CCA GCC CCA TGC CTG TCA GCC-FAM 
HDC 
Forward CCC TGA GCC GAC GGT TT 
Reverse GTA CCA TGT CTG ACA TGT GCT TGA 
Probe 
CTC TGT TAA ACT CTG GTT CGT GAT 
TCG GTC C- FAM 
MMP-1 
Forward 
CCA ACA ATT TCA GAG AGT ACA ACT 
TAC AT 
Reverse 
TGA AGG TGT AGC TAG GGT ACA TCA 
AA 
Probe 
TTG CAG CTC ATG AAC TCG GCC ATT C-
FAM 
 
Table 2.2 – Forward, reverse and probe sequences used for qPCR. 
The qPCR mixture was prepared using 4 µL (267 ng) cDNA, 50 µL 2 x mastermix, 3 
µL 10 µM forward primer, 3 µL 10 µM reverse primer, 4 µL 5 µM probe and 36 µL 
of DEPC-treated water to total 100 µL. Then, 25 µL of PCR mixture was pipetted in 
triplicate into clear 96 well plates (Starlab UK), sealed and exposed to a thermal profile 
of one cycle at 50°C for two minutes, one cycle at 95°C for 10 minutes then 40 cycles 
comprising 15 seconds at 95°C and one minute at 60°C with fluorescent data 
collection at the end of the 60°C period. 
Each plate contained a no template control, three quality controls and a standard curve 
in order to quantify mRNA abundance. Results were only considered accurate if the 
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three quality controls were within 15% of expected mean values, PCR amplification 
efficiency was between 90-110% and the correlation coefficient of the standard curve 
was >0.97. 
2.4.4 Multiplex qPCR of biopsy cDNA 
Real time qPCRs were carried out using an Applied Biosystems AB7500 system with 
manufacturer supplied software (version 2.3). Reagents used were PrecisionPLUS low 
ROX mastermix (PrimerDesign, UK) and Taqman™ primer/probe pairs. Primers and 
probes were designed using Primer Express v3.0 to be intron spanning and were 
purchased from Eurogentec (Belgium) except those for COX-2 (ThermoFisher 
scientific, UK), CCK2R and SHH (PrimerDesign). 
 Primer and probe sequences used that feature in method 2.3.3 above were retained for 
multiplex reactions, however the GAPDH probe was reformulated to the same 
sequence with a conjoined TAMRA dye rather than FAM to avoid spectral overlap 
and allow accurate multiplexing with FAM labelled probes. Primer and probe 
sequences used in multiplexed qPCR reactions are shown in table 2.3. 
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Gene 
Designation 
Sequence 
MMP-7 
Forward GGA TGG TAG CAG TCT AGG GAT TAA CT 
Reverse GGA ATG TCC CAT ACC CCA AGA A 
Probe 
CCT GTA TGC TGC AAC TCA TGA ACT TGG 
C-FAM 
COX-2 
Proprietary sequences designed by ThermoFisher, assay 
ID:Hs00153133_m1 
CCK2R 
Forward TGA CTC TGG GAT GCT CCT AGT 
Reverse TGG TCA GAG GTA TGA GAT TAG GC 
Probe 
ACC TCA CAG TGA CCC TTC CCA ATC 
AGC-FAM 
TFF1 
Forward GCC CAG ACA GAG ACG TGT ACA G 
Reverse CGT CGA AAC AGC AGC CCT TA 
Probe CTG GTG TCA CGC CCT CCC AGT GT-FAM 
TFF2 
Forward GGG TCC CCT GGT GTT TCC 
Reverse GAG ACC TCC ATG ACG CAC TGA  
Probe CCC CCT CCC AAA GCA AGA GTC GG-FAM 
SHH 
Forward GAA GAG GAG GCA CCC CAA AA 
Reverse CCT TAA ATC GCT CGG AGT TTC TG 
Probe 
ACC CCT TTA GCC TAC AAG CAG TTT ATC 
CCC A-FAM 
 
Table 2.3 - Forward, reverse and probe sequences used for multiplex qPCR. 
Primers were diluted from a stock concentration of 100 µM to 5 µM with probe diluted 
to 4 µM in DEPC-treated H2O then, using the combined diluted primer/probe pairs, 
the qPCR mixture was prepared using 8 µL (8 ng) cDNA, 40 µL 2 x mastermix, 4 µL 
combined GAPDH probe/primer mix, 4 µL combined target probe/primer mix and 36 
µL of DEPC-treated water to total 92 µL. Then, 20 µL of PCR mixture was pipetted 
in triplicate into clear 96 well plates (Starlab UK), sealed and exposed to a thermal 
profile of one cycle at 95°C for 10 minutes, then 40 cycles comprising 20 seconds at 
94°C, 10 seconds at 59°C and one minute at 60°C with fluorescent data collection at 
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the end of the 60°C period. Each plate also included a no template control to rule out 
possible contamination of PCR reagents. 
2.4.5 Optimisation of multiplex qPCR 
Initially, the same qPCR reaction mixture employed in the singleplex qPCR assay was 
attempted for use in multiplex assays with the volume of DEPC-treated H2O adjusted 
to account for extra primer/probe volume. However, this resulted in uneven 
amplification of cDNA as shown in figure 2.4.5.1. 
 
 
 
 
 
 
 
 
Figure 2.4.5.1 – A comparison of the qPCR amplification curves generated via a 
singleplex qPCR and a multiplexed qPCR reaction before optimisation. 
Amplification curves generated utilising a primer/probe pair for CgA using the same 
starting cDNA samples. Curves generated using the singleplex method (A) show 
smooth logarithmic amplification curves plateauing as expected towards the final few 
cycles of amplification. Curves generated using a multiplexed qPCR reaction mix 
including a GAPDH primer/probe pair similar to that of the singleplex mixture 
however (B) exhibit uneven amplification in some samples towards the end of the 
reaction (circled above). 
This observation cast doubt over the validity of such qPCRs and was suspected to be 
the result of either spectral overlap of the qPCR FAM probes or due to insufficient 
concentrations of reagents within the mastermix to facilitate logarithmic amplification 
of two cDNA sequences. This led to the formulation of new qPCR probes with dyes 
that did not feature a spectral overlap and the altering of reagent volumes in the qPCR 
A B 
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reaction mixture to ensure sufficient reagents were present to carry out the reactions. 
Post optimisation the qPCRs exhibited the expected smooth logarithmic amplification 
curves as shown in figure 2.4.5.2. 
 
Figure 2.4.5.2 – Successful logarithmic amplification of both target sequences 
post-optimisation of multiplex qPCR protocol. As with figure 2.4.5.1B, figure 
2.4.5.2 represents multiplexed GAPDH and CgA qPCRs using real patient biopsy 
cDNA samples. Difference in screenshot appearance derives from different versions 
of Applied Biosystems analysis software used as detailed in sections 2.4.3 and 2.4.4.  
2.4.6 Validation of multiplex qPCR results compared to singleplex 
Considering the necessary changes in qPCR protocol between singleplex and 
multiplex reactions outlined in 2.4.4 and 2.4.5, it was crucial to compare the results of 
both protocols to identify whether comparisons could be made between data acquired 
via each method. Comparing the results obtained using the quality control samples 
included in a set of singleplex and multiplex reactions the mean co-efficient of 
variation between methods was calculated at 1.05% with expected quality control 
values well within the acceptable range for an assay (within the 15% accepted variance 
between assays). 
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2.5 MicroRNA expression analysis 
2.5.1 Extraction of microRNA from serum 
Cell free microRNAs were extracted from human patient samples using the Qiagen™ 
miRNeasy serum/plasma kit (Qiagen, UK) according to the manufacturer’s 
instructions. In brief, 200 µL of serum was added to 1 mL QIAzol lysis reagent 
(Qiagen) aspirated three times and incubated at room temperature for 5 min. To each 
sample, were then added 3.5 µL C. elegans miR-39 miRNA mimic as a reverse 
transcription control at a concentration of 1.6 x 108 copies per µL, then 200 µL 
chloroform. Samples were vortexed at max speed for 15 sec and incubated again at 
room temperature for three min. The samples were then centrifuged for 15 min at 
12,000 x g and 4°C, at which point 600 µL of the top clear layer of each sample was 
carefully removed by pipetting and transferred to a fresh Eppendorf tube, the rest of 
the sample was discarded. To the 600 µL sample, 900 µL of 100% ethanol was added 
and mixed by aspirating three times by pipette; after which the sample was passed 
through a supplied miRNeasy spin column 700 µLs at a time by centrifugation at 8000 
x g for 30 sec at room temperature (two passes required for full sample). The flow 
through was discarded, then 700 µL of supplied buffer RWT was passed through the 
column by centrifugation (8000 x g, 30 sec), again flow through was discarded before 
500 µL of supplied buffer RPE was passed through the column in an identical fashion. 
2.5.2 Reverse transcription of serum extracted microRNA 
Extracted microRNAs were reverse transcribed using the Qiagen™ miScript II RT kit 
(Qiagen) according to the manufacturer’s instructions. In brief, microRNA trapped 
within the columns provided with the extraction kit was eluted into 14 µL DEPC 
treated DNase/RNase-free distilled water and quantified using a Nanodrop 2000c. 
Samples were normalised to 60ng RNA per reverse transcription reaction and the 
following added: 4 µL 5x miScript hiSpec buffer 2 µL 10x miScript Nucleics Mix, 2 
µL miScript reverse transcriptase mix and DEPC-treated H2O to 20 µL.
 
Samples were then briefly mixed before incubation at 37°C for 60 min in a 
thermomixer, at which point the samples were then incubated at 95°C for 5 min. 
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2.5.3 Reverse transcription of biopsy extracted microRNA 
Biopsy-derived miRNAs were reverse transcribed using the same method as in 2.4.2, 
however the original RNA was extracted using method 2.3.1 not 2.4.1 as with serum. 
2.5.4 qPCR of microRNA 
Real time qPCRs were carried out using an Applied Biosystems AB7500 system with 
manufacturer supplied software (version 2.3). Reagents used were Qiagen miScript 
SYBR green mastermix (Qiagen) and Qiagen miScript primer assay primer pairs. 
Primers were designed in-house by Qiagen, UK and as such remain proprietary so 
sequences cannot be listed here. 
The qPCR reactions were prepared using 10 µL (10 ng) miRNA, 50 µL mastermix, 10 
µL miScript assay primer mix and 30 µL DEPC-treated H2O. Then, 25µL of PCR 
mixture was pipetted in triplicate into white 96 well plates (Starlab), sealed and then 
exposed to a thermal profile of one cycle at 95°C for 15 minutes then 40 cycles 
comprising 15 seconds at 94°C, 30 seconds at 55°C and 35 seconds at 70°C with 
fluorescent data collection at the end of the 70°C period. 
Each plate contained two sets of identical miRNA samples – one being analysed for 
endogenous control (RNU6B) abundance and the other for abundance of miRNA of 
interest, so all normalisation was performed using data derived from the same plate, 
mastermix preparation and qPCR run to minimise variance. Each plate also included 
a no template control to rule out possible contamination of PCR reagents. 
2.5.5 Representation of qPCR Data 
All qPCR Data presented within this thesis, unless otherwise stated, have been 
converted to fold difference relative to the relevant control group (controls for series 
1 biopsies, serum gastrin <30 pM for series 2 biopsies/serum) which is depicted as 
having a mean fold change of 1.0 ± SEM. Transformation of raw Ct values to fold 
change was performed by taking the Ct value of the housekeeping gene (GAPDH) and 
subtracting it from the Ct value of the target sequence -producing a ΔCt value. Then 
the mean ΔCt value of the control group was subtracted from the mean ΔCt value of 
the groups with elevated gastrin to produce the ΔΔCt value. The ΔΔCt value was 
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converted to fold change by use of the equation 2^-(ΔΔCt) to account for the 
logarithmic function of qPCR. 
SEM was calculated from raw mean Ct data where variance was expressed as a 
percentage of the original value and scaled to represent the same percentage variation 
when applied to the fold change value. 
2.6 Cell culture 
2.6.1 Recovery of frozen cell lines 
Cells were removed from liquid nitrogen stored in cell culture freezing medium 
(ThermoFisher scientific) and thawed in a water bath at 37°C before plating in 20 mL 
cell-appropriate media in a T-75 culture flask (ThermoFisher scientific). 
2.6.2 Cell maintenance 
AGS (CRL-1739, American Type Culture Collection, USA)  and AGS-GR (AGS cells 
stably transfected with the CCK2R under puromycin selection 72) cells were 
maintained in 10 mL Ham's F-12 medium (Sigma-Aldrich) supplemented with 10% 
FBS (ThermoFisher scientific) and 1% (wt/vol) penicillin/streptomycin (Sigma-
Aldrich) referred to as full media (FM). Serum-free (SF) media consisted of all 
components of FM except 10% FBS. Cells were grown at 37°C in a 5% v/v CO2 
atmosphere with medium changes every 48 h. 
HGT  cells kindly donated by Dr. C. Laboisse (INSERM U239, Hôspital Bichat, Paris, 
France)299 were stably transfected with the CCK2R using the same method as the AGS 
cells referenced above. HGT-GR cells were maintained in 10mL RPMI-1640 medium 
(Sigma-Aldrich) supplemented with 10% FBS and 1% (wt/vol) 
penicillin/streptomycin referred to as full media (FM). Serum-free (SF) media consists 
all components of FM except 10% FBS. Cells were grown at 37°C in a 5% v/v CO2 
atmosphere with medium changes every 48 hours. 
2.6.3 Treatment protocol 
Cells were plated at a density of 5x106 cells per flask in FM and returned to the 
incubator for one day to allow for adherence to the flask. The next day FM was 
removed and cells washed twice with 10 mL sterile PBS (ThermoFisher scientific) 
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before 10 mL SF media was added. To cells being treated with G-17, a volume of 
synthetic human G-17 (Sigma-Aldrich) diluted in 0.05 M ammonium bicarbonate 
buffer (AmBic) (BDH Chemicals, UK) was added equivalent to the final concentration 
required per flask. Cells were then returned to the incubator and incubated for 24 hours 
before removal of media/cells. 
2.6.4 Removal and protein purification of treated media 
After 24 h treatment cell media was removed from the culture flasks via a pipette, 
transferred to a 15 mL Falcon™ centrifuge tube (FisherScientific, UK) and stored 
immediately on ice. Tubes were then centrifuged at 800 x g for 7 min at 4°C before 
the top 9 mL of media was carefully transferred to a new centrifuge tube, discarding 
the last 1 mL as a possible source of cell contamination of media/cell fragments. To 
the new tubes, 25 µL of StrataClean resin (Agilent technologies, UK) was added and 
the tubes vortexed for 1 min to ensure complete mixing before centrifugation (2000 x 
g, 3 min, 4°C). Media were then removed and discarded and the resin pellet 
resuspended in 0.5 mL AmBic buffer, transferred to a clean Eppendorf tube and 
vortexed to ensure thorough washing of the resin. The tube was then centrifuged (2000 
x g, 2 min, 4°C) to re-pellet resin, supernatant removed and the washing process 
repeated three times before a final resuspension of resin in 80 µL AmBic before 
storage at -80°C. 
2.6.5 Preparation of whole cell lysates 
After removal of media cells were washed twice with 10 mL sterile PBS and 100 µL 
RIPA lysis buffer added to the flask (25 mM Tris-HCL pH 7.6, 150mM NaCl, 1% w/v 
NP-40, 1% w/v sodium deoxycholate and 0.1% w/v sodium dodecyl sulphate) 
containing 1% v/v protease inhibitor set III, EDTA-free (Calbiochem, Germany) and 
1% v/v phosphatase inhibitor cocktail set III, EDTA-free (Calbiochem). Cells were 
manually scraped from the flask base in the presence of this buffer and then the cell-
containing buffer solution removed and pipetted into Eppendorf tubes, sonicated for 5 
min and incubated on ice for 30 min. The lysates were then centrifuged (12000 x g, 
4°C, 30 min) and the supernatants stored at -80°C. 
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2.7 Western blots 
2.7.1 Protein quantification 
To ensure equal loading in western blotting, protein concentrations were quantified 
using modified Lowry DC protein assays (Amersham pharmacia, UK). Bovine serum 
albumin (Jackson immunoresearch) was used to establish a standard curve spanning 
0.125-2 µg/mL in triplicate in 96 well Nunc-Immuno Maxisorp™ plates (Sigma-
Aldrich). Similarly, triplicates of 5 µL of sample diluted in RIPA lysis buffer (1:10) 
were added followed by the addition of 25 µL reagent A and 200 µL of reagent B. The 
samples were incubated at room temperature for 30 min and absorbance was measured 
at 450 nm on a Tecan GENios plate reader using manufacturer supplied software. Cell 
media protein concentration was unable to be quantified due to the presence of the 
resin purification beads combined with a very low concentration of secreted protein, 
thus for normalisation an equal volume of cell media sample was used for each 
treatment condition when blotting. 
2.7.2 SDS polyacrylamide gel electrophoresis 
Proteins were resolved by discontinuous sodium dodecyl polyacrylamide gel 
electrophoresis (SDS-PAGE). A separating gel of 4-12% (TIMPS) or 12% (MMPs) 
w/v sodium dodecyl polyacrylamide (ThermoFisher scientific) was inserted into an 
XCell surelock™ mini-cell electrophoresis assembly (ThermoFisher scientific) 
according to the manufacturer’s instructions and immersed in 500 mL 1 x NuPAGE 
MOPs running buffer and  1%  NuPAGE antioxidant (ThermoFisher scientific) with 
2 gels run simultaneously in the same assembly. Each gel was loaded with 5 µL 
MagicMark™ XP western protein standard (ThermoFisher scientific) to provide 
molecular weight standards and to monitor electro-blotting progression. Cell media 
samples were reduced by combining 20 µL cell media with 8 µL NuPAGE LDS 
sample buffer (ThermoFisher scientific), 3.2 µL NuPAGE reducing agent 
(ThermoFisher scientific) and 0.8 µL H2O. Cell lysate samples were reduced by 
combining a volume equivalent to 20 µg total protein with the same reducing mix, 
varying H2O volume to match the total volume of that used for cell media reduction 
(32 µL). Once samples were prepared for reduction they were incubated at 100°C for 
5 min after which 25 µL of each sample was carefully pipetted into the wells of the 
gel. The gel was then run at a constant voltage of 200v for 50 min. 
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2.7.3 Electrophoretic transfer 
Proteins were electrotransferred from the gel onto Amersham Protran 0.45 
nitrocellulose membranes (GE healthcare life sciences, UK) in 1 x NuPage transfer 
buffer and 1% NuPAGE antioxidant (ThermoFisher scientific) at a constant voltage 
of 30 v for 1 h. Membranes were then washed in 10 mL Tris-buffered saline containing 
0.1% Tween 20 (TBS-T) (Sigma-Aldrich) on a rocking platform for 10 min, repeating 
three times. They were then blocked for 1 h with 10 mL blocking buffer (TBS-T 
containing 5% w/v skimmed milk powder). 
2.7.4 Application of antibodies 
Primary antibody was diluted in 5 mL blocking buffer and applied to membranes 
overnight on a rocking platform at 4°C. On the next day, membranes were washed 
three times in TBS-T on a rocking platform and 5 mL horseradish peroxidase (HRP)-
conjugated secondary antibodies were applied, diluted in the same buffer as primary 
antibodies, for 1 h on a rocking platform. Membranes were then washed again three 
times in TBS-T on a rocking platform. Primary and secondary antibody information 
is listed in table 2.4. 
2.7.5 Development of blots 
Membranes were semi-dried with Whatman™ filter paper (GE Healthcare Life 
Sciences) before having a thin layer of Clarity™ ECL substrate (Bio-Rad, UK) 
pipetted on top and then incubated for 5 min protected from light. They were then 
exposed and images captured using a ChemiDoc XRS imaging system (Bio-Rad). 
2.7.6 Densitometry evaluation of band intensity 
The intensity of bands was quantified using BioRad Imagelab software version 5.2.1 
and for cell lysate samples normalisation was performed relative to the intensity of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
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Antibody Species Dilution Supplier Cat. No 
GAPDH Mouse 1:1000 
Meridian life science, 
USA 
H86504M 
TIMP-1 Goat 1:100 R&D Systems, UK AF970 
TIMP-3 Mouse 1:500 R&D Systems, UK MAB973 
MMP-1 Goat 1:500 R&D Systems, UK AF901 
MMP-2 Goat 1:200 R&D Systems, UK AF902 
MMP-3 Rabbit 1:1000 Abcam, UK AB52915 
MMP-7 Rabbit 1:1000 
University of 
Liverpool, UK 
L522(G) 
Anti-mouse Goat 1:10,000 Sigma-Aldrich, UK A4416 
Anti-goat Rabbit 1:10,000 Sigma-Aldrich, UK A5420 
Anti-rabbit Goat 1:10,000 ThermoScientific, UK 31460 
 
Table 2.4 - Primary and secondary antibodies, their dilutions, suppliers and 
catalogue numbers used for western blot analysis. 
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Chapter 3 
Validation of Circulating Gastrin Assay 
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3.1 Introduction 
As detailed in section 1.3.1, multiple biologically active peptides can be produced 
from the gastrin gene, including the C-terminally amidated gastrins, G17 and G34, 
along with N-terminally extended forms G17-Gly, G34-Gly and G17-CFP.58 
Currently the most well understood forms of gastrin, in relation to biological activity 
on tissues, are the amidated gastrins and thus the first step in investigating potential 
biomarkers of gastrin stimulation on tissues is the availability of an accurate and 
specific assay of circulating gastrin peptides. To this end, the present study made use 
of a gastrin radioimmunoassay since (a) there are doubts concerning the accuracy of 
commercially available ELISAs,300 (b) the laboratory had previous experience with 
the technique,50 and (c) a range of specific antibodies to gastrin were available from 
previous studies. Importantly, however, these antibodies had been in storage for 
approximately 40 years and, in spite of changes in RIA technology, had not been 
validated for many years. The re-validation of the gastrin RIA was therefore 
considered essential. 
It is known that H. pylori infection,301 PPI usage302 and age302 can influence circulating 
gastrin concentration.303 It was therefore considered important to take this into account 
in designing the study. Two series of samples were available. The first (i.e. series 1) 
had been archived some years previously and the relevant clinical data was available, 
including histological reports. The second (i.e. series 2) was collected during this study 
and in this cohort all patients were already being treated with PPIs. H. pylori status for 
series 1 patients had already been performed and data were available whereas for series 
2 patients current or previous infection by H. pylori bacteria was determined by 
serology during the course of the study.  
Samples for series 2 were collected across two study centres – the Royal Liverpool 
University Hospital (RLUH) and the Gastroenterology Unit of the University of 
Szeged (UoSz), so the development of a gastrin and patient profile for both cohorts is 
crucial in identifying any regional differences (change in rates of H. pylori prevalence 
for example) that may skew the data and prevent them from being considered a 
singular cohort. 
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3.1.1 Objectives 
Specific objectives of this chapter were: 
 To validate the gastrin RIA. 
 Using this assay, determine the circulating gastrin profile in patients of series 
1 and 2. 
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3.2 Materials and methods 
3.2.1 Determination of circulating gastrin concentration 
3.2.1.1 Validation of antibodies  
Three different gastrin antibodies were assessed for specificity to gastrin peptides in 
radioimmunoassay (RIA) – namely antibodies L2,297 L650 and 1295298  at dilutions of 
1:300,000, 1:40,000 and 1:100,000 respectively. 
3.2.1.2 Radioimmunoassay 
Circulating gastrin concentration was quantified by RIA according to the protocol 
outlined in section 2.2.3, by comparing the ratio of free/bound radiolabel in patient 
samples to a 10 point standard curve generated using synthetic G17. A range of gastrin 
peptides (figure 3.2.1) were studied to determine antibody specificity. 
G34 - QLGPQGPPHLVADPSKKQGPWLEEEEEAYGWMDF-NH2                                                                                                                                                                      
                                 G17 - QGPWLEEEEEAYGWMDF-NH2 
                           G17-Gly - QGPWLEEEEEAYGWMDFG 
                                    G17-CFP - QGPWLEEEEEAYGWMDFGRRSAEDEN 
Figure 3.2.1 – Amino acid sequences of gastrin peptides used for antibody 
validation.304 
3.2.2 Production of stripped plasma 
Human stripped plasma, to be used as a suitable diluent matrix for human samples 
and standard curve standards, was generated using the protocol detailed in methods 
section 2.2.2. 
3.2.3 Determination of H. pylori infection status 
Infection status was determined using a Biohit H. pylori IgG ELISA kit via the 
protocol detailed in methods section 2.3.1.  
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3.3 Results 
3.3.1 Specificity of gastrin antibodies 
3.3.1.1 Antibody L2 is specific for C-terminally amidated gastrins 
To identify the specificity of antibody L2, concentration curves were established using 
G34, G17, G17-Gly and G17-CFP synthetic peptides. Within a concentration range of 
0.1-100 pM antibody L2 only exhibited specificity for the major biologically active 
forms of gastrin (G17 and G34); inhibition of antibody binding of C-terminally 
extended G-17 only occurred at a concentration of >1 nM (figure 3.3.1).  
3.3.1.2 Antibody L6 is specific for amidated G17 
To identify the specificity of antibody L6, concentration curves were established using 
G34, G17, G17-Gly and G17-CFP synthetic peptides. Within a concentration range of 
0.1-100 pM antibody L6 only exhibited specificity for amidated G-17; inhibition of 
antibody binding of G34, or of C-terminally extended G-17 only occurred at a 
concentration of >0.1 - 1 nM (figure 3.3.2).  
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Figure 3.3.1 – Antibody L2 is specific for C-terminally amidated gastrins. 
Antibody L2 exhibited specificity towards amidated G-17 and G-34 (0.1-100 pM). 
Inhibition of binding due to C-terminally extended gastrin only occurred at 
concentrations >1 nM. N=1. 
 
 
 
 
 
 
 
 
 
Figure 3.3.2 – Antibody L6 is specific for amidated G17. Antibody L6 exhibited 
specificity towards amidated G-17 (0.1-100 pM). Inhibition of binding due to C-or N-
terminally extended, gastrin forms only occurred at a concentration >1 nM. N=1. 
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3.3.1.3 Antibody 1295 is specific for the N-terminus of G17  
To identify the specificity of antibody 1295, concentration curves were established 
using G34, G17, G17-Gly and G17-CFP peptides. Within a concentration range of 
0.1-100 pM antibody 1295 exhibited specificity for only G17 and its C-terminally 
extended forms -Gly and -CFP (figure 3.3.3).  
3.3.1.4 Summary of antibody specificity 
Comparing the affinity of our three gastrin antibodies, normalised to 1.0 for G17: L2 
was specific for G17 and G34, L6 was specific for G17 and 1295 exhibited specificity 
for G17, G17-Gly and G17-CFP (table 3.3.1). 
 
 
 
 
 
 
 
Figure 3.3.3 – Antibody 1295 is specific for the N-terminus of G17. Antibody 1295 
exhibited specificity towards G17 and its C-terminal extended forms, but not G34, 
across the range 0.1-100 pM. N=1. 
 
 L2 1295 L6 
G17 1.0 1.0 1.0 
G34 0.86 <0.01 <0.01 
G17-Gly <0.01 0.19 <0.01 
G17-CFP <0.01 0.12 <0.01 
 
Table 3.3.1 – Relative potency of four peptides for three antibodies. The data are 
normalised to 1.0 based on the IC50 for G17 binding compared to other gastrin 
peptides for each antibody. 
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3.3.2 Effect of matrix on antibody binding 
3.3.2.1 Human plasma does not influence binding of antibody L2 
To ensure that the matrix of human samples (i.e. serum or plasma) does not non-
specifically influence the affinity of antibody L2 for G17, standard curves were 
compared after preparation in assay diluent versus diluent containing human plasma 
stripped of endogenous gastrin. The introduction of stripped plasma caused a 
negligible change in sensitivity of antibody L2 to G17 over the 0.1-100 pM 
concentration range (figure 3.3.4). 
3.3.2.2 Human plasma reduces sensitivity of antibody L6 
To ensure that the matrix of human samples does not non-specifically influence the 
affinity of antibody L6 for G17, standard curves were compared after preparation in 
assay diluent versus diluent containing human plasma stripped of endogenous gastrin.  
The introduction of stripped plasma caused a decrease in antibody affinity shown by 
a slight shift to the right of the standard curve over the 0.1-100 pM concentration range 
(figure 3.3.5).  
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Figure 3.3.4 – Human plasma does not significantly influence binding of antibody 
L2. The introduction of stripped plasma caused a negligible change in sensitivity of 
antibody L2 to G17 over the 0.1-100 pM concentration range. Mean ±SEM, N=3. 
 
 
 
 
 
 
 
Figure 3.3.5 – Human plasma reduces sensitivity of antibody L6. When stripped 
human plasma was included in the G17 standard curve (0.1-100 pM) the curve was 
slightly shifted to the right. N=2. 
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3.3.2.3 Human plasma reduces sensitivity of antibody 1295 
To ensure that human plasma does not non-specifically influence the affinity of 
antibody 1295 for G17, standard curves were compared after preparation in assay 
diluent versus diluent containing human plasma stripped of endogenous gastrin.  
The introduction of stripped plasma caused a decrease in antibody affinity shown by 
a shifting to the right of the standard curve over the 0.1-100 pM concentration range 
(figure 3.3.6). 
3.3.2.4 Summary of matrix effects 
Thus, human plasma had a non-specific inhibited binding of antibodies L6 and 1295 
to G17 while with antibody L2 there was a slight increase in binding in the presence 
of matrix (table 3.3.2).  
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Figure 3.3.6 – Testing the effect of human plasma on binding of antibody 1295 to 
gastrin-17. Antibody 1295 exhibited a slight decrease in sensitivity towards G17 
when human plasma was included across the 10-100 pM standard curve range, with a 
decrease in sensitivity across the 0.1-5 pM range. N=1. 
 
 
 
Table 3.3.2 – A comparison of the relative affinity of each antibody for G17 in the 
presence of stripped human plasma. Adding stripped plasma to the standard curve 
caused a loss in sensitivity (i.e. a shift to the right of the curve) increasing the IC50 
value for antibodies L6 and 1295. Conversely, adding stripped plasma to an L2 
standard curve caused an increase in sensitivity of the antibody for G17. Normalised 
to 1.0 at maximal inhibition of antibody binding. 
 
 
 
  L2 1295 L6 
IC50 G17 (pM) 1.4 5.51 3.36 
Normalised IC50 G17 1.0 1.0 1.0 
IC50 G17 + Stripped Plasma 
(pM) 
1.2 6.05 4.2 
Normalised IC50 G17 + stripped 
plasma 
0.85 1.10 1.25  
G a s tr in  C o n c e n tra tio n  (p M )
N
o
r
m
a
li
s
e
d
 B
/F
0 .1 1 1 0 1 0 0
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
G 17
G 1 7  +  S tr ip p e d  P la s m a
80 
 
3.3.3 Selection of G17 standards 
As part of validating the gastrin radioimmunoassay, three commercially available G17 
peptides were compared to identify which produced the most sensitive concentration 
curve for quantification.  
3.3.3.1 Sigma-marketed G17 exhibits greatest sensitivity to antibody L2 
Despite all peptides producing a near identical concentration curve, the Sigma-
produced G17 peptide exhibited slightly higher sensitivity at the lowest gastrin 
concentrations tested. The Sigma-produced peptide was thus selected for 
quantification of all patient gastrin concentrations moving forward (figure 3.3.7). 
3.3.3.2 Assay variability 
Inter-assay variation was calculated based on repeat measurements of the same patient 
sample across multiple L2 assays, intra-assay variation was calculated using six 
patient samples from series 1 within the same assay and the limit of quantification was 
determined by reading the smallest potential gastrin quantity from the standard curve 
before it plateaued and become unreliable for quantification, and then multiplying by 
the dilution factor for patient samples (table 3.3.3). Non-specific binding of antibody 
to radiolabel was accounted for in the binding ratio calculation, however was below 
10% for all assays and typically less than 5%. 
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Figure 3.3.7 – Three commercially available G17 standards exhibited similar 
activity with antibody L2. Synthetic human G17 was sourced from three 
manufacturers. The concentration curves were virtually identical. N=1. 
 
 
 
 Antibody L2 
Inter-assay variation 6.3% 
Intra-assay variation 15.7% 
Limit of detection 2 pM 
 
Table 3.3.3 – Precision of L2 gastrin radioimmunoassay. Measures of inter- and 
intra- assay variation for the L2 gastrin radioimmunoassay along with the average limit 
of detection for patient samples. 
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3.3.4 Patient groups analysed for study 
Throughout this study two sets of patient groups were analysed. Series 1 refers to a 
number of control and Barrett’s patients selected from an archive of over 1300 patient 
samples for which gastric biopsies and matching serum samples were available.  
Within the archive there were a total of 922 patient samples exhibiting no GI pathology 
suitable for use as controls. Of these, serum and cDNA from biopsy were available for 
114 patients from which a subset of 85 samples was selected based on previously 
determined qPCR data to form a control group. 
In the whole archive there were 55 patients with Barrett’s oesophagus, three of whom 
also had oesophageal cancer and so were omitted creating a 52 patient Barrett’s cohort. 
Series 2 refers to a group of Barrett’s patients for which Barrett’s mucosa biopsies and 
matching serum samples were obtained. 
3.3.5 Gastrin profile of series 1 
3.3.5.1 Comparison between series 1 control and Barrett’s patients 
Across control and Barrett’s patients from the series 1 data set average age was ± 10 
years, with a higher proportion in the Barrett’s cohort being male than in the control 
cohort. Fasting circulating gastrin concentration in the Barrett’s group was 
approximately two-fold higher than in the control group (table 3.3.4). 
 
Individual data points displayed together as a box plot with central bars indicating the 
median, upper and lower bars representing the 75th and 25th percentiles respectively 
and whiskers indicating range (fig 3.3.8) exhibited a broadly similar overall range of 
circulating gastrin concentrations with a tendency to fewer very low gastrin 
concentrations in the Barrett’s group and proportionately more in the range 30 -100 
pM. 
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Table 3.3.4 – Comparison between series 1 control and Barrett’s patients. Across  
all control and Barrett’s patients from series 1, average age was ± 10 years, with a 
higher proportion in the Barrett’s cohort being male than in the control cohort. 
Circulating gastrin concentration within the Barrett’s cohort was significantly higher 
than that of the control group. Values represented as mean ± SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.8 – Gastrin concentration is significantly higher in series 1 Barrett’s 
Patients. There was significantly higher circulating gastrin concentration in Barrett’s 
patient’s compared with controls. Unpaired t-test t-with Welch’s correction p<0.05. 
 
 
 
 
  
Mean 
Age 
Circulating 
Gastrin 
Concentration 
(pM) 
Male 
(N)  
Female 
(N) 
H. pylori 
positive 
(N)  
Control 54 ± 2.0 42.2 ± 5.6 36 50 0 
Barrett’s 64 ± 1.6 86.9 ± 15.4 31 22 7 
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3.3.5.2 Gastrin concentration in series 1 patients is significantly higher with PPI 
usage 
Circulating gastrin concentration in both control and Barrett’s patients was 
significantly higher in patients treated with PPIs compared with those who were not. 
However Barrett’s patients on PPIs exhibited gastrin concentrations significantly 
higher than control patients on PPIs (fig 3.3.9).  
 
 
 
 
 
 
 
 
 
Figure 3.3.9 – Gastrin concentration in series 1 patients is significantly increased 
by PPI usage. Circulating gastrin concentration in control and Barrett’s patients was 
significantly higher when treated with PPIs compared with patients not on PPIs. Mean 
± SEM, p<0.05, one-way ANOVA and t-test with Welch’s correction. 
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3.3.5.3 Gastrin concentration is significantly higher in series 1 Barrett’s patients 
when matched for age, sex and H. pylori status 
In view of the differences between controls and Barrett’s patient groups, in particular 
the fact that there were seven H. pylori positive patients in the Barrett’s cohort and 
none in the control cohort, it was considered important to repeat the comparison on 
groups matched for age, sex and H. pylori status to eliminate them as potentially 
skewing factors. A new matched control group was formed, with the majority of 
samples derived from the previous 86 patient control group where appropriate and 
from the remaining 922 control samples if matches could not be found. For gastrin 
concentration comparison between groups, PPI status was ignored however the 
number of patients taking PPIs was equal in both groups. Mirroring the data shown in 
figure 3.3.9, mean circulating gastrin concentration remained significantly higher in 
the Barrett’s patient group compared with the age, sex and H. pylori matched control 
group. The Barrett’s patient group also exhibited a greater range of gastrin 
concentrations than patients in the control group (fig 3.3.10).  
 
 
 
 
 
 
 
 
 
Figure 3.3.10 – Gastrin concentration is significantly higher in series 1 Barrett’s 
patients matched for age, sex and H. pylori status. Average circulating gastrin 
concentration in Barrett’s patients is significantly higher when compared with controls 
matched for age, sex and H. pylori status. Central bars indicate median, upper and 
lower represent 75th and 25th percentiles respectively and whiskers indicate range. 
Analysis by unpaired t-test with Welch’s correction, p<0.05.  
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3.3.5.4 Gastrin concentration in series 1 patients is significantly increased with PPI 
usage when matched for age, sex and H. pylori status 
Even when the most common factors with the potential to influence circulating gastrin 
concentration were removed by rigorously matching the control group, circulating 
gastrin concentration in Barrett’s patients remained significantly higher in those 
treated with PPIs compared with either control or Barrett’s patients not treated with 
PPIs (fig 3.3.11 and table 3.3.5). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.11 – Gastrin concentration is significantly increased in series 1 
Barrett’s patients with PPI use when matched for age, sex and H. pylori status. 
There were significantly higher circulating gastrin concentrations in Barrett’s patients 
on PPIs compared with either controls or Barrett’s patients not on PPIs. Mean ± SEM, 
p<0.05, one-way ANOVA. 
 
 
Table 3.3.5 – Comparison between series 1 control and Barrett’s patients matched 
for age, sex and H. pylori status.  
 
 
  Mean Age 
Mean Circulating Gastrin 
Concentration (pM) 
Male N 
number 
Female N 
Number 
Control 64 ± 1.6 50.7  ± 5.5 31 22 
Barrett’s 64 ± 1.6 86.9 ± 15.4 31 22 
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3.3.6 Gastrin profile of series 2 patients 
3.3.6.1 Circulating gastrin concentration in series 2 patients was similar across 
research centres 
Barrett’s biopsies composing series 2 were collected from two separate hospitals, the 
Royal Liverpool University hospital and the Gastroenterology Unit of the University 
of Szeged, Hungary. Circulating gastrin concentration was compared between 
institutions to ensure samples were comparable between patient populations. No 
significant difference was identified between samples collected in Liverpool or 
Hungary (fig 3.3.12 and table 3.3.6). 
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Figure 3.3.12 – Circulating gastrin concentration in series 2 patients was similar 
across research centres. Series 2 samples were collected from the Royal Liverpool 
University hospital and the Gastroenterology Unit of the University of Szeged, 
Hungary. There was no significant difference between samples collected in either 
location. Central bars indicate median, upper and lower represent 75th and 25th 
percentiles respectively and whiskers indicate range. Analysis by unpaired t-test, 
p<0.05. 
 
Table 3.3.6 – Comparison between series 2 RLUH and UoSz recruited patients. 
Across both cohorts, average age was ± 10 years, with a higher proportion of patients 
in both cohorts being male. Circulating gastrin concentration across cohorts exhibited 
no significant difference. 
 
 
 
 
 
 
  Mean Age 
Mean Circulating Gastrin 
Concentration (pM) 
Male N 
number 
Female N 
Number 
RLUH 68 ± 1.5 102 ± 18.9 19 10 
UoSz 58 ± 2.4 99 ± 18.8 31 1 
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3.3.6.2 Circulating gastrin in series 2 Barrett’s patients spans the dynamic 
physiological range 
In order to interpret the circulating gastrin concentrations in a physiological context, 
a dose-response curve for gastrin-stimulated acid secretion was adapted from Blair et. 
al 1987.305 Individual circulating gastrin concentrations are shown along the x-axis for 
all series 2 Barrett’s patients. Note that they cover the range below, within and above 
the dynamic range for stimulation of acid secretion (fig 3.3.13). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.13 – Circulating gastrin in series 2 Barrett’s patients spans the dynamic 
physiological range. A dose-response curve for gastrin-stimulated acid secretion was 
adapted from Blair et. al 1987.305 Individual circulating gastrin concentrations are 
shown along the x-axis. Note that they cover the range below (N=18), within (N=22) 
and above (N=21) the dynamic range for stimulation of acid secretion.  
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3.3.6.3 Distribution of circulating gastrin concentration of series 2 patients 
On the basis of the data from figure 3.3.13, it was considered reasonable to divide 
subjects into three groups based on circulating gastrin concentrations matched to 
unstimulated acid secretion (<30 pM), within the dynamic range (between 30-100 pM) 
and supra-maximal (>100 pM).  
Approximately similar numbers of patients had a fasting gastrin concentration that was 
within the dynamic range for acid secretion (N=22), compared with supra-maximal 
for acid secretion (N=21) or below the range for stimulation of acid secretion (N=18) 
(fig 3.3.14). 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.14 – Distribution of circulating gastrin concentration of series 2 
patients. Using the data from figure 3.3.13, the circulating gastrin concentrations of 
series 2 patients were linked to level of gastric acid secretion and separated into three 
groups based on below the threshold for stimulation of acid secretion (<30 pM), within 
the dynamic range (between 30-100 pM) or supra-maximal for acid secretion (>100 
pM). 
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3.3.7 H. pylori infection status of series 2 patients 
With the aim of ensuring patient samples obtained from both institutions were 
comparable, H. pylori status was determined by ELISA using patient serum samples. 
Across both RLUH and UoSz obtained biopsies, the majority of samples tested 
negative for H. pylori antigen.  
H. pylori positive samples made up 21% of RLUH samples and 23% of UoSz samples, 
showing no significant difference in infection rate between samples collected from 
either institutions (fig 3.3.15). Average circulating gastrin concentration in H. pylori 
negative patients when pooling both research centres was 12 pM, with H. pylori 
positive patients exhibiting a gastrin concentration of 86 pM. 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.15 – H. pylori infection status of Series 2 patients. Across both RLUH 
and UoSz obtained biopsies, the majority of samples tested negative for H. pylori 
antigen in serum. H. pylori positive samples made up 21% of RLUH samples and 23% 
of UoSz samples, exhibiting no significant difference in infection rates between 
samples collected from either institution. 
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3.4 Discussion 
Currently, the majority of gastrin diagnostic measurements in blood (serum or plasma) 
are performed using commercially available ELISA kits.306 Our decision to use RIA 
instead was influenced by two factors: the availability of a long term in-house 
technique and a recent review of all commercially available options, both RIA and 
ELISA, which identified inaccurate measurements in over half of commercial ELISA 
kits.300 
 
The novel aspect of this work is the re-validation of three >40-year old antibodies. 
There are important similarities and differences between the present and previous 
findings.50,297 Overall, the specificity of three antibodies was as expected. Antibody 
L2 exhibited specificity for the C-terminal of both G17 and G34 but not any N-
terminally extended peptides; L6 for intact G17, and 1295 for the N-terminus of G17. 
However, there were important differences between antibodies in the effects of matrix 
that meant the sensitivity of assays using L6 and 1295 were decreased, while that of 
L2 was slightly increased. At the outset it was hoped that the availability of three 
different antibodies would make it possible to establish the peptide profile of 
circulating gastrin forms in Barrett’s disease. In the event, the low sensitivity of L6 
and 1295 in serum meant that this was not possible. The present study was therefore 
based on antibody L2; it is worth stressing that the specificity of L2 corresponds to 
that of most other antibodies used for routine determination of circulating gastrin 
concentration. It seems likely that difference in matrix effects in the present study 
compared with previous ones is attributable to changes in assay technique and in 
particular the radiolabelled peptide employed and the method of separation of 
antibody bound and free label.  
 
There has been renewed concern recently surrounding the reliable validation of 
antibodies used in assays. In particularly the basic characterisation of the specificity 
and sensitivity of commercial and in-house developed antibodies is performed less 
frequently than it should be.307 This has led to what some have called a “reproducibility 
crisis” in fields depending on antibody-based research methods. One result has been 
researchers wasting time and money only to discover that the antibodies they used 
were inappropriate under their particular experimental conditions.308 
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Current guidelines issued by the Food and Drug Administration (FDA) in America for 
formally validating a ligand binding assay, state that researchers must demonstrate that 
antibodies are selective, specific and reproducible within the context in which they are 
used.309,310 More specifically, there are strict standards governing selectivity, accuracy 
and precision, calibration curve, sensitivity, reproducibility and stability of reagents 
used. 
 
Selectivity of our antibodies was determined by using a panel of gastrin peptides of 
different lengths including samples of peptides from different suppliers, the effect of 
matrix on antibody binding versus standard assay diluent and the non-specific binding 
of antibody to radiolabel was taken into account into the binding ratio calculation and 
was less than 10% in all assays and generally about 5%. 
Mean coefficient of variation of our L2 assay was determined by using six runs of 
multiple patient samples from series 1 within the same assay and was calculated as 
15.7%, well within the 20% specified within the guidelines.310 Mean inter-assay 
precision, utilising the same patient sample repeated across each L2 assay (N=7), had 
a co-efficient of variation of 6.3%, again well within guidelines for assay validation. 
The inter-assay variability is also a measure of the reproducibility of the assay, as it 
covers multiple experimental runs on different days, with different batches of 
radiolabel. 
 
The calibration curve used for gastrin quantification exceeds the specifications laid 
out in FDA guidelines, namely it is a 10-point curve (recommended 5) fitted with a 5-
parameter logarithmic sigmoidal curve prepared within an appropriate matrix 
(stripped plasma). The lower and upper limits of quantification varied slightly between 
calibration curves present in each assay, however they can be broadly determined to 
be a dilution-corrected gastrin concentration of 2 and 400 pM respectively. This also 
covers the sensitivity of the assay, as the smallest concentration readable would be 2 
pM in a patient sample. 
 
Stability of the assay was taken into account again across multiple assays utilising 
different batches of radiolabel tested between freeze-thaw cycles of both label and 
peptide and tested between freeze-thaw cycles of QC patient sample tested in each 
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run. The buffer reagents were made up fresh each run and the antibody was kept at 
4°C so was not at risk of freeze-thaw related degradation. 
 
What my work shows is that our L2-based gastrin assay for circulating gastrin has 
been rigorously tested to FDA standards and rather than being a liability, the antibody 
is well characterised, validated and may be utilised for decades for accurate 
quantification of gastrin. Performing this validation work prior to the rest of the work 
presented in this thesis was considered vital as all biomarker analyses were performed 
in relation to gastrin concentration, requiring a rigorous quantification of gastrin 
concentration for each patient to avoid a “reproducibility crisis”. 
 
Uniquely, our work aims to link circulating gastrin concentration within samples to 
the classically known physiological output of gastrin, gastric acid secretion from 
parietal cells. Many published research articles work with circulating gastrin 
concentration and its relationships to disease conditions such as neuroendocrine 
tumour formation311 and gastric cancer development116, but very few consider gastrin 
concentration in the context of the dynamic range for acid secretion.74 
 
The data shows that within our initial series 1 control and Barrett’s unmatched 
patients, treatment with PPIs was associated with a significantly higher circulating 
gastrin concentration in both groups, as expected. Significantly higher circulating 
gastrin concentration with PPI treatment remained in both groups even when using a 
control group matched for other variables known to influence circulating gastrin 
concentration such as H. pylori infection status,301 age,302 and sex312 effectively 
accounting for their contribution to gastrin concentration in the analysis. Analysis of 
the mean circulating gastrin concentration in series 2 patients between H. pylori 
positive and negative samples revealed higher gastrin concentration in H. pylori 
positive samples, as expected from previously published work in the field, and 
highlights the importance of accounting for H. pylori status in our series 1 analysis. 
 
We observed a trend towards higher circulating gastrin concentration in Barrett’s 
patients without PPI treatment compared to controls without PPI treatment (significant 
in the unmatched group) and a greater increase in circulating gastrin in Barrett’s 
patients when treated with PPIs compared to the PPI induced increase in control 
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patients. Higher circulating gastrin concentration in Barrett’s patients with PPI 
treatment compared to controls is in line with currently published research on long-
term PPI treatment,74 however many of those patients exhibited some degree of ECL 
cell hyperplasia which our Barrett’s gastric samples did not. Currently, gastric 
research in Barrett’s patients remains overlooked and no research has been published 
to explain why, in Barrett’s patients without ECL cell hyperplasia, circulating gastrin 
concentration without PPI treatment would be higher than in controls or why Barrett’s 
patients would respond with a greater increase in gastrin concentration to PPI 
treatment than controls. This represents a novel finding in our research and offers 
potential for further study. 
 
The main findings of this results chapter are that a) all of our tested gastrin antibodies 
are still specific even after approximately 40 years of storage, b) antibody L2 proved 
the best candidate for total circulating gastrin assay validation, which was performed 
to FDA standards, c) the gastrin profiles for both control and Barrett’s patients are 
similar with respect to changes in response to PPI treatment, however Barrett’s 
patients consistently exhibit higher circulating gastrin concentration than control 
patients regardless of PPI status. 
  
96 
 
 
 
 
 
 
 
 
97 
 
Chapter 4 
Putative biomarker expression in gastric biopsies 
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4.1 Introduction 
To begin the identification of putative biomarkers of gastrin activity, initial work 
sought to define the response of putative biomarkers in the best characterised targets 
of gastrin – the ECL and parietal cells of the stomach - in control and Barrett’s subjects 
and to determine their response to PPI treatment and associated hypergastrinaemia.194 
Putative ECL cell markers of gastrin activity, HDC and CgA, have previously been 
employed as biomarkers of the direct action of gastrin on ECL cells in patients and so 
represent the best candidates for use in tracking any differences in response between 
the control and Barrett’s stomach with PPI treatment and associated 
hypergastrinaemia.185, 293 Included in our analysis of gene expression within the two 
patient groups was quantification of the abundance of CCK2R transcripts to determine 
whether there might be changes in sensitivity to circulating gastrin between patient 
groups and PPI treatment status. In addition to putative biomarkers of ECL cell 
activity, there is evidence that gastrin regulates the expression of enzymes responsible 
for tissue remodelling, specifically MMP-1,211 which potentially relates to changes in 
the cellular microenvironment conducive to cancer development and thus could have 
potential relevance as an indirect putative marker of gastrin regulated transformative 
responses. 
Somewhat surprisingly, much still remains to be discovered about how common 
treatments such as PPI therapy influence the expression of HDC, CgA, CCK2R or 
MMP-1 in the normal stomach and the stomach of Barrett’s patients. As identified in 
the previous chapter, in our patient samples there was a difference in the magnitude of 
response in circulating gastrin concentration to PPI treatment in Barrett’s patients 
when compared to matched controls. This implies that gastric cellular responses in 
Barrett’s patients may differ with PPI treatment compared to normal subjects as may 
the transcript abundance of gastrin-regulated putative biomarkers. Thus, the first 
objective of the work in this chapter was to characterise the expression of putative 
gastrin-regulated biomarkers in the stomach of control and Barrett’s patients and their 
response to treatment with PPIs. 
Preneoplastic changes in the stomach, notably those that include glandular atrophy, 
are associated with increased circulating gastrin concentrations.313 A second objective 
of the work in this chapter was therefore to compare the abundance of putative gastrin-
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regulated transcripts in control subjects and patients with defined preneoplastic 
changes in gastric architecture as detailed in figure 4.1.1. 
  
 
 
 
 
 
 
 
 
Figure 4.1.1 –Micrographs of gastric biopsies stained with a Haematoxylin and 
eosin stain. Panel A depicts an example of normal gastric mucosa, panel B depicts 
gastric mucosa with atrophy leading to extensive loss of glands and panel C depicts 
intestinal metaplasia of the gastric mucosa.314 
4.1.1 Objectives 
Specific objectives of this chapter were: 
 To determine how putative biomarkers of gastrin responsiveness change in 
relation to circulating gastrin in control and Barrett’s patient gastric biopsies. 
 To compare the biomarker expression profile of control and Barrett’s patients 
with and without PPI treatment. 
 To characterise the expression of putative gastrin-regulated biomarkers in 
gastric biopsies exhibiting preneoplastic morphology. 
  
A B C 
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4.2 Materials and methods 
Dr Andy Moore and Dr Sentil Murugesan had previously recruited patients, obtained 
patient information, blood samples and biopsies for the patients in series 1. Gastric 
biopsies were retrieved from -20°C long-term storage and RNA was extracted and 
converted to cDNA via the protocols detailed in section 2.4. For some samples, 
archived cDNA had already been prepared by Dr Islay Steele for previous studies and 
in these cases this material was used. If biopsies had previously had RNA extracted 
for previous studies but no cDNA remained, original RNA (again prepared by Dr Islay 
Steele) was retrieved from -80°C long-term storage and reverse transcribed. 
 
Biopsies analysed in the first part of this chapter were processed via qPCR using the 
singleplex method outlined in methods section 2.4.3 using the primer/probe sets 
described within that section. 
 
Biopsies analysed in the second part of this chapter were processed via qPCR using 
the multiplex method outlined in methods section 2.4.4 using the primer/probe sets 
referenced in both section 2.4.3 and 2.4.4. 
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4.3 Results 
4.3.1 Putative biomarker expression in normal stomach 
4.3.1.1 Relative CgA abundance is significantly higher with PPI treatment 
Relative abundance of CgA mRNA, normalised to GAPDH mRNA abundance, in 
series 1 gastric biopsies was significantly higher in both control and Barrett’s subjects 
treated with PPIs compared with untreated. However, control patients exhibited a 
greater increase in CgA abundance with PPI treatment than Barrett’s (3.78-fold 
increase vs. 2.08-fold) (fig 4.3.1A). 
When control and Barrett’s patients were matched based on their age, sex and H. pylori 
status, relative CgA abundance remained significantly higher in both groups with PPI 
treatment (fig 4.3.1B). 
Comparing the relationship between relative CgA abundance and circulating gastrin 
concentration in combined control and Barrett’s gastric biopsies, a Spearman’s rank 
correlation identified a significant, relationship between the two, r=0.44 df=137 
p<0.05 (fig 4.3.1C). When analysed individually, a significant relationship between 
circulating gastrin and CgA abundance remained in both groups (control r=0.49 df=84 
p<0.05; Barrett’s r=0.31 df=51 p<0.05). 
In order to determine whether the sensitivity to circulating gastrin in control and 
Barrett’s patients was similar, a control group was selected that was matched to the 
Barrett’s groups for similarity in circulating gastrin concentrations (±2 pM). Within 
both groups relative CgA abundance was significantly higher with PPI treatment (fig 
4.3.1D).  
102 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
Figure 4.3.1 – Relative CgA abundance is significantly higher with PPI treatment. 
Relative abundance of CgA mRNA, expressed normalised to GAPDH mRNA 
abundance, was significantly higher with PPI treatment in both groups (A). Relative 
CgA abundance with PPI treatment remained significantly higher in both patient 
groups when controls were age, sex and H. pylori status matched (B). Across all 
samples a significant relationship existed between relative CgA expression and 
circulating gastrin concentration (C). Significantly higher relative CgA expression 
with PPI in groups matched for circulating gastrin (D). Mean ±SEM, p<0.05, unpaired 
two-tailed t-test with Welch’s correction. 
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4.3.1.2 Relative CCK2R abundance is significantly lower with PPI treatment 
Abundance of the CCK2R was analysed in gastrin-matched control and Barrett’s 
patient gastric biopsies to identify any loss of sensitivity to endogenous gastrin within 
the stomach which may impact the abundance of gastrin sensitive biomarkers. 
Unexpectedly, in both control and Barrett’s patient groups (fig 4.3.2), patients treated 
with PPIs exhibited significantly lower receptor transcript abundance, relative to 
GAPDH mRNA abundance, with both patient groups exhibiting a similar degree of 
change. 
Comparing the relationship between relative CCK2R abundance and circulating 
gastrin concentration in gastrin matched combined control and Barrett’s gastric 
biopsies, Spearman’s rank correlation identified a significant relationship between the 
two, r=0.48 df=96 p<0.05. When analysed individually, a significant relationship 
between circulating gastrin and CCK2R abundance remained in both groups (control 
r=0.50 df=47 p<0.05; Barrett’s r=0.50 df=47 p<0.05). 
4.3.1.3 Relative HDC abundance is significantly higher with PPI treatment 
Within the unmatched cohort of control and Barrett’s patient biopsies HDC mRNA 
abundance, relative to GAPDH mRNA abundance, was significantly higher with PPI 
treatment in both groups compared with untreated subjects (fig 4.3.3A). However, 
when samples were gastrin-matched only the Barrett’s group exhibited higher relative 
HDC abundance with PPI treatment. Despite this, there was a clear upward trend in 
HDC abundance in the control patient group treated with PPIs compared with 
untreated although the variance was higher (fig 4.3.3B). 
Comparing the relationship between relative HDC abundance and circulating gastrin 
concentration in unmatched control and Barrett’s gastric biopsies, Spearman’s rank 
correlation identified no significant relationship between the two. In gastrin matched 
samples however, Spearman’s rank identified a significant relationship between the 
two r=0.29 df=101 p<0.05. When analysed individually, a significant relationship was 
only identified between circulating gastrin and HDC abundance in the Barrett’s group, 
r=0.30 df=47 p<0.05. 
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Figure 4.3.2 – Relative CCK2R abundance is significantly lower with PPI 
treatment. Significantly lower abundance of CCK2R mRNA with PPI treatment in 
control and Barrett’s groups when matched for circulating gastrin concentrations. 
Mean ±SEM, p<0.05, unpaired two-tailed t-test with Welch’s correction. 
 
 
  
 
 
 
 
 
 
 
Figure 4.3.3 – Relative HDC abundance is significantly higher with PPI 
treatment. Significantly higher abundance of HDC mRNA in control and Barrett’s 
patients treated with PPIs compared with untreated (A). In a control group with 
circulating gastrin concentrations matched to those of the Barrett’s group, relative 
HDC abundance was significantly higher in the Barrett’s patient group with PPI 
treatment (B). Mean ±SEM, p<0.05, unpaired two-tailed t-test with Welch’s 
correction. 
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4.3.1.4 Relative MMP-1 abundance is significantly higher with PPI treatment in 
control biopsies 
Within the unmatched cohort of control and Barrett’s patient biopsies, MMP-1 mRNA 
abundance, relative to GAPDH mRNA abundance, was significantly higher with PPI 
treatment in the control group only (fig 4.3.4A). The relationship between serum 
gastrin and MMP-1 abundance was analysed using Spearman’s rank correlation and 
identified a significant positive relationship (r=0.47, p<0.05) within the control group, 
however no significant relationship existed in Barrett’s biopsies. 
When controls were gastrin-matched to Barrett’s samples, neither group exhibited a 
significant change in MMP-1 abundance with PPI treatment. Both groups did however 
exhibit a similar upward trend in MMP-1 abundance with PPI treatment (fig 4.3.4B). 
 
 
 
 
 
 
 
 
Figure 4.3.4 – Relative MMP-1 abundance is significantly higher with PPI 
treatment in control biopsies. Significantly higher abundance of MMP-1 mRNA, 
expressed relative to GAPDH mRNA abundance, in control patients with PPI 
treatment (A). No significant changes in gastrin matched controls or Barrett’s patients 
(B). Mean ± SEM, p<0.05, unpaired two-tailed t-test with Welch’s correction. 
 
 
 
 
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
 M
M
P
-1
0
1
2
3
4
C o n tro l B a rre tt 's
N = 1 8
N = 3 4
N = 5 0
N = 3 6
*
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
 M
M
P
-1
0
1
2
3
4
C o n tro l B a rre tt 's
N = 1 5
N = 3 1
N = 3 1
N = 1 5
-P P I
+ P P I
A B 
106 
 
4.3.2 Gastric biomarker expression in preneoplastic biopsies 
4.3.2.1 Preneoplastic patients exhibit significantly higher gastrin concentration 
To identify if putative biomarker abundance was altered in preneoplastic conditions 
of the stomach, a number of samples were retrieved from the series 1 archive. Three 
groups of patients were recovered with appropriate age and sex matched controls – 
namely those with gastric atrophy, gastric intestinal metaplasia, and the combination 
of both atrophy and metaplasia. 
Each patient group exhibited significantly higher circulating gastrin concentration 
compared to control groups, however the degree of increase in gastrin concentration 
was directly related to severity of progression of preneoplasia along the Correa 
cascade. Atrophy patients exhibited the lowest increase in gastrin concentration (fig 
4.3.5A), intestinal metaplasia patients exhibited a greater increase in gastrin 
concentration than atrophy (fig 4.3.5B) and the combined atrophy and intestinal 
metaplasia group exhibited the greatest increase in serum gastrin concentration (fig 
4.3.5C). 
 
 
 
 
 
  
 
 
  
Figure 4.3.5 – Preneoplastic patients exhibit significantly higher circulating 
gastrin concentration. Significantly higher gastrin concentration observed in patients 
with gastric atrophy (A), intestinal metaplasia (B) and combined atrophy with 
metaplasia (C). Mean ± SEM, p<0.05 unpaired two-tailed t-test with Welch’s 
correction.  
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4.3.2.2 Relative CgA mRNA abundance is significantly lower in biopsies exhibiting 
intestinal metaplasia 
Unlike gastric biopsies obtained from control and Barrett’s patients, the significantly 
higher gastrin concentration associated with preneoplastic changes in the stomach did 
not translate to a higher abundance of CgA, expressed relative to GAPDH mRNA 
abundance (fig 4.3.6A and C). 
All preneoplastic biopsies exhibited a trend towards lower CgA abundance compared 
to controls, and in the intestinal metaplasia group this difference was statistically 
significant (fig 4.3.6B). 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.6 – Relative CgA mRNA abundance is significantly lower in biopsies 
exhibiting intestinal metaplasia. CgA abundance, expressed relative to GAPDH 
mRNA abundance, was significantly lower in IM patients (B) but not atrophy (A) or 
atrophy with IM patients (C). Mean ± SEM, p<0.05 unpaired two-tailed t-test with 
Welch’s correction. 
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4.3.2.3 Relative CgA mRNA abundance is significantly higher in patients with 
gastrin >30 pM 
Breaking down the preneoplastic CgA abundance results further, sub-groups were 
defined based on those with circulating gastrin below the dynamic range for 
stimulation of acid secretion (<30 pM) and those within and above that dynamic range 
(>30 pM). In both control (fig 4.3.7A) and preneoplastic (fig 4.3.7B) groups, relative 
CgA abundance was significantly higher when circulating gastrin concentration was 
above 30 pM. Separating by preneoplastic condition was less informative, with only 
the atrophy (fig 4.3.7C) and IM (fig 4.3.7D) control groups exhibiting a significant 
difference in abundance between gastrin groups (fig 4.3.7E). 
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Figure 4.3.7 – Relative CgA mRNA abundance is significantly higher in patients 
with gastrin >30 pM. Relative CgA mRNA abundance was significantly higher in 
the control group (A) and the combined atrophy and IM patient groups (B) with 
circulating gastrin >30 pM. Breaking those groups down further by preneoplastic 
condition, atrophy and IM controls exhibited significantly higher CgA abundance 
compared with the <30 pM gastrin group (C, D) no significant changes were identified 
in disease states (C, D, E). Mean ± SEM, p<0.05 unpaired two-tailed t-test with 
Welch’s correction. 
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4.3.2.4 CCK2R mRNA abundance is significantly lower in all preneoplastic groups 
Analysing the expression of the CCK2R, all preneoplastic conditions exhibited 
significantly lower receptor mRNA abundance compared to control subjects that were 
matched to patients based on age and sex (fig 4.3.8A, B and C). Atrophy patients 
exhibited the least reduction in receptor abundance, intestinal metaplasia exhibited a 
greater reduction and combined atrophy plus intestinal metaplasia group exhibited the 
greatest reduction in receptor abundance. 
A significant negative correlation between circulating gastrin concentration and 
relative CCK2R mRNA expression was identified in the control groups for gastric 
atrophy and IM preneoplastic control groups by Spearman’s rank correlation (atrophy 
r=-0.48, df=52; IM r=-0.38, df=3; p<0.05) however no significant correlation was 
identified in the control group for atrophy + IM control group. Within patient groups 
however this significant correlation was lost, with no preneoplastic group exhibiting a 
significant relationship with circulating gastrin concentration. 
 
 
 
  
 
 
 
 
 
Figure 4.3.8 – Relative CCK2R mRNA abundance is significantly lower in all 
preneoplastic groups. Relative CCK2R abundance is significantly lower compared 
to controls in atrophy (A), IM (B) and atrophy with IM preneoplastic patient groups 
(C). Mean ± SEM, p<0.05 unpaired two-tailed t-test with Welch’s correction.  
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4.3.2.5 Relative CCK2R mRNA abundance expression was significantly lower in 
atrophy patients exhibiting elevated gastrin 
The groups of control subjects (fig 4.3.9A) and atrophy (fig 4.3.9B) patients were then 
sub-divided by gastrin concentration into those below the dynamic range for 
stimulation of acid secretion (<30 pM) and those within and above that dynamic range 
(>30 pM). Within both groups, CCK2 receptor abundance was not significantly 
different between low and high gastrin groups. 
Separating by preneoplastic condition, the atrophy group exhibited significantly lower 
CCK2R abundance compared to controls when circulating gastrin was >30 pM (fig 
4.3.9C). Within intestinal metaplasia and combined atrophy and intestinal metaplasia 
groups, CCK2R abundance exhibited no significant changes in either control or 
preneoplastic patients based on low vs high gastrin concentration (fig 4.3.9D, E). 
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Figure 4.3.9 – Relative CCK2R mRNA abundance was significantly lower in 
atrophy patients exhibiting elevated gastrin. Relative CCK2R abundance was not 
significantly different in controls (A) or atrophy (B) when grouped by gastrin 
concentration. Broken down by preneoplastic condition, CCK2R abundance exhibited 
significantly lower abundance only within atrophy patients (C) with no significant 
change in IM (D) or combined atrophy with IM (E). Mean ± SEM, p<0.05 unpaired 
two-tailed t-test with Welch’s correction. 
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4.4 Discussion 
In this chapter, I have characterised the expression profile of putative biomarkers of 
gastrin-responsiveness (CgA, HDC, MMP-1, CCK2R) in the stomach of both normal 
(H. pylori negative, histologically verified), and Barrett’s patients and shown how this 
profile is affected by PPI treatment and associated hypergastrinaemia. We have also 
characterised the putative biomarker expression profiles for CgA and CCK2R in 
preneoplastic conditions of the stomach. This work is novel, as previously abundance 
of these transcripts appears to have not been investigated in control subjects or in 
gastric biopsies of Barrett’s or preneoplastic patients.  
4.4.1 Changes in abundance of CgA 
The first biomarker selected for testing, CgA, was chosen because of its well 
characterised use as a serum-based biomarker released by many neuroendocrine cells 
including neuroendocrine tumours (NETS).315 A large meta-analysis recently found 
significantly increased circulating CgA to be a highly specific and sensitive biomarker 
for the detection of NETs.315 However there is some dispute as to the usefulness of 
serum based CgA assays due to a number of factors. Firstly, CgA is extensively 
processed and modified post secretion in a pattern which varies individually with 
tumour type and origin, consequently circulating CgA is heterogeneous and the 
concentrations of any one fragment are, inevitably, highly variable. Thus, 
immunoassays employing antibodies with limited specificity (often unknown) can be 
difficult to interpret. Secondly, circulating CgA concentrations may be increased in 
renal and cardiac disease as well as non-endocrine malignancies so again 
interpretation of the data can be difficult.316 Not surprisingly then, circulating CgA 
assays in common forms of hypergastrinaemia including atrophic gastritis203 have 
proven to be unreliable for diagnosis and studies have shown that significant 
hypergastrinaemia does not necessarily correlate with significantly higher circulating 
CgA.317 Despite these limitations we did perform some preliminary investigation into 
circulating CgA concentration in both normal and Barrett’s patients with and without 
PPI treatment which can be found in appendix I.I. 
Our approach attempts to circumvent these problems by measuring the relative 
abundance of the CgA mRNA at the tissue transcriptional level. This has allowed us 
to focus specifically on changes in the tissue of interest, in this case the stomach. 
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A similar approach has been used previously to assess the efficacy of the novel gastrin 
antagonist netazepide185 in treating type 1 NETs utilising biopsies and qPCR and 
before that in a study which combined the use of ECL carcinoid biopsies and northern 
blots.195 The novelty of this study is the extension of these techniques (use of biopsy 
and mRNA abundance quantification) to the normal stomach and preneoplastic 
conditions associated with high circulating gastrin. 
Previously, a few studies using rat stomachs found that expression of CgA at the tissue 
mRNA level was significantly higher with PPI treatment by both qPCR318 and 
standard PCR and western blotting.200 Treatment of the rats with PPIs induced 
significantly higher mRNA expression regardless of whether the rats were fasted or 
not, which was inhibited by CCK2R antagonists suggesting that CgA mRNA 
abundance is gastrin linked. However, a literature search provided no evidence that 
this question had been investigated in humans. 
In agreement with previously published work in the rat, patients treated with PPIs 
exhibited significantly higher CgA mRNA abundance in gastric biopsies compared to 
appropriate controls. Moreover, when samples were matched based on their age, sex 
and H. pylori status, or for circulating gastrin concentration, the elevation of CgA 
mRNA abundance was similar between both Barrett’s and control subjects treated 
with PPIs, suggesting that CgA abundance is indeed linked to circulating gastrin 
concentration in both the control and Barrett’s stomach.  
In biopsies from patients exhibiting preneoplastic changes divided on the basis of 
circulating gastrin below (<30 pM) or above (>30 pM) the reference range, CgA 
mRNA abundance was not significantly different, highlighting the loss in the ECL cell 
population in atrophy, IM and atrophy with IM patients. In fact, patients exhibiting IM 
exhibited no change in CgA mRNA abundance with increased circulating gastrin 
concentration whereas in patients exhibiting gastric atrophy there was still a trend 
towards increased CgA abundance with high gastrin, presumably as a result of some 
ECL cell population remaining. 
Breaking down further into low (<30 pM), medium (30-100 pM) and high (>100 pM) 
gastrin concentrations for each condition and patient group proved unhelpful, with too 
low an N number in the >100 pM group to perform reliable analysis. 
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4.4.2 Changes in abundance of CCK2R 
The abundance of the main gastrin receptor, CCK2, in gastric samples is not well 
studied. Kimura et. al. reported a significant increase in receptor mRNA abundance 
over the course of treatment with PPIs in rats. However, controlled human studies 
regarding the effect of PPI treatment on gastric CCK2R expression appear not to have 
been published. The question is interesting, given that recently the CCK2R has 
become a novel therapeutic target with studies reporting CCK2R antagonists in 
NSAID-associated gastric ulceration,319 type 1 gastric neuroendocrine tumours185 and 
pancreatic cancer precursor legions179. Understanding more about how gastrin 
influences receptor expression may help build a better understanding of how useful 
novel anti-gastrin treatment methods (such as CCK2 antagonists and anti-gastrin 
antibodies) will be in the prevention of gastrin-responsive malignancies.  
Our work identified that PPI treatment was associated with a significant reduction in 
the abundance of CCK2R mRNA, possibly a result of adaptation to extended periods 
of hypergastrinaemia. This complicates the aim of detecting possible biomarkers to 
track the effect of gastrin on Barrett’s tissue, as changes in CCK2R abundance may 
impact on the sensitivity of cells to gastrin and in turn have an effect on any possible 
biomarker expression. The decrease in CCK2R abundance could compensate for any 
increase in suspected biomarker expression, meaning any putative biomarkers would 
need to be sufficiently sensitive to changes in gastrin to overcome the reduced receptor 
expression. Further study on the issue with much larger datasets is now required to 
explore variations in CCK2R abundance across patients and ranges of circulating 
gastrin concentration. 
The significantly lower CCK2R abundance exhibited in preneoplastic patient biopsies 
was to be expected as a result of loss of CCK2R expressing ECL cells and parietal 
cells. As previously mentioned, loss of parietal cells and the intrinsic factor secreted 
by them can result in pernicious anaemia due to an inability to absorb vitamin B12 from 
the diet. Some preliminary work was performed analysing serum B12 concentration in 
control and corpus atrophy patients, detailed in appendix I.II. 
Breaking down further into low (<30 pM), medium (30-100 pM) and high (>100 pM) 
gastrin concentrations for each condition and patient group proved unhelpful, with too 
low N number in the >100 pM group to perform reliable analysis. 
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4.4.3 Changes in abundance of HDC 
The regulation of the histamine generating enzyme, HDC, has been extensively 
studied in relation to changes in circulating gastrin concentration.197, 320-323 In the 
stomach of adult rats, extended fasting resulted in a reduction in both serum gastrin 
concentration and corpus HDC mRNA abundance whereas PPI-induced 
hypergastrinaemia induced significantly higher mRNA abundance.324,325 Introduction 
of a selective CCK2 receptor antagonist blocked the higher HDC mRNA abundance 
associated with elevated circulating gastrin.324 These data support the idea that gastrin 
may play a regulatory role in the expression of HDC mRNA and as such, HDC mRNA 
abundance changes may be useful as a putative biomarker of gastrin responsiveness 
in GI tissues. 
Therefore, it was not surprising that the present data indicate that significantly elevated 
circulating gastrin concentration, in this case induced by PPI treatment, correlates with 
a significantly higher abundance of HDC mRNA. This held true in both control and 
Barrett’s patients. 
4.4.4 Changes in abundance of MMP-1 
Previous work has identified a role of gastrin in stimulating MMP-1 expression from 
gastric epithelial cells211 implicated in cell migration which again may prove useful a 
putative biomarker of gastrin activity on cells of the GIT. 
 
Within our gastric samples, only control patients exhibited statistically higher MMP-
1 mRNA abundance with PPI treatment and its associated increase in serum gastrin 
concentration. Further studies of this are need, however, given the large variance in 
MMP-1 mRNA expression and the relatively lower sample size for the gastrin-
matched Barrett’s and control samples. As a possible biomarker of gastrin activity on 
CCK2 expressing cells, despite there being some indication of a trend towards 
increased abundance, it would seem that MMP-1 is less sensitive to changes in gastrin 
concentration than either CgA or HDC, making them preferable biomarkers to use 
moving forward. 
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4.4.5 Conclusion 
Our work is novel in several ways; firstly it is based on histologically verified normal 
human gastric samples where the main variable is treatment with PPIs and associated 
hypergastrinaemia; secondly, we have similar data from the stomachs of Barrett’s 
patients again where the main variable is treatment with PPIs and associated 
hypergastrinemia; thirdly we have similar biomarker abundance data from a variety of 
preneoplastic conditions of the stomach increasing in severity of cancer risk with 
which to compare to controls. Nevertheless, these are all cross-sectional studies, and 
in the future, there are opportunities for longitudinal studies of the system. 
In summary, the main findings of this chapter are that a) in gastric biopsies derived 
from normal and Barrett’s patients PPI treatment is associated with significantly 
higher relative CgA abundance in both groups, significantly lower relative CCK2R 
abundance in both groups, significantly higher relative HDC abundance in the 
Barrett’s patient group and only control biopsies exhibited a significant change in 
relative MMP-1 abundance with PPI treatment; b) patients with preneoplastic 
conditions of the stomach exhibited significantly higher serum gastrin concentration 
with the magnitude of gastrin concentration increase relative to progression of the 
condition along the Correa cascade, gastric preneoplastic conditions exhibit 
significantly lower relative CCK2R mRNA abundance whilst CgA mRNA abundance 
was significantly lower in biopsies exhibiting intestinal metaplasia.  
 
Identification of a relationship between gastrin concentration and CCK2R abundance 
was unexpected and may have an impact on putative biomarkers of gastrin-
responsiveness in Barrett’s oesophagus, the next stage of the study therefore sought to 
identify whether a similar gastrin-CCK2R relationship existed in Barrett’s 
oesophageal biopsies and if so whether it might influence putative biomarker 
abundance. 
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Chapter 5 
Putative biomarker expression in Barrett’s 
oesophagus biopsies
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5.1 Introduction 
Gastrin has previously been identified as an inducer of gene expression in CCK2R 
expressing ECL and parietal cells of the stomach.196, 200, 323, 324 These changes in 
expression were mediated by CCK2R activation.231,185 It was assumed that with the 
discovery of functional CCK2Rs in BO,160 their activation would also induce similar 
changes in gene expression in BO. In turn, these could then be measured with qPCR 
to establish a gastrin-regulated gene expression profile. It was hypothesised that any 
changes in gene expression would be related to circulating gastrin concentration, 
which has previously been associated with greater risk of BO progression to ACO.289 
A literature search identified a number of potential candidates that were identified as 
being gastrin-regulated or de-regulated in cases of ACO or gastric cancer including 
potential markers of gastrin activity on endocrine cells (CgA), markers of mucosal 
damage (COX-2, TFF1 and 2) and markers of cellular invasion (SHH and MMPs).200, 
326-332 We also aimed to examine expression of CCK2R itself, relative to circulating 
gastrin concentration, as in the previous chapter studies in gastric biopsies suggested 
altered expression with PPI treatment and a relationship between circulating gastrin 
and expression of CCK2R.  
Recent advancements in qPCR techniques have facilitated the study of microRNAs 
(miRNAs) – small non-coding RNA molecules that play a role in regulating gene 
expression - and has revealed their potential as biomarkers of multiple cancers.227, 333, 
334 MicroRNAs represent an ideal candidate for biomarker studies as they are 
relatively stable in both tissue and serum, so the potential exists for serum miRNA 
profiles to be used as a surrogate for assay of miRNAs in tissue. A number of 
publications have investigated the use of a variety of miRNA candidates as biomarkers 
of BO and its progression,335-337 however none to date have been validated as sensitive 
enough to track progression. Likewise no comparison has been made of the expression 
of miRNAs in BE, either at serum or tissue level, and circulating gastrin concentration. 
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5.1.1 Objectives 
Specific objectives of this chapter were: 
 Identification of putative biomarkers of gastrin responsiveness in BO relative 
to the circulating concentrations of gastrin. 
 Determination of the microRNA expression profile in serum and BO relative 
to circulating concentrations of gastrin 
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5.2 Methods 
Biopsies of Barrett’s oesophagus with matching serum samples were obtained from 
patients undergoing routine Barrett’s surveillance at either the Royal Liverpool 
University hospital (RLUH) or the Szeged University hospital (UoSz), Hungary. Dr 
Andy Moore, Dr Ashley Bond and Prof. Mark Pritchard recruited patients and 
obtained blood samples and biopsies for samples obtained at the RLUH whilst Dr. 
András I. Rosztóczy and Prof. Tibor Wittman were responsible for the same duties at 
the UoSz. Biopsies from both institutions were sent to the University of Szeged for 
histological analysis by Prof. Laszlo Tiszlavicz and Dr. Zita Reisz. Biopsies destined 
for qPCR were immediately processed via the protocol outlined in section 2.1.3.3 and 
then frozen and stored at -20°C (RLUH) or frozen and transported on dry ice to 
Liverpool (UoSz).  
 
RNA was extracted and converted to cDNA for qPCR utilising the method detailed in 
sections 2.4.1 and 2.4.2; qPCR was performed utilising the multiplexed method as 
detailed in section 2.4.4. Transcript abundance was normalised to GAPDH, and then 
expressed as fold difference relative to the mean abundance in the control group, 
defined as those patients with fasting circulating gastrin concentrations in the normal 
range i.e. <30 pM. 
 
Serum and biopsy miRNA extraction, conversion to cDNA and subsequent qPCR was 
performed using the Qiagen suite of micro RNA processing kits (miRNeasy, miScript 
II RT kit, miScript SYBR green PCR kit coupled with miScript miRNA PCR assay 
primers) according to the manufacturer’s instructions described in section 2.5. Putative 
mRNA and miRNA biomarkers analysed by qPCR are listed in table 5.2.1. 
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mRNA miRNA 
CgA -21 
MMP-1 -221 
MMP-7 -222 
COX-2  
CCK2R  
TFF1  
TFF2  
SHH  
 
Table 5.2.1 – Putative biomarkers of gastrin responsiveness investigated in tissue 
and serum biopsies of patients with BO. Specific primer sequences used for qPCR 
are listed in tables 2.1 and 2.2. 
 
Data obtained by qPCR was initially analysed in all Barrett’s oesophagus biopsies and 
is presented for this group and, separately, for the sub-group with intestinal metaplasia 
(IM) only. This sub-group was selected for presentation as it was the largest 
homologous group available within the Barrett’s cohort (see table 2.1). 
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5.3 Results 
5.3.1 The association between serum gastrin and relative putative biomarker 
abundance in Barrett’s oesophagus biopsies 
5.3.1.1 GAPDH mRNA abundance is gastrin insensitive 
Previous work in the laboratory using a commercial panel of housekeeping genes had 
identified GAPDH as being the most robust reference point for normalisation of qPCR 
data in gastric biopsies.134, 338 However, it was important to validate the use of GAPDH 
in Barrett’s oesophagus biopsies and in particular to ensure that GAPDH expression 
did not change with variations in circulating gastrin concentration. When the average 
GAPDH expression across all multiplexed qPCRs for each biopsy sample was 
combined and related to circulating gastrin concentration, no significant relationship 
was identified (r=-0.09 df=52 p<0.05) (fig 5.3.1) indicating no association between 
serum gastrin and GAPDH abundance in oesophageal biopsies. 
 
 
 
 
 
 
 
 
 
Figure 5.3.1 - GAPDH mRNA abundance is gastrin insensitive. Spearman’s rank 
correlation identified no significant relationship between GAPDH abundance and 
circulating gastrin concentration in BO biopsies. 
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5.3.1.2 Relative CgA mRNA abundance is significantly higher when circulating 
gastrin is between 30-100 pM 
Putative biomarker expression in Barrett’s oesophagus biopsies was analysed across 
all samples and is described here in the group as a whole and, separately, in the sub-
group that exhibited only intestinal metaplasia without evidence of dysplasia/cancer, 
or evidence of gastric metaplasia (table 2.1). 
CgA mRNA abundance, relative to GAPDH abundance, within both the whole 
Barrett’s oesophagus biopsy patient cohort (fig 5.3.2A) and samples selected for 
intestinal metaplasia (fig 5.3.2B) was significantly higher in patients with circulating 
gastrin concentrations across the post-prandial dynamic range of gastrin (30-100 pM) 
compared to the reference range for fasting circulating gastrin (<30 pM), or above the 
post-prandial range (>100 pM). 
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Figure 5.3.2 – Relative CgA mRNA abundance is significantly higher when 
circulating gastrin is between 30-100 pM. Relative abundance of CgA mRNA, 
normalised to GAPDH mRNA abundance, was significantly higher in Barrett’s 
oesophagus biopsies of patients with circulating gastrin between 30-100 pM (A). In 
the subgroup selected for intestinal metaplasia, relative CgA mRNA abundance 
remained significantly higher in patients with circulating gastrin between 30-100 pM 
(B). Mean ± SEM, p<0.05, one-way ANOVA with Holm-Sidak correction. 
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5.3.1.3 Relative MMP-1 mRNA abundance is significantly lower when circulating 
gastrin is >30 pM 
MMP-1 mRNA abundance, relative to GAPDH abundance, within the whole Barrett’s 
oesophagus patient cohort (fig 5.3.3A) exhibited no significant changes relative to 
circulating gastrin concentration. 
Selecting for patients exhibiting only intestinal metaplasia (fig 5.3.3B), relative MMP-
1 mRNA abundance was significantly lower at circulating gastrin concentrations 
within the post-prandial physiological range (30-100 pM) and above (>100 pM) 
compared to the reference range for fasting circulating gastrin (<30 pM). 
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Figure 5.3.3 – Relative MMP-1 mRNA abundance is significantly lower when 
circulating gastrin is >30 pM. MMP-1 mRNA expression, relative to GAPDH, 
exhibits no significant change with changes in circulating gastrin concentration across 
all biopsies (A). Relative MMP-1 mRNA abundance was significantly lower with 
circulating gastrin >30 pM in the subgroup selected for intestinal metaplasia (B). Mean 
± SEM, p<0.05, one-way ANOVA with Holm-Sidak correction. 
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5.3.1.4 Relative MMP-7 abundance is significantly higher when circulating gastrin 
is >100 pM 
MMP-7 mRNA abundance, relative to GAPDH abundance, within both the whole 
Barrett’s oesophagus patient cohort (fig 5.3.4A) and samples exhibiting only intestinal 
metaplasia (fig 5.3.4B) was significantly higher when circulating gastrin concentration 
was above the post-prandial physiological range of gastrin (>100 pM) compared to the 
reference range for fasting circulating gastrin (<30 pM). 
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Figure 5.3.4 – Relative MMP-7 abundance is significantly higher when circulating 
gastrin is >100 pM. MMP-7 mRNA expression, relative to GAPDH, is significantly 
higher in biopsies of Barrett’s oesophagus in patients when circulating gastrin is >100 
pM (A). MMP-7 mRNA abundance is also significantly higher when circulating 
gastrin is >100 pM in the subgroup selected for intestinal metaplasia (B). Mean ± 
SEM, p<0.05, one-way ANOVA with Holm-Sidak correction. 
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5.3.1.5 Relative COX-2 mRNA abundance is significantly higher when circulating 
gastrin is >30 pM 
COX-2 mRNA abundance, relative to GAPDH abundance, within the whole Barrett’s 
oesophagus biopsy cohort (fig 5.3.5A) was significantly higher when circulating 
gastrin concentration was within the post-prandial physiological range (30-100 pM) 
or above (>100 pM) compared to the reference range for fasting circulating gastrin 
(<30 pM). In samples selected for exhibiting only intestinal metaplasia (fig 5.3.5B) 
however, relative COX-2 mRNA abundance was only higher when circulating gastrin 
was above the post-prandial range (>100 pM) compared to fasting gastrin (<30 pM). 
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Figure 5.3.5 – Relative COX-2 mRNA abundance is significantly higher when 
circulating gastrin is >30 pM. COX-2 mRNA expression, relative to GAPDH, is 
significantly higher in Barrett’s oesophagus biopsies in patients when circulating 
gastrin is >30 pM (A). COX-2 abundance is significantly higher when circulating 
gastrin is >100 pM in the subgroup selected for intestinal metaplasia (B). Mean ± 
SEM, p<0.05, one-way ANOVA with Holm-Sidak correction. 
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5.3.1.6 Relative CCK2R mRNA abundance is significantly lower when circulating 
gastrin is >30 pM 
In the whole Barrett’s oesophagus biopsy cohort, CCK2R mRNA abundance, relative 
to GAPDH abundance, remained unchanged across the post-prandial physiological 
range of gastrin (30-100 pM) compared to the reference range for fasting circulating 
gastrin (<30 pM). However, with circulating gastrin concentrations above the 
physiological range (>100 pM) there was significantly lower CCK2R abundance (fig 
5.3.6A). 
In the subgroup of patients selected for only intestinal metaplasia, relative CCK2R 
mRNA abundance was significantly higher across the post-prandial physiological 
range of gastrin (30-100 pM) compared to the reference range for fasting circulating 
gastrin (<30 pM). However, at concentrations above the physiological range (>100 
pM) relative abundance was significantly lower compared to the reference range for 
fasting circulating gastrin (<30 pM) (fig 5.3.6B 
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Figure 5.3.6 - Relative CCK2R mRNA abundance is significantly lower when 
circulating gastrin is >30 pM. CCK2R mRNA expression, relative to GAPDH, is 
significantly lower in Barrett’s oesophagus biopsies when circulating gastrin is >100 
pM (A). CCK2R is significantly higher when circulating gastrin is between 30-100 
pM, however significantly lower when circulating gastrin is >100 pM in the subgroup 
selected for intestinal metaplasia (B). Mean ± SEM, p<0.05, one-way ANOVA with 
Holm-Sidak correction. 
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5.3.1.7 Relative TFF1 mRNA expression in Barrett’s biopsies is significantly lower 
when circulating gastrin is between 30-100 pM 
TFF1 mRNA abundance, relative to GAPDH abundance, was only gastrin sensitive 
within the whole Barrett’s oesophagus biopsy cohort, where abundance was 
significantly lower within the post-prandial physiological range (30-100 pM) of 
gastrin compared to the reference range for fasting circulating gastrin (<30 pM) (fig 
5.3.7A). This trend however did not present in the samples selected for only intestinal 
metaplasia (fig 5.3.7B) in which relative TFF1 mRNA abundance was not 
significantly different in any gastrin groups when compared to the reference range for 
circulating gastrin (<30 pM). 
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Figure 5.3.7 - Relative TFF1 mRNA expression in Barrett’s biopsies is 
significantly lower when circulating gastrin is between 30-100 pM. TFF1 mRNA 
abundance, relative to GAPDH, was significantly lower in Barrett’s oesophagus 
biopsies (A) however was not gastrin sensitive in the subgroup selected for intestinal 
metaplasia (B) Mean ± SEM, p<0.05, one-way ANOVA with Holm-Sidak correction. 
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5.3.1.8 Relative TFF2 mRNA expression in Barrett’s biopsies is largely gastrin 
insensitive 
TFF2 mRNA abundance, relative to GAPDH abundance, was insensitive to changes 
in circulating gastrin concentration in both groups, with no statistically significant 
changes in relative abundance identified. However, across the whole Barrett’s 
oesophagus biopsy patient cohort (fig 5.3.8A) and there did appear to be a trend 
towards higher relative abundance of TFF2 at circulating gastrin concentrations above 
the post-prandial physiological range (>100 pM) compared to the reference range for 
fasting circulating gastrin (<30 pM). In biopsies selected for only intestinal metaplasia 
(fig 5.3.8B) there also appeared a trend towards higher relative abundance of TFF2 
with circulating gastrin concentration above the reference range for fasting gastrin 
(>30 pM). 
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Figure 5.3.8 - Relative TFF2 mRNA expression in Barrett’s biopsies is gastrin 
insensitive. TFF2 mRNA abundance, relative to GAPDH, exhibited no significant 
changes in Barrett’s oesophagus biopsies (A) or in the subgroup selected for intestinal 
metaplasia (B) with circulating gastrin. Mean ± SEM, p<0.05, one-way ANOVA with 
Holm-Sidak correction. 
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5.3.1.9 Relative SHH mRNA abundance was significantly lower when circulating 
gastrin was >100 pM 
SHH mRNA abundance, relative to GAPDH abundance, within the whole Barrett’s 
oesophagus biopsy patient cohort (fig 5.3.9A) and only samples selected for only 
intestinal metaplasia (fig 5.3.9B), remained unchanged across the post-prandial 
physiological range of circulating gastrin (30-100 pM) compared to the reference 
range for fasting circulating gastrin (<30 pM). However, at circulating gastrin 
concentrations above the physiological range (>100 pM) there was significantly lower 
relative abundance compared to the reference range for fasting circulating gastrin (<30 
pM). 
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Figure 5.3.9 – Relative SHH mRNA abundance was significantly lower when 
circulating gastrin was >100 pM. SHH mRNA abundance, relative to GAPDH, was 
significantly lower when circulating gastrin was >100 pM in Barrett’s oesophagus 
biopsies (A) and in the subgroup selected for intestinal metaplasia (B). Mean ± SEM, 
p<0.05, one-way ANOVA with Holm-Sidak correction. 
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5.3.2 The effect of gastrin on miRNA expression in serum of Barrett’s patients 
5.3.2.1 RNU6B abundance in serum is gastrin insensitive 
Previous work performed by Lloyd et. al.230 within our department using a panel of 
snoRNA sequences, generated for normalisation of microRNA expression, identified 
RNU6B as the most abundant and stably expressed sequence to use for normalisation. 
As with GAPDH, it was important to validate the use of RNU6B in serum for data 
normalisation across samples that covered a large range of circulating gastrin 
concentrations (to identify any influence gastrin may have on abundance which may 
affect normalisation). Across all samples serum RNU6B abundance remained stable 
and no statistically significant relationship was identified by Spearman’s rank analysis 
between circulating gastrin concentration and RNU6B abundance (r=-0.24 df=52 
p<0.05) (fig 5.3.1). 
 
 
 
 
 
 
 
 
 
Figure 5.3.10 – RNU6B abundance in serum is gastrin insensitive. Spearman’s rank 
correlation identified no significant relationship between RNU6B abundance and 
circulating gastrin concentration. 
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5.3.2.2 Relative serum miR-21 abundance is significantly higher when gastrin 
concentration is between 30-100 pM 
Serum miR-21 abundance, relative to RNU6B abundance, within the whole Barrett’s 
patient cohort (fig 5.3.11A) and in the sub-group selected for intestinal metaplasia 
only (5.3.11B) was significantly higher when circulating gastrin was in the post-
prandial physiological range (30-100 pM) compared to the reference range for fasting 
circulating gastrin (<30 pM). At circulating gastrin concentrations above the 
physiological range (>100 pM) however, relative miR-21 mRNA abundance was not 
significantly different compared to the reference range for fasting gastrin. 
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Figure 5.3.11 – Relative serum miR-21 abundance is significantly higher when 
gastrin concentration is between 30-100 pM. Abundance of miR-21 miRNA, 
relative to RNU6B, in serum was significantly higher when circulating gastrin was 
between 30-100 pM in both the whole Barrett’s patient cohort (A) and in the subgroup 
with intestinal metaplasia only (B). Mean ± SEM, p<0.05, one-way ANOVA with 
Holm-Sidak correction. 
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5.3.2.3 Relative serum miR-221 abundance is significantly higher when gastrin 
concentration is between 30-100 pM 
Serum miR-221 abundance, relative to RNU6B abundance, within the whole Barrett’s 
patient cohort (fig 5.3.12A) and in the sub-group selected for intestinal metaplasia 
only (5.3.12B) was significantly higher when circulating gastrin was in the post-
prandial physiological range (30-100 pM) compared to the reference range for fasting 
circulating gastrin (<30 pM). At circulating gastrin concentrations above the 
physiological range (>100 pM) however, relative miR-221 mRNA abundance was not 
significantly different compared to the reference range for fasting gastrin. 
Relative abundance changes of miR-221 with circulating gastrin therefore mirrors the 
changes seen in miR-21 (fig 5.3.11). 
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Figure 5.3.12 – Relative serum miR-221 abundance is significantly higher when 
gastrin concentration is between 30-100 pM. Abundance of miR-221 miRNA, 
relative to RNU6B, in serum was significantly higher when circulating gastrin was 
between 30-100 pM in both the whole Barrett’s patient cohort (A) and in the subgroup 
with intestinal metaplasia only (B). Mean ± SEM, p<0.05, one-way ANOVA with 
Holm-Sidak correction. 
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5.3.2.4 Serum miR-222 is significantly higher when gastrin concentration is between 
30-100 pM 
Serum miR-222 abundance, relative to RNU6B abundance, within the whole Barrett’s 
patient cohort (fig 5.3.13A) and in the sub-group selected for intestinal metaplasia 
only (5.3.13B) was significantly higher when circulating gastrin was in the post-
prandial physiological range (30-100 pM) compared to the reference range for fasting 
circulating gastrin (<30 pM). At circulating gastrin concentrations above the 
physiological range (>100 pM) however, relative miR-222 mRNA abundance was not 
significantly different compared to the reference range for fasting gastrin. 
Relative abundance changes of miR-222 with circulating gastrin therefore mirrors 
the changes seen in mir-221 (fig 5.3.12) and miR-21 (fig 5.3.11). 
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Figure 5.3.13 – Relative serum miR-222 abundance is significantly higher when 
gastrin concentration is between 30-100 pM. Abundance of miR-222 miRNA, 
relative to RNU6B, in serum was significantly higher when circulating gastrin was 
between 30-100 pM in both the whole Barrett’s patient cohort (A) and in the subgroup 
with intestinal metaplasia only (B). Mean ± SEM, p<0.05, one-way ANOVA with 
Holm-Sidak correction. 
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5.3.3 Gastrin’s effect on miRNA expression in biopsies of BO 
5.3.3.1 RNU6B abundance in BO biopsies is gastrin insensitive 
As with GAPDH and RNU6B abundance in serum, it was important to validate the 
use of RNU6B in Barrett’s oesophageal biopsies for data normalisation across samples 
that covered a large range of circulating gastrin concentrations (to identify any 
influence gastrin may have on abundance which may affect normalisation). Across all 
samples RNU6B abundance remained stable and no statistically significant 
relationship was identified by Spearman’s rank analysis between circulating gastrin 
concentration and RNU6B abundance in biopsies of BO (r=0.11 df=52 p<0.05) (fig 
5.3.14). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.14 – RNU6B abundance in biopsies of BO is gastrin insensitive. 
Spearman’s rank correlation identified no significant relationship between RNU6B 
abundance and circulating gastrin concentration. 
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5.3.3.2 Relative miR-21 miRNA abundance is significantly lower when circulating 
gastrin is >100 pM 
Since serum miRNA could originate from any tissue in the body, it was considered 
crucial to also examine abundance of miRNAs at the tissue level in biopsies of 
Barrett’s oesophagus. Tissue miR-21 miRNA abundance, relative to RNU6B 
abundance, within the whole Barrett’s patient cohort (fig 5.3.15A) and oesophageal 
biopsy samples exhibiting intestinal metaplasia only (fig 5.3.15B), remained 
unchanged across the post-prandial physiological range of circulating gastrin (30-100 
pM) compared to the reference range for fasting circulating gastrin (<30 pM). 
However, at circulating gastrin concentrations above the physiological range (>100 
pM) there was significantly lower relative abundance compared to the reference range 
for fasting circulating gastrin (<30 pM). 
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Figure 5.3.15 – Relative miR-21 miRNA abundance is significantly lower when 
circulating gastrin is >100 pM. Abundance of miR-21 miRNA, relative to RNU6B, 
was significantly lower when circulating gastrin was >100 pM in biopsies of Barrett’s 
oesophagus (A) and in the subgroup selected for intestinal metaplasia (B). Mean ± 
SEM, p<0.05, one-way ANOVA with Holm-Sidak correction. 
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5.3.3.3 Relative miR-221 miRNA abundance is significantly lower when circulating 
gastrin is >100 pM  
Tissue miR-221 miRNA abundance, relative to RNU6B abundance, within the whole 
Barrett’s patient cohort (fig 5.3.16A) and oesophageal biopsy samples exhibiting 
intestinal metaplasia only (fig 5.3.16B), remained unchanged across the post-prandial 
physiological range of circulating gastrin (30-100 pM) compared to the reference 
range for fasting circulating gastrin (<30 pM). However, at circulating gastrin 
concentrations above the physiological range (>100 pM) there was significantly lower 
relative abundance compared to the reference range for fasting circulating gastrin (<30 
pM). 
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Figure 5.3.16 – Relative miR-221 miRNA abundance is significantly lower when 
circulating gastrin is >100 pM. Abundance of miR-221 miRNA, relative to RNU6B, 
was significantly lower when circulating gastrin was >100 pM in biopsies of Barrett’s 
oesophagus (A) and in the subgroup selected for intestinal metaplasia (B). Mean ± 
SEM, p<0.05, one-way ANOVA with Holm-Sidak correction. 
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5.3.3.3 Relative biopsy miR-222 abundance is significantly lower when gastrin 
concentration is >100 pM 
Barrett’s oesophagus miR-222 transcript abundance, relative to RNU6B abundance, 
was significantly lower in the whole Barrett’s patient cohort (fig 5.3.16A) at 
circulating gastrin concentrations above the physiological range (>100 pM) compared 
to the reference range for fasting circulating gastrin (<30 pM).  
Selecting for oesophageal biopsy samples exhibiting intestinal metaplasia only (fig 
5.3.16B) however, exhibited no significant changes in relative abundance with 
circulating gastrin concentration when compared to the reference range for fasting 
circulating gastrin (<30 pM). Despite this, there remained a general trend towards 
lower miR-222 abundance with all gastrin concentrations >30 pM. 
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Figure 5.3.17 – Relative miR-222 miRNA abundance is significantly lower when 
circulating gastrin is >100 pM. Abundance of miR-222 miRNA, relative to RNU6B, 
was significantly lower when circulating gastrin was >100 pM in Barrett’s oesophagus 
biopsies (A) and in the subgroup selected for intestinal metaplasia (B). Mean ± SEM, 
p<0.05, one-way ANOVA with Holm-Sidak correction. 
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5.4 Discussion 
The main findings derived from this chapter are: 
The expression profile of putative biomarkers of gastrin responsiveness within 
Barrett’s epithelium is complex, with sensitivity and direction of change varying 
depending on gene selected and circulating gastrin concentration. Of genes for which 
mRNA abundance was tested (CgA, MMP-1, MMP-7, COX-2, CCK2 and SHH) all 
exhibited some changes in abundance when samples were separated by circulating 
gastrin.  
The expression profile of circulating miRNA proved remarkably similar across all 
miRNAs investigated, miR-21, -221 and -222 were all significantly higher within the 
post-prandial physiological range of gastrin when compared to the to the reference 
range for fasting circulating gastrin. Above the physiological range of gastrin the 
abundance of the miRs returns to that of the reference range for fasting circulating 
gastrin. 
The expression profile of biopsy miRNA differed dramatically to that in serum, with 
miR-21 showing no significant changes in response to gastrin and a very large variance 
within gastrin groups. The profile of tissue miRs -221 and -222 share similarities with 
those in serum, they both exhibit similar changes in abundance however these changes 
are a significant lowering of abundance as opposed to significantly higher abundance 
compared to the reference fasting range of gastrin. 
Biomarker and miRNA profiles were separated and analysed in the context of the 
heterogeneity of the group. There were small sub-groups of Barrett’s patients that 
exhibited dysplasia or gastric metaplasia but these were considered insufficient for 
separate analysis and presentation. There was, however, a large sub-group of patients 
that exhibited intestinal metaplasia and this was considered adequate for separate 
presentation. This is, of course, the most common form of the disease and the form 
associated with the development of ACO.261 The present study was therefore based on 
both a heterogeneous group and a slightly smaller relatively homogeneous group.    
Separation by grades of metaplasia and dysplasia has been employed before in gene 
expression studies339 which concluded that cardiac and intestinal metaplasia share 
approximately 95% of the same gene expression profile whereas gastric remained 
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distinct. Within the wider literature however, rarely are Barrett’s samples separated by 
types of metaplasia or dysplasia. Our data shows that when investigating abundance 
of putative biomarkers, consideration of types of metaplasia or dysplasia can make a 
significant difference. Four genes of interest – MMP-1, COX-2, TFF1 and CCK2R, 
exhibited significantly different abundance profiles in IM compared with the whole 
Barrett’s group. This highlights the importance of rigorous histological identification 
of the type of metaplasia or dysplasia present in BO when investigating BO at the 
genetic level. 
 Serum miRNA abundance exhibited no significant differences between either group, 
which was not unexpected considering serum based miRNA abundance is non-specific 
to any particular tissue due to its circulating nature. Biopsy miRNA abundance 
however did exhibit a significant difference between sub-groups in the mir-222 group, 
although the trend remained the same albeit no longer significant as it was in the larger 
group.  
Separation of samples by circulating gastrin concentration by the most well 
characterised physiological function of gastrin – gastric acid secretion - was performed 
as previously very few papers have related changes in gastrin-regulated gene 
expression to the physiological range of circulating gastrin.340, 74, 341 
Comparing the abundance of putative biomarkers within Barrett’s biopsies to the 
preneoplastic stomach biopsies analysed in Chapter 4: in the case of CgA, biopsies of 
BO exhibited higher abundance with gastrin above the fasting reference range (>30 
pM) but above the post-prandial physiological range (>100 pM) exhibited no 
significant changes in abundance. Within gastric biopsies however, increased 
circulating gastrin (>30 pM) was associated with significantly lower abundance of 
CgA compared to controls. Abundance of CCK2R mRNA exhibited a similar change 
in biopsies of both BO and gastric preneoplastic conditions – namely with circulating 
gastrin there was significantly lower CCK2R mRNA abundance.  
The modulation in CCK2R mRNA abundance observed relative to changes in 
circulating gastrin in both biopsies of BO and gastric biopsies, if confirmed to also 
effect mature protein production and abundance of receptor at the cell surface, may 
hinder further gastrin-regulated biomarker discovery in BO. It may be the case that 
decreases in receptor abundance at the cell surface compensate for increases in 
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circulating gastrin concentration, altering the sensitivity of BE to gastrin relative to 
gastrin concentration, in turn having an effect on the abundance of gastrin-regulated 
biomarkers. This highlights a crucial area where further research is needed to complete 
our understanding of how CCK2R expression is controlled and how changes in 
receptor expression relate to changes in other gastrin-regulated proteins, particularly 
in BO. In other words, it may simply be futile to try to discover and implement 
biomarkers of gastrin-responsiveness in BO if CCK2R expression itself is gastrin-
dependent. 
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Chapter 6 
Putative biomarker expression in gastric 
adenocarcinoma cell lines 
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6.1 Introduction 
Whilst qPCR provides information regarding the abundance of mRNA of putative 
biomarker proteins, it cannot provide information on protein expression per se. In the 
present context, direct study of protein expression at the tissue level in vivo was limited 
by the amount of extra biopsy material that could be safely removed from patients 
alongside the biopsies required to be taken for routine Barrett’s surveillance. To 
maximise the number of putative biomarkers that could be analysed with this limited 
biopsy material, a decision was made to use the tissue for qPCR, rather than using 
larger masses of biopsy material for protein analysis at the cost of only being able to 
examine a few putative biomarker targets.  
However, it is possible to use established cell lines derived from human gastric 
adenocarcinoma, transfected with a copy of the human CCK2R72, to measure changes 
in both intra- and extra-cellular protein abundance in response to gastrin. If treatment 
of these cells with gastrin produces similar changes in mature protein abundance to 
those predicted from qPCR studies, performed in the previous chapter, it may identify 
which putative biomarkers are more closely associated with the development of 
adenocarcinoma than simply benign BO. Extra-cellular proteins in particular could be 
highly informative because they may contribute to the tumour microenvironment by 
modifying the extracellular matrix to allow tumour cells to invade as well as providing 
a source of circulating putative biomarkers, the “gold-standard” for biomarker 
identification in patients.  
6.1.1 Objectives 
 Analyse the expression of putative biomarkers of gastrin responsiveness in 
gastric adenocarcinoma cells with and without expression of the CCK2R. 
 Compare the expression of candidate proteins based on changes seen in mRNA 
abundance in biopsies. 
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6.2 Methods 
Cell lines were maintained as detailed in section 2.6.2 and were plated at a density of 
5 million cells per 75 cm3 treatment flask. To each flask excluding controls, an 
appropriate volume of unsulphated human G17 diluted in 0.05 M ammonium 
bicarbonate was added from a stock solution of either 1 or 10 µM to produce the 
required final concentration. Cells were then returned to the incubator. Cells were 
exposed to G17 (where applicable) for a treatment period of 24 hours before cell media 
and extracts were recovered and processed (as outlined in section 2.6.3). Key findings 
were replicated, but where results were uninformative the experiments were only 
performed once. 
 
Cell extracts and media were prepared using the previously defined methods (sections 
2.6.4, 2.6.5) and frozen at -80°C until being defrosted, on ice, when required for SDS-
PAGE and western blotting. SDS-PAGE and western blotting experiments were 
performed as detailed in section 2.7.  
Densitometry was used to quantify the intensity of protein bands revealed via western 
blot using BioRad™ image lab software version 5.2.1. The latter converts HRP-
fluorescence into a numerical value suitable for comparison between samples and, in 
the case of cell extracts, was also used for normalisation to the housekeeping protein 
GAPDH. 
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6.3 Results  
6.3.1-4 Biomarker secretion and cellular expression in AGS cells 
Treatment of AGS cells with G17 at concentrations of 1 and 10 nM induced no 
notable, dose-related changes in abundance in media of either pro- or active MMP-1, 
however there was a slight increase in cellular abundance. Treatment with PMA 
induced a sizeable increase in both pro- and active MMP-1 abundance in cell extracts 
and cell media (fig 6.3.1A,B,C,D). 
MMP-2 abundance did not change appreciably with gastrin treatment in cells or media 
but treatment with PMA slightly reduced the abundance of MMP-2 in both cells and 
media when compared to untreated controls (fig 6.3.2A,B,C,D). 
Pro- and active MMP-3 abundance was below the limit of detection in control and 
gastrin-stimulated medium, but were detectable in cells. Interestingly, the cellular 
abundance of proMMP-3 remained below the limit of detection at all gastrin 
concentrations. Whilst active MMP-3 was detectable, abundance exhibited no 
apparent trend in response to a rising concentration of gastrin. Treatment of cells with 
PMA however stimulated a profound increase in pro- and active MMP-3 abundance 
in media, with a modest increase in proMMP-3 accompanied by a modest decrease in 
active MMP-3 abundance in cell extracts (fig 6.3.3A,B,C,D). 
Pro- and active TIMP-1 abundance in media and cells exhibited no discernible changes 
with gastrin treatment. However, PMA treatment induced a profound increase in 
abundance of active TIMP-1 in media, and of both pro- and active TIMP-1 in cell 
extracts (fig 6.3.4A,B,C,D).  
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Figure 6.3.1 – MMP-1 abundance in media is gastrin insensitive, in cell extracts 
is gastrin sensitive in AGS cells. Abundance of pro- (54 kDa) and active MMP-1 (52 
kDa) in media (A - western blot, B - densitometry) exhibited no notable, dose-related 
response to gastrin. In cell extracts, pro- and active MMP-1 abundance, relative to 
GAPDH (C - western blot, D - densitometry), exhibited a slight increase in response 
to G17. PMA strongly stimulated an increase in pro- and active MMP-1 abundance in 
media and cell extracts that saturated the system. N=1. 
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Figure 6.3.2 – MMP-2 abundance in media and cell extracts is gastrin insensitive 
in AGS cells. Abundance of MMP-2 (~54 kDA) in media (A - western blot, B - 
densitometry) and cell extracts, relative to GAPDH (C - western blot, D - 
densitometry), exhibited no appreciable dose-dependent response to G17. PMA was 
associated with a modest reduction of MMP-2 abundance in both media and cell 
extracts. N=1. 
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Figure 6.3.3 – MMP-3 abundance in media and cell extracts is gastrin insensitive 
in AGS cells. Abundance of pro-MMP-3 (57 kDA) and MMP-3 (54 kDA) in media 
(A - western blot, B - densitometry) and cell extracts, relative to GAPDH (C - western 
blot, D - densitometry), exhibited no appreciable dose-dependent response to G17. 
PMA induced an increase in abundance of both pro- and active MMP-3 in media and 
cell extracts. N=1. 
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Figure 6.3.4 – TIMP-1 abundance in media and cell extracts is gastrin insensitive 
in AGS cells. Abundance of proTIMP-1 (30 kDa) and TIMP-1 (28 kDa) in media (A 
- western blot, B - densitometry) and cell extracts, relative to GAPDH (C - western 
blot, D - densitometry), exhibited no appreciable dose-dependent response to G17. 
PMA induced an increase in abundance of TIMP-1 in media and both proTIMP-1 and 
TIMP-1 in cell extracts. N=1. 
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6.3.5 MMP-1 abundance in media is gastrin-sensitive in AGS-GR cells 
In contrast to the results in AGS cells above, treatment of AGS-GR cells with  
increasing concentrations of G17 (0.1-10 nM) stimulated a dose-dependent increase 
in pro-MMP-1 abundance in media at concentrations >0.3 nM and dose-dependent 
increases in media of active MMP-1 at concentrations of 1 nM and above (fig 6.3.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3.5 – MMP-1 abundance in media is gastrin-sensitive in AGS-GR cells. 
Abundance of pro- (52 kDa) and active MMP-1 (54 kDa) in media (A - western blot, 
B -densitometry) exhibited no appreciable response to G17 at <0.3 nM. However at 
concentrations >0.3 nM there was a dose-dependent increase in media of proMMP-1; 
concentrations >1 nM also stimulated an increase in media of active MMP-1. N=1. 
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6.3.6 MMP-2 abundance in media and cells is gastrin insensitive in AGS-GR cells 
Treatment of AGS-GR cells with increasing concentrations of G17 (0.1-10 nM) 
provided no clear evidence of a dose-dependent relationship with MMP-2 (fig 
6.3.3A,B). Abundance of MMP-2 in cell extracts remained below the limit of detection 
at all G17 concentrations (fig 6.3.6C). 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 6.3.6 – MMP-2 abundance in media and cells is gastrin insensitive in AGS-
GR cells. Abundance of MMP-2 (~54 kDa) in media (A - western blot, B - 
densitometry) exhibited no appreciable dose-dependent response to G17. Abundance 
of MMP-2 in cell extracts, relative to GAPDH, remained below the limit of detection 
at all G17 concentrations (C - GAPDH western blot, blank MMP-2 western blot not 
shown). N=2. 
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6.3.7 MMP-3 abundance in media and cell extracts is gastrin sensitive in AGS-GR 
cells 
Treatment of AGS-GR cells with increasing concentrations of G17 (0.1-10 nM) 
stimulated a dose-dependent increase in media of pro- and active MMP-3 at 
concentrations of 1 nM and above (fig 6.3.7A,B) and a dose-dependent increase in 
active MMP-3 abundance in cell extracts (fig 6.3.7C,D). 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 6.3.7 – MMP-3 abundance in media and cell extracts is gastrin sensitive in 
AGS-GR cells. Abundance of both pro- (57 kDa) and active MMP-3 (54 kDa) in 
media (A - western blot, B - densitometry) exhibited an increase G17 concentrations 
≥1 nM, but MMP-3 abundance in cell extracts exhibited an increase across all G17 
concentrations except 1 nM (C - western blot, D - densitometry). N=2. 
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6.3.8 MMP-7 cellular abundance is gastrin sensitive in AGS-GR cells 
MMP-7 abundance in media remained below the limit of detection across all G17 
concentrations (fig 6.3.8A). However, treatment with an increasing concentration of 
G17 (0.1-10 nM) did stimulate a dose-dependent increase in pro- and active MMP-7 
abundance in cells at concentrations of 0.1 and 0.3 nM. Concentrations >0.3 nM 
however appeared to induce a reduction in pro- and active MMP-7 abundance to below 
the limit of detection at concentrations ≥3 nM (fig 6.3.8B,C).  
 
 
 
          
 
 
 
 
 
 
  
  
 
 
 
 
 
Figure 6.3.8 – MMP-7 cellular abundance is gastrin sensitive in AGS-GR cells. 
Abundance of pro (29 kDa) and active MMP-7 (27 kDa) in media remained below the 
limit of detection at all G17 concentrations (A - blank MMP-7 western blot not 
shown). However pro- and active MMP-7 abundance in cell extracts exhibited an 
increase at G17 concentrations between 0.1-0.3 nM before decreasing at 
concentrations ≥1 nM (B - western blot, C - densitometry). N=1. 
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6.3.9 TIMP-1 abundance in media and cell extracts is gastrin sensitive in AGS-GR 
cells 
Treatment of AGS-GR cells with increasing concentrations of G17 (0.1-10 nM) 
stimulated a small dose-dependent increase in TIMP-1 abundance in media at 
concentrations >1 nM (fig 6.3.9A,B). Abundance of both pro and active TIMP-1 in 
cell extracts was stimulated by G17 treatment at all concentrations, with a clear dose-
dependent relationship (fig 6.3.8C,D). 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
Figure 6.3.9 – TIMP-1 abundance in media and cell extracts is gastrin sensitive in 
AGS-GR cells. Abundance of TIMP-1 (28 kDa) in media exhibited an increase at G17 
concentrations >1 nM (A - western blot, B - densitometry). Abundance of both pro 
(30 kDa) and active TIMP-1 in cell extracts also exhibited an increase at all G17 
concentrations (C - western blot, D - densitometry). N=1. 
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6.3.10 MMP-1 abundance in media is gastrin-sensitive in HGT-GR cells 
In order to determine whether the results in AGS-GR cells might be replicated in a 
second cell line, the experiments were repeated with HGT-GR cells. Treatment of 
HGT-GR cells with increasing concentrations of G17 (0.1-10 nM) stimulated an 
increase in abundance of proMMP-1 at concentrations >0.3 nM with an increase in 
active MMP-1 at a concentration of 1 nM (fig 6.3.10A,B). Cellular abundance of 
MMP-1 remained below the limit of detection in controls and across all G17 
concentrations (fig 6.3.10C).  
 
         
      
                                                                                                               
 
                                        
                                                                                                                                                    
 
 
 
 
 
 
 
 
 
 
Figure 6.3.10 – MMP-1 abundance in HGT-GR cells is gastrin sensitive. 
Abundance of proMMP-1 (54 kDa) in media exhibited an increase at G17 
concentrations >0.3 nM, with an increase in active MMP-1 (52 kDa) at a concentration 
of 1 nM (A - western blot, B - densitometry). Abundance of MMP-1 in cells remained 
undetectable at all G17 concentrations (C – GAPDH western blot, blank MMP-1 
western blot not shown). N=1. 
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6.3.11 MMP-2 abundance in media is gastrin-sensitive in HGT-GR cells 
Treatment of HGT-GR cells with increasing concentrations of G17 (0.1-10 nM) 
stimulated a dose-dependent increase in MMP-2 abundance in media at concentrations 
>0.3 nM (fig 6.3.11A,B). Abundance of MMP-2 in cell extracts exhibited no 
discernible dose-dependent response to G17 treatment (fig 6.3.11C). 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
Figure 6.3.11 – MMP-2 abundance in media is gastrin-sensitive in HGT-GR cells. 
Abundance of MMP-2 (~54 kDa) in media exhibited a dose-dependent increase at G17 
concentrations >0.3 nM (A - western blot, B - densitometry), MMP-2 abundance in 
cell extracts however remained gastrin independent (C - western blot, D - 
densitometry). N=2. 
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6.3.12 MMP-3 abundance in HGT-GR media and cells is undetectable  
Abundance in both media (fig 6.3.12A) and cell extracts (fig 6.3.12B) of MMP-3 
remained below the limit of detection in controls and with G17 treatment in HGT-GR 
cells. 
 
                                                                                          
 
 
 
 
 
Figure 6.3.12 – MMP-3 abundance in HGT-GR cells is undetectable. Abundance 
of MMP-3 (54 kDa) in media (A) and cell extracts (B – GAPDH western blot, blank 
MMP-3 western blot not shown) of MMP-3 remained below the limit of detection 
irrespective of G17 concentration. N=2. 
 
6.3.13 MMP-7 abundance in HGT-GR Cells is undetectable 
Abundance in both media (fig 6.3.13A) and cell extracts (fig 6.3.13B) of MMP-7 
remained below the limit of detection in controls and with G17 treatment in HGT-GR 
cells. 
                                                                                  
 
 
 
 
 
Figure 6.3.13 – MMP-7 abundance in HGT-GR Cells is undetectable. Abundance 
of MMP-7 (27 kDa) in media (A) and cell extracts (B - GAPDH western blot, blank 
MMP-7 western blot not shown) of MMP-7 remained below the limit of detection 
irrespective of G17 concentration. N=1. 
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6.3.14 TIMP-1 abundance in media and cell extracts is gastrin sensitive in HGT-
GR cells 
Treatment of HGT-GR cells with increasing concentrations of G17 (0.1-10 nM) 
stimulated a dose-dependent increase in TIMP-1 media abundance at concentrations 
0.1-1 nM. However at concentrations >1 nM media abundance (whilst remaining 
greater than controls) exhibited abundance similar to a concentration of 0.3 nM (fig 
6.3.14A,B). Abundance of TIMP-1 in cell extracts remained below the limit of 
detection in controls and all G17 concentrations (fig 6.3.14C). 
 
 
 
                                                                                                                                            
 
  
 
 
 
  
 
 
 
 
Figure 6.3.14 – TIMP-1 abundance in media and cell extracts is gastrin sensitive 
in HGT-GR cells. Abundance of TIMP-1 (28 kDa) in media exhibited a dose-
dependent increase at G17 concentrations between 0.1-1 nM, however concentrations 
>1 nM exhibited TIMP-1 abundance similar to a concentration of 0.3 nM (A - western 
blot, B - densitometry). Abundance of TIMP-1 in cell extracts remained below the 
limit of detection at all G17 concentrations (C – GAPDH western blot, blank TIMP-1 
western blot not shown). N=2. 
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6.3.15 TIMP-3 abundance in HGT-GR cells is undetectable 
Abundance in both media (fig 6.3.15A) and cell extracts (fig 6.3.15B) of TIMP-3 
remained below the limit of detection in controls and with G17 treatment in HGT-GR 
cells. 
 
  
 
 
 
 
Figure 6.3.15 – TIMP-3 abundance in HGT-GR Cells is undetectable. Abundance 
of TIMP-3 (24 kDa) in media (A) and cell extracts (B – GAPDH western blot, blank 
TIMP-3 western blot not shown) remained below the limit of detection at all G17 
concentrations. N=1. 
6.3.16 Overall summary of biomarker sensitivity to gastrin in cell lines tested 
In order to compare the data obtained across both cell lines, sensitivity to gastrin 
stimulation was expressed as the lowest gastrin concentration required for a change in 
abundance in cell media (Table 6.1). Only MMP-1 emerges as a robust indicator of 
gastrin sensitivity in both cell lines. 
 
Table 6.1 – Overall summary of biomarker sensitivity to gastrin in cell lines 
tested. +++++ = response at 0.1 nM G17, ++++ = response at 0.3 nM G17, +++ = 
response at 1 nM G17, ++ = response at 3 nM G17 and + = response at 10 nM G17 
and - = no response to gastrin. N/A means that particular biomarker was not analysed 
in that cell line. 
 AGS AGS-GR HGT-GR 
TIMP-1 - ++ +++++ 
TIMP-3 N/A N/A - 
MMP-1 - +++ +++ 
MMP-2 - - +++ 
MMP-3 - +++ - 
MMP-7 N/A - - 
B 
GAPDH 
Undetectable 
A 0 1 10 0.1 0.3 3 0 1 10 0.1 0.3 3 
G17 Concentration (nM) G17 Concentration (nM) 
20 
30 
20 
30 
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6.4 Discussion 
AGS cells proved to be insensitive to gastrin-stimulated putative biomarker 
expression, as expected, due to the absence of CCK2R expression. However activation 
of PKC via PMA induced changes in expression of MMP-1, MMP-3 and TIMP-1 
indicating the capacity of these cells to mount a response to the appropriate stimulus. 
In sharp contrast, in cells expressing CCK2R i.e. AGS-GR cells, and in another cell 
line (HGT-GR cells) there were robust responses to G17. The responses of the two 
cell lines were, however, different and only MMP-1 and TIMP-1 emerged as robust 
indicators of gastrin sensitivity. This difference in biomarker expression profile to the 
same stimulus in two seemingly similar cells lines sharing a common origin, highlights 
the importance of using multiple cell lines to validate potential biomarker targets even 
within the same cancer type. The difference also indicates the complexity of the 
biomarker profile expressed by even similar cancers. 
 
Whilst determining the abundance of circulating or cell specific putative biomarkers 
can be informative in the discovery of novel biomarkers, it does not offer a complete 
view relating to the mechanisms involved. Measuring abundance in cell extracts and 
media, as performed here, reflects the total balance between biomarker synthesis, 
secretion and degradation. In cases of increased abundance, in cells and media, with 
gastrin treatment the balance of evidence would suggest gastrin stimulated synthesis 
and subsequent secretion from cells into media although further research would be 
required to confirm this.  
 
Working towards the initial aim of identifying a potential circulating biomarker of 
gastrin-regulated changes in BO, it is arguably more important to consider gastrin-
regulated putative biomarker abundance in media compared to cells, especially when 
considering the function of molecules investigated (modulators of extracellular matrix 
degradation) are extracellular in function. Hence the consideration of media 
abundance, rather than cellular, in the assessment of biomarker sensitivity in formation 
of table 6.1. However, if examining the expression of putative biomarkers in biopsy 
material was the final goal then consideration of cellular abundance would have been 
more important. 
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Utilising cell lines allowed us to overcome some of the inherent limitations we faced 
examining gastrin-regulated protein expression in vitro. These limitations included 
being unable to examine protein secretion from BO in response to gastrin (as 
measurements from blood would be non-specific due to its circulatory nature); being 
able to examine protein abundance in more than one cell line confirmed to be cancer-
derived compared to BO cells, the majority of which would never progress to aquiring 
cancerous mutations, and thus have a different protein expression profile and being 
able to examine the response in protein abundance across a range of G17 
concentrations from the same cells, rather than the fixed, singular gastrin 
concentration point we had for each BO biopsy patient. 
 
The CCK2 receptor is a G protein-coupled receptor, and activation of the receptor 
activates intracellular signal transduction pathways that begin with members of the 
receptor coupled Gq subfamily of GTP-binding proteins, which mediate receptor 
activation of phospholipase C- β (PLC- β). PLC- β in turn produces secondary 
messengers 1,4,5-inosital triphosphate (IP3) and 1,2-diacylglycerol (DAG), with IP3 
inducing Ca2+ from the endoplasmic reticulum into the cell cytoplasm. The increased 
Ca2+ in cytoplasm coupled with DAG in turn activate numerous Ca2+ and lipid-
regulated proteins including members of the protein kinase C (PKC) family.342 PKC 
signalling is often dysregulated in gastric cancer and previous work has implicated a 
role of PKC signalling in altered expression of putative biomarkers such as MMP-1,343 
MMP-2,344 MMP-3345 and MMP-7.346 
 
Phorbal 12-myristate 13-acetone (PMA), a potent activator of protein kinase C was 
included as a positive control in the treatment of AGS cells as a method of mimicking 
the action of CCK2R activated PKC signalling within non-CCK2R expressing cells. 
PKC activation via PMA induced an increase in MMP-1,-3 and TIMP-1 and a decrease 
in MMP-2 abundance in media and cells in AGS cells; a similar pattern of response 
was observed with gastrin treatment in AGS-GR cells. Thus, PMA provides a useful 
positive control and the data are consistant with the idea that gastrin is acting via the 
PKC pathway to induce the changes in putative biomarker abundance that we observed 
in CCK2R expressing cells. 
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Comparing our results to those in published work, Kumar et. al.211 have previously 
identified  gastrin-stimulated release of MMP-1 in both AGS-GR and HGT-GR cell 
lines and linked it to cell migration, a crucial function for cancer invasion and 
development of ACO. This matched with our data as we also saw significant increases 
in MMP-1 secretion in both CCK2R expressing cell lines when treated with gastrin.  
 
MMP-2 expression has previously been examined within AGS-GR cells and it was 
also found that gastrin stimulated a small decrease in media abundance of MMP-2 in 
cells212 which concurs with our findings of AGS and AGS-GR cells exhibiting lower 
and variable expression with gastrin treatment. A literature search provided no 
evidence however of the analysis of MMP-2 secretion or production in HGT-GR cells 
with which to compare our findings.  
 
Previous work analysing gastric cancer tissue has identified a significant increase in 
MMP-3 expression in advanced stage gastric cancer when compared to early stage328 
however gastrin concentrations within patients were not considered in this study. 
Other work detailing a direct link between gastrin stimulation of gastric cancer or 
either cell line tested and MMP-3 expression has not been previously published.  
 
Previous studies have identified circulating and gastric MMP-7 stimulation by gastrin 
in human gastric corpus biopsies and patient plasma samples, mouse gastric biopsies 
and a G17 concentration-dependent increase in MMP-7 promotor activity in AGS-GR 
cells.132 Treatment of cultured gastric glands with G17 stimulated MMP-7 in medium 
which in turn stimulated proliferation in human gastric myofibroblasts. Kumar et. 
al.211 also noted that there was a significant increase in the relative transcript 
abundance of pro-MMP-7 in gastric corpus biopsies from human patients treated with 
PPIs compared to controls with circulating gastrin above the reference range of  
normal serum gastrin, there was no significant different however between patients 
treated with PPIs and controls when circulating gastrin concentrations were within the 
reference range. Our results were broadly in line with those published for AGS-GR 
cells, despite secreted MMP-7 in media being undetectable, there was gastrin 
stimulated  pro and active MMP-7 production in cells up to a concentration of 1 nM 
above which pro and active MMP-7 production fell below the limit of detection. This 
supports the published data132 relating to increased promotor activity and production 
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of MMP-7 in response to gastrin within AGS-GR cells however in our hands increased 
production of MMP-7 did not translate to an increase in secreted MMP-7 to media. A 
literature search provided no previous studies of MMP-7 production or secretion in 
HGT-GR cells with which to compare our findings. 
 
Previously, a meta-review analysing the expression of TIMP-1 in tumour tissue or 
blood as a potential biomarker of gastric cancer showed that elevated TIMP-1 
expression correlates with poor patient outcome326 and has previously been associated 
with MMP-1 as a biomarker of significant interest in the field.327 Our data identified 
gastrin-stimulated secretion of TIMP-1 in both cell lines, with greater sensitivity in 
HGT-GR compared to AGS-GR cells. 
 
Comparing gene expression experiments to protein expression within my own 
research, MMP-1 was the only biomarker for which gene expression data from 
Barrett’s patients (gastrin and Barrett’s biopsies) and protein expression data from 
gastric adenocarcinoma cells was available for comparison, due to the cell lines used 
not expressing CgA or HDC.347 Gastric biopsies from Barrett’s patients exhibited a 
trend towards increased gene expression of MMP-1 with PPI treatment, likewise in 
Barrett’s oesphagus biopsies MMP-1 gene expression was significantly higher when 
fasting gastrin concentration was between 30-100 pM and in both cell lines tested 
MMP-1 exhibited a gastrin-stimulated increase in secretion of similar sensitivity.  
 
The main findings of this chapter is that despite the similarities between cell lines 
(both being gastric adenocarcinoma derived) there is variability in the expression 
profile of putative biomarkers in response to gastrin. Not surprisingly, there is also 
variability in the expression profiles of putative gastrin-regulated biomarkers in cell 
lines when compared to qPCR in BO derived biopsies. Across all results chapters and 
all putative biomarker targets analysed, MMP-1 stands out as the best candidate for 
further study due to its ubiquitous sensitivity to gastrin in all systems examined.  
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Chapter 7 
Discussion 
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7.1 Overview 
The main findings of this thesis are that:  
a) patients with BO treated with PPIs are more likely to exhibit elevated circulating 
gastrin concentration than normal subjects;  
b) in gastric biopsies derived from normal and Barrett’s patients there is a similar 
relationship between serum gastrin and abundance of CgA, CCK2R and HDC mRNA, 
however only control biopsies exhibited a relationship between circulating gastrin and 
MMP-1 mRNA abundance; 
c) patients with preneoplastic conditions of the stomach exhibited significantly 
increased circulating gastrin concentration relative to progression of the condition 
along the Correa cascade, reduction in CCK2R mRNA abundance was also linked to 
degree of cascade progression; CgA mRNA abundance was significantly decreased in 
biopsies exhibiting intestinal metaplasia; 
d) across all BO biopsies, putative biomarker mRNA abundances that exhibited a 
relationship with serum gastrin concentration where: CgA exhibited no significant 
abundance change in subjects with gastrin <100 pM and significantly lower abundance 
>100 pM; MMP-1 exhibited significantly higher abundance with gastrin between 30-
100 pM and significantly lower abundance with gastrin >100 pM; MMP-7 exhibited 
significantly higher abundance in patients with gastrin between 30-100 pM; COX-2 
exhibited the same abundance expression profile as MMP-1; SHH exhibited 
significantly lower abundance with gastrin >100 pM; unexpectedly, CCK2R 
abundance was significantly lower with gastrin >100 pM; 
e) in BO patients, serum abundance of miRs-21, -221 and -222 was significantly 
higher in patients with gastrin between 30-100 pM; 
 f) BO patient biopsy miRNA abundance for miR-21 exhibited significant variance in 
all gastrin concentration groups precluding statistical analysis; miR-221 abundance 
was significantly lower with circulating gastrin concentration >30 pM while miR-222 
abundance was significantly lower with >100 pM gastrin concentration; 
 g) cell models of gastric adenocarcinoma expressing the CCK2R (ie AGS-GR and 
HGT-GR cells) treated with gastrin exhibit different putative biomarker expression 
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profiles and sensitivities; however TIMP-1 and MMP-1 present as common markers 
of gastrin activity. 
7.2 Recent changes in the state of the field 
7.2.1 Liquid biopsy for biomarker detection 
During the course of this thesis substantial progress was reported by others in using 
“liquid biopsy” i.e. plasma biomarkers to detect cancer; in particular, impressive 
success was obtained using multiple biomarkers at both the DNA and protein level.348 
The latter combine detection of ctDNA for the presence of cancer in the body 
combined with protein tests to determine localisation of the cancer, overcoming some 
previous limitations of liquid biopsies. These biomarkers were obtained from previous 
research analysing the mutations common in various localised cancers and applying 
that library to liquid biopsies; theoretically a similar development pathway could be 
followed for blood-based biomarkers of preneoplastic progression in which biopsy 
analysis (as I have performed) would form the first step.  
One of the most important attributes of a liquid biopsy based test is the ability to detect 
cancer as early as possible, preferably in patients with preneoplastic conditions or 
those in a high risk group before cancer has a chance to develop to improve prognosis. 
Despite covering a range of 16 genes and 8 proteins median sensitivity for the test 
overall remained at 70% covering a range of 98-33% for ovarian and breast cancers 
respectively. Most applicable to my research was the discovery rates for oesophageal 
and stomach cancer: 70 and 75% respectively. As noted by the authors of the paper 
however, the median specificity of the test for early stage cancers dropped to only 
43%, with oesophageal cancer being the lowest at 20%.  
This drop in detection rate highlights the limitations in utilising a test based on ctDNA 
in blood from dying cancer cells, since a) cancer has to be already established for 
detection and b) the sensitivity of the test is directly proportional to the number of 
cancer cells dying and releasing ctDNA. However limitations also exist in protein 
analysis of liquid biopsies, whilst changes in the abundance of circulating protein 
biomarkers linked to cancer can be detected with high-sensitivity they’re rarely 
specific enough to identify the location of the cancer.  
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This study utilised a combination of both types of biomarkers to try and overcome 
these limitations, to some success, and provide cancer detection and localisation in 
one test. It highlights the importance of examining multiple biomarkers together as 
part of a panel and multiple sources of biomarkers (proteins, ctDNAs, miRNAs etc.) 
to account for limitations of any singular biomarker or biomarker source. 
7.2.2 Application of a GI blood based biomarker 
At the start of the present thesis, it was considered that MMP-7 might be a particularly 
promising biomarker. In this context it is therefore interesting that using a combination 
of metabolomic and proteomic techniques it was found that circulating MMP-7 + ɣ-
glutamyltranspeptidase as a result of epithelial injury was specific for the detection of 
biliary atresia.349 Again, the use of multiple platforms facilitated the development of a 
rigorous biomarker panel. 
The idea that MMP-7 could be used as a biomarker for epithelial injury in the GIT 
mirrors one of the potential hypotheses I was investigating in BO. In our work 
however, it would appear that MMP-7 is not a reliable marker for tracking the effect 
of gastrin on BO. 
7.3 Effect of PPI treatment in patients with Barrett’s oesophagus 
7.3.1 Gastrin response to PPIs 
There has been evidence that patients with BO exhibit significantly lower circulating 
gastrin concentration than control patients when neither were treated with PPIs350 
which, considering extensive research detailing PPI induced hypergastrinaemia,74 
raises the question of how circulating gastrin concentration would respond to PPI 
treatment in Barrett’s patients. Rather few studies appear to have specifically 
determined if PPI treatment influences circulating gastrin in Barrett’s patients, 
however a previous study did find that in Barrett’s patients, long-term PPI treatment 
induced a significant increase in circulating gastrin. This increase stimulated increased 
restitution of BE in the short-term, however long-term treatment did not induce 
significant changes in the length of BO between low and high dose PPI treatment 
groups.351 Thus the concept for the first stage of our research was to identify if in our 
cohort of BO patients PPI treatment was associated with hypergastrinaemia which 
may have an effect on BE as previously reported. When controlled for age, sex and H. 
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pylori infection status patients with BO treated with PPIs exhibited significantly 
higher circulating gastrin concentration compared to controls treated with PPIs. 
A possible reason for this difference for this may be that Barrett’s patients initially 
have had a higher circulating gastrin concentration prior to PPI treatment, a possibility 
supported by the higher mean gastrin concentration in Barrett’s patients without PPI 
treatment compared to controls without treatment. However the change in circulating 
gastrin concentration in response to PPI treatment within patient groups was still 
greater in Barrett’s patients than controls, implying that BO patients respond 
disproportionally to PPI treatment. Within our cohort other common causes of 
hypergastrinaemia such as H. pylori infection, atrophic gastritis or ZES were ruled out 
and no studies have reported changes in the stomach of Barrett’s patients that would 
suggest changes in the stomach associated with hypergastrinaemia to explain this 
disparate response. Currently no studies have been performed on circulating gastrin 
concentration in matched control and Barrett’s patients which tracked individual 
patients prior to and post-PPI administration, however this kind of study would be the 
“gold standard” in providing further evidence to support the idea of Barrett’s patients 
circulating gastrin concentration responding differently to controls when both are 
treated with PPIs.  
It is also possible that Barrett’s patients had been treated with PPIs longer than control 
patients as patient information did not address this directly, which represents another 
point for further study - comparing length of PPI treatment to changes in circulating 
gastrin in both groups to identify if gastrin increase is time-dependent or perhaps PPI 
dose-dependent. 
It would also be pertinent to involve fasting and post-prandial gastrin measurements 
to assess whether or not gastrin response to food was typical, or whether Barrett’s 
patients’ response was disproportional. A longitudinal study of this nature would also 
address the factor of whether PPI treatment length impacts changes in circulating 
gastrin concentration. An intervention study comparing BO and control patients 
administered PPIs for the first time (with circulating gastrin monitoring from pre-
administration onwards) would be the gold-standard however may prove unfeasible 
on a large scale. A well-designed, well-powered cohort study as described above 
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would be the next logical step in investigation of PPIs effect on circulating gastrin in 
patients with BO. 
7.3.2 Stomach response to PPI treatment 
Despite BO being an oesophagus focused condition, our research exhibited evidence 
of changes in gastrin-regulated genes occurring in the stomach of Barrett’s patients 
when treated with PPIs, even when gastrin matched. All samples analysed were 
histologically examined to ensure that patients with BO did not exhibit altered gastric 
mucosal morphology. However, it is possible that in the stomach of Barrett’s patients 
there are subtle changes in ECL or parietal cell populations that were not detectable 
during histology but would be detectable using much more sensitive qPCR analysis.  
 The increases we observed in CgA and HDC abundance would suggest increased 
ECL-cell mass in keeping with the known effects of prolonged PPI 
therapy/hypergastrinaemia.74 This leaves either parietal cell loss (a nominal 
contributor to total CCK2R expression) or more likely, reduced expression in either 
or both of those cell types. Previous work on whether CCK2R expression was 
regulated by gastrin174 indicated that gastric CCK2R abundance was increased by 
hypergastrinaemia in transgenic mouse models and gastrin treatment of mouse gastric 
pit precursor cell line GSM06.352 Decreased expression of the CCK2R with increased 
gastrin concentration was therefore unanticipated and raises important questions as to 
how changes in CCK2R expression are related to gastrin concentration and sensitivity 
to gastrin. Currently the mechanisms that control CCK2R expression are not fully 
understood so further research in that area may provide an understanding of the 
phenomenon we observed. This finding could have wide-reaching implications in the 
field of gastrin study, offering a new perspective on older studies and in the search for 
biomarkers of the activity of gastrin on cells, specifically BO and ACO. 
The use of gastric cell lines transfected with the CCK2R may provide us with more 
answers concerning how CCK2R expression is controlled. By utilising cell models, 
we can apply a number of inhibitors downstream of CCK2R activated signal 
transduction pathways and using qPCR determine if relative abundance changes.174 If 
a decrease in CCK2R abundance is not replicable in cell lines, it could indicate that 
CCK2R expression is modulated via a paracrine pathway and animal models will need 
to be used to examine further. 
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7.4 Biomarkers of Barrett’s Oesophagus 
7.4.1 Expression of putative biomarkers of gastrin stimulated progression 
None of the potential biomarkers analysed exhibited our predicted trend of a 
significant change in abundance in the most at-risk patient group. These findings 
however follow logically when considering our analysis of changes in the expression 
of the CCK2 receptor within our samples. 
7.4.2 CCK2 receptor expression is associated with gastrin concentration 
The most novel finding of my work (and indeed that with most wide-reaching impact) 
was an inverse correlation between CCK2R mRNA abundance and circulating gastrin 
concentration in BO biopsies. This finding is crucially important because it indicates 
that in patients with elevated gastrin, for example, due to PPI therapy, there may exist 
an auto-regulatory compensation mechanism that reduces BE responsiveness to 
gastrin. 
If so, the search for gastrin regulated biomarkers of progression in BO will be much 
more complex, as one would expect reduced expression of biomarkers in cases of 
reduced CCK2R expression, which coincides with the most at-risk group – those who 
would potentially most benefit from discovery of a biomarker for gastrin driven BO 
progression.  
Our data, being qPCR based rather than targeted to mature CCK2Rs at the cell surface, 
is novel in CCK2R expression studies. In the cell work performed by Dimaline et. al, 
hypergastrinaemia caused the CCK2R to be internalised and stored in vesicles, this is 
consistent with the possibility that when receptors are in abundance, transcription of 
CCK2R mRNA could be downregulated. Likewise comparing to the rat data whereby 
rises in gastrin concentration stimulate increased gastrin receptor abundance it would 
follow a rise in transcription of CCK2R mRNA would accompany. 
These results outlining the variance in CCK2R population and between different 
expression models of the receptor emphasize the importance of 
studying receptor abundance as well as hormone levels to the total understanding of 
an endocrine response. A lack of elucidated mechanisms that control and influence 
expression of the CCK2R represents a key missing component in gastrin research that 
requires further study to fully understand the role gastrin plays in BO progression. 
188 
 
Clinically, the observed variance in CCK2R abundance may also impact the 
usefulness of CCK2R antagonists as an alternative to PPI therapy for use in treating 
reflux disorders and potentially BO. 
7.4.3 Strengths and limitations of the Barrett’s study 
The study design outlined in chapter 5 had several advantages compared to previous 
Barrett’s biomarker studies. Principally it included primary human tissue samples of 
BO rather than animal models or transfected cell lines, so results derived are 
representative of human physiology. Secondly, we have linked circulating gastrin 
concentration to its physiological function within the body (stimulation of gastric acid 
secretion) and expressed our biomarker results along that range. This is unique as large 
scale meta-analysis of BO and ACO rarely include a section on gastrin concentration 
(indeed many individual studies do not consider it) even in studies specifically 
considering PPI usage and Barrett’s to ACO progression risk.353 This represents an 
oversight considering the predictability that a) many Barrett’s patients will be taking 
PPI medication b) Barrett’s patients taking PPIs do not all exhibit the same change in 
circulating gastrin concentration as a result and c) gastrin has possible proliferative 
effects on BO.129, 289 Lastly, circulating gastrin concentration was determined with a 
rigorously validated assay. 
There were however some limitations to our study. At the beginning of the study it 
was not possible to do formal power calculations on biomarkers of gastrin driven BO 
progression simply because no previous research had been done on the phenomenon. 
A correlation between circulating concentration and BO progression risk was only 
suggested in 2010289 and 2011354 meaning research elucidating a possible link is still 
in its infancy. This made determination of an appropriate cohort size for the discovery 
of putative biomarkers difficult. Lastly our study was cross-sectional, with the 
majority of gastrin concentrations falling below the “high risk” group of interest for 
biomarker discovery. It would be advantageous to design prospective studies to focus 
solely on high-gastrin patients over an extended period of time and examine how 
gastrin-regulated gene expression changed relative to degree of dysplasia.  
7.5 Consideration of alternative models of BO 
189 
 
Whilst human biopsies represent the gold standard of starting material for potential 
biomarker analysis, there is potential to use animal models of BO as a platform for 
putative biomarker discovery and pathophysiology of the condition.355 Animal models 
with induced BO such as by surgical intervention could also be used to provide normal 
biopsy tissue (pre-induction) to provide a better control starting point with which to 
compare changes in gene expression in BO and progression thereof relative to gastrin.  
Although cell culture and organotypic models of BO have been used previously, they 
cannot represent the genetic diversity, clonal dynamics and stromal and host-immune 
interactions involved in clinical neoplastic progression.355 Although they do provide a 
much quicker method of obtaining proteins suspected to be able to act as biomarkers 
in response to specific stimuli (in our case, gastrin) and as such play a pivotal role in 
primary screening for biomarkers. Another exciting possibility is the use of patient 
derived organoids356 of both tumour and preneoplastic tissue that would allow detailed 
in vitro screening for putative biomarkers for the effects of gastrin prior to in vivo 
studies. 
A novel method of obtaining cells from the lower oesophagus without the need for 
endoscopy– the cytosponge – is currently being trialled for Barrett’s diagnosis and 
biomarker analysis. Whilst use of the cytosponge has boasted a high-degree of 
accuracy in BO diagnosis (sensitivity 79.5-87%, specificity 92.4%) it has limitations 
in that it samples oesophageal epithelium cells from the entire length of the 
oesophagus, not just Barrett’s metaplasia, and the research group behind it has yet to 
identify a suitable panel of biomarkers to accurately identify patients at a high-risk of 
progression.291 
Methods of biomarker discovery either focus on the DNA, RNA, protein or epigenetic 
level, referred to as genomics, transcriptomics, proteomics or epigenomics 
respectively.357 A number of biomarkers discovered within these disciplines have 
already been developed into assays for human cancers. These include prostate-specific 
antigen test for prostate cancer in blood (proteomics), methylated vimentin as a DNA 
based biomarker (genomics) and DNA based FISH assays utilised for bladder cancer 
detection (genomics).358  
The majority of cancer biomarkers are measured either in the tumour mass or in blood, 
however in our study there was no existing tumour to investigate, meaning the gold 
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standard for a biomarker of the effect of gastrin on BO would be a blood based assay. 
A blood based assay would be the most minimally invasive method of tracking 
changes in biomarker abundance, would require no extra training or equipment to 
obtain samples and would not interfere with scheduled surveillance of BO.  
7.6 Future experiments 
An obvious progression from my work would be to analyse whether changes observed 
at the transcriptional level relative to gastrin concentration translated to comparable 
changes in mature protein production. 
Immunohistochemistry based experiments could provide data on the location of 
changes in protein abundance in response to gastrin; for example cells within biopsies 
that display a more dysplastic phenotype may also be those exhibiting more extreme 
changes in protein expression. Currently all my qPCR data obtained from biopsies 
assumes that the cells within the biopsy consist of a homologous population of 
similarly metaplastic Barrett’s epithelium, displaying similar changes in mRNA 
expression. It would also be possible to study the location of the CCK2R within the 
cells of biopsies and see if it correlates with changes in protein expression, further 
strengthening the proposed hypothesis that activation of the CCK2R by gastrin is 
responsible for changes in gene expression. 
Characterisation of an isoform of the CCK2R linked to increased risk of pancreatic 
cancer359 and shown to be constitutionally active172 indicates further experimentation 
should involve characterisation of the specific variant (or variants) found in BO. There 
has been success with the use of a monoclonal antibody raised to the unique 69 amino 
acids included in the variant, so experiments previously used to detect the variant in 
pancreatic tumours could be applied to ACO biopsies. Currently there is no research 
investigating whether the variant is expressed in ACO as it is in pancreatic cancers. 
Very recently attention has focused on how natural genetic variations in GPCRs could 
impact pharmacological response360 of GPCR therapies, under the umbrella of the 
emerging field of personalised medicine. It could be the case that genetic variation in 
the CCK2R sequence can impact the responsiveness to gastrin in BO and the potential 
usefulness of emerging CCK2R antagonists as a treatment option. 
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7.7 Conclusion 
To conclude, I set out to identify biomarkers that could be used to detect the effect of 
gastrin on BO. They could then potentially be used to create an assay identifying 
progression risk of gastrin-driven BO to ACO to identify patients earlier, before 
histological changes are noticeable during endoscopy. What I discovered is despite 
published work identifying significantly increased risk of BO progression at high 
gastrin concentrations, none of the biomarkers we analysed suggested a robust 
association with circulating gastrin concentration over the range up 500 pM. We did 
however identify significant changes in the abundance of the CCK2R within samples, 
relative to gastrin concentration. This finding could have large biological implications 
in future research concerning the role of gastrin on tissues expressing the CCK2R, 
antagonist therapies for reflux disease and beyond. 
The approach taken within this thesis also provides a paradigm for further biomarker 
studies and emphasises the importance of using multiple approaches, techniques and 
biological sources, for rigorous putative biomarker discovery. 
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Appendices 
I.I Measurement of serum CgA concentration 
Alongside measurement of CgA transcript abundance in gastric biopsies, serum CgA 
from the samples was also analysed using RIA.  
I.I.I Method 
Serum chromogranin A (CgA) concentrations were determined by RIA utilising a 
proprietary kit (Eurodiagnostica, Cat No. RB321) according to the manufacturer’s 
instructions. In brief, serum samples were diluted 1/10 in assay diluent and incubated 
with 125 I-CgA and a CgA specific antibody alongside appropriate standards and 
quality controls for 24 hours at 4°C.Antibody-bound and free radiolabel were 
separated by addition of 500L of a double antibody solid phase solution to each tube. 
The tubes were then briefly vortexed and incubated at 4°C for 60 minutes before being 
centrifuged at 3000rpm for 15 minutes still at 4°C. 
The supernatant was decanted from the pellet, with the radioactivity of each counted 
for one minute using a Packard Bell RIAstar gamma counter. The B/F ratio was 
calculated allowing for non-specific binding of the radiolabel determined from control 
tubes (no antibody). 
I.I.II Serum CgA abundance was significantly higher in patients treated with PPIs 
 
 
 
 
 
Figure I.II.I - A comparison of the serum chromogranin A concentration in 
normal and Barrett’s patients as measured by RIA. Data is presented as mean ± 
SEM, p<0.05 2-way ANOVA with Tukey’s correction. 
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I.II.III Conclusion 
As with transcript abundance in gastric biopsies, CgA concentration in serum also 
appears to be increased in both control and Barrett’s patients when treated with PPIs 
(fig I.II.I). 
I.II Measurement of serum B12 in patients with corpus atrophy 
Due to the requirement of intrinsic factor secretion from parietal cells for the 
absorbance of vitamin B12 from the diet, serum B12 concentration was investigated in 
patients with corpus atrophy when treated with PPIs. 
I.II.I Method 
Serum samples were tested for the concentration of active vitamin B12 in serum 
samples using a commercial active B12 ELISA kit (Biohit HealthCare, UK) according 
to manufacturer’s instructions. Serum samples were diluted 1:200 on manufacturer’s 
recommendation using the supplied diluent and vortexed. To the plate 100 µL of 
diluent buffer (blank), supplied calibrator solutions (for creating a standard curve) and 
supplied positive and negative control samples were added in duplicate as well as 
patient samples; samples were then sealed and incubated for 30 min at 37°C. The 
solution was then removed by inverting the plate and firmly tapping on absorbent 
tissue, and the plate was washed three times with 350 µL of supplied wash buffer per 
well, ensuring all wash buffer was removed between washes by firmly tapping the 
inverted plate onto absorbent tissue. To each well, 100 µL of conjugated antibody 
solution was added and the plate incubated at 37°C for 30 min before removal, after 
which the washing step was repeated. Next, 100 µL of supplied substrate solution was 
added to each well and incubated in the dark at room temperature for 30 min before 
100 µL of provided stop solution was added to complete the reaction. The absorbance 
of the well was then measured at 450 nM on a Tecan GENios plate reader using 
manufacturer supplied software. Comparison of the absorbance values for the serum 
samples to the standard curve values allowed extrapolation of patient B12 
concentration. 
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I.II.II Results 
 
 
 
 
 
 
 
Figure I.II.II - A comparison of the serum active B12 concentration in normal and 
Barrett’s patients as measured by ELISA. Data is presented as mean ± SEM, p<0.05 
2-way ANOVA with Tukey’s correction. 
I.II.III Conclusion 
No significant differences in active B12 concentration were identified between normal 
patients or those exhibiting corpus atrophy. Likewise no significant difference in B12 
concentration was identified as a result of treating patients with PPIs (fig I.II.II). 
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